{"classes":["STUDY_DESIGN","LOCATION","COUNTRY","BODY_PART","INTERVENTION","DRUG","ASSESSMENT_TOOL","CONDITION","ORG","POPULATION","OCCUPATION","BIOLOGICAL","SUBSTANCE","PUBLIC_HEALTH_CONCERN"],"annotations":[["study components aims.",{"entities":[]}],["First, cluster-randomized controlled trial quantitatively estimate effectiveness parenting program child development caregiver outcomes.",{"entities":[[7,42,"STUDY_DESIGN"]]}],["study sample, villages Busia Homabay counties randomly selected randomly assigned county intervention waitlist control group.",{"entities":[[23,28,"LOCATION"],[29,36,"LOCATION"]]}],["Villages intervention receive parenting program first, villages control receive program completion study.",{"entities":[]}],["total, 64 villages selected study.",{"entities":[]}],["village, primary caregivers children 0-24 months age enrolled study total 640 caregiver-child dyads.",{"entities":[]}],["caregiver survey observational assessment child development skills administered study participants baseline endline evaluate outcomes time.",{"entities":[]}],["Second, completion program, qualitative in-depth interviews conducted participants stakeholders (e.g., program participants, parenting facilitators, community health volunteers, ChildFund program staff) understand roles experiences parenting program challenges successes inform future implementation.",{"entities":[[28,59,"STUDY_DESIGN"]]}],["qualitative implementation evaluation seek identify barriers facilitators program impact, quality delivery, scale-up, sustainability.",{"entities":[]}],["",{"entities":[]}],["preventable, cancer cervix leading cancer death Kenya low- middle-income countries (LMIC).",{"entities":[[13,26,"CONDITION"],[35,41,"CONDITION"],[48,53,"COUNTRY"]]}],["Cervical cancer prevented cervix, called cervical precancer, detected screening, adequately treated.",{"entities":[[0,15,"CONDITION"],[26,32,"BODY_PART"],[41,59,"CONDITION"]]}],["Cervical precancer treatment includes surgical procedure called Loop Electrosurgical Excision Procedure (LEEP), removed involved cervix.",{"entities":[[0,18,"CONDITION"],[64,110,"INTERVENTION"],[129,135,"BODY_PART"]]}],["countries Kenya, LEEP procedure referral hospitals trained consultants, difficult access women live rural tertiary facilities.",{"entities":[[10,15,"COUNTRY"],[17,21,"INTERVENTION"]]}],["Additionally, LEEP procedure increases chance woman carry pregnancy term, cervix shorter procedure.",{"entities":[[14,18,"INTERVENTION"],[58,67,"CONDITION"],[74,80,"BODY_PART"]]}],["reasons, alternative treatments, including self-administered treatments Artesunate investigated alternative cervical precancer treatment self-administered.",{"entities":[[72,82,"DRUG"],[108,126,"CONDITION"]]}],["",{"entities":[]}],["Study Design investigators conduct mixed-methods evaluation peer providers, participants, key delivery stakeholders FHOK staff.",{"entities":[[35,48,"STUDY_DESIGN"]]}],["investigators collect quantitative data from: (1) peer mentors prior training delivery screening treatment, (2) participants prior entering treatment treatment.",{"entities":[]}],["investigators track rates retention, engagement, attrition screening treatment delivery.",{"entities":[]}],["Lastly, investigators collect qualitative data including interviews purposively sampled participants Focus peer mentors key delivery stakeholders post-treatment.",{"entities":[]}],["Study Sample.",{"entities":[]}],["Based rates investigators anticipate identifying 360 teens mental health 6-month period (20 teens day, global rate adolescent mental health \\\\~15%)22.",{"entities":[[59,72,"CONDITION"],[126,139,"CONDITION"]]}],["Linkage treatment retention rates population ranging 28%-78%23 .",{"entities":[[8,17,"INTERVENTION"]]}],["investigators conservatively anticipate 45% attrition, final sample 162 receiving treatment.",{"entities":[[82,91,"INTERVENTION"]]}],["estimate pilot treatment participants, sample 40 participants detect medium treatment 80% power alpha 0.05.",{"entities":[[15,24,"INTERVENTION"],[76,85,"INTERVENTION"]]}],["commensurate previous RCT trials PST delivered lay providers24.",{"entities":[[22,32,"STUDY_DESIGN"],[33,36,"INTERVENTION"]]}],["such, investigators participants estimate treatment determine sample size estimates future cluster RCT trial.",{"entities":[[42,51,"INTERVENTION"],[99,108,"STUDY_DESIGN"]]}],["power calculator estimate sample size detect medium size sample (Rosner B.",{"entities":[]}],["Fundamentals Biostatistics.",{"entities":[]}],["7th ed.",{"entities":[]}],["Boston, MA: Brooks/Cole; 2011.) Notably, effects study preliminary indicators implementation intervention estimate power future, larger trial PST.",{"entities":[[142,145,"INTERVENTION"]]}],["investigators convenience sampling, screening participants family health center services.",{"entities":[[14,34,"STUDY_DESIGN"]]}],["approach mirrors real practice provide key preliminary data reach service penetration inform implementation strategies applied improve implementation outcomes.",{"entities":[]}],["Sample gender distribution mirror rates gender distribution youth attending Family Health services.",{"entities":[[76,98,"INTERVENTION"]]}],["Data Collection Peer Logbooks/Forms: Peers screening therapy logbooks record study data.",{"entities":[[37,60,"INTERVENTION"]]}],["record screened, screening results, attendance PST sessions evaluating metrics reach, adoption, implementation.",{"entities":[[47,50,"INTERVENTION"]]}],["Forms SDQ, YTP, PHQ-9, GAD-7 peers baseline screening, 1-month follow-up 6-month follow-up measuring effectiveness.",{"entities":[[6,9,"ASSESSMENT_TOOL"],[11,14,"ASSESSMENT_TOOL"],[16,21,"ASSESSMENT_TOOL"],[23,28,"ASSESSMENT_TOOL"]]}],["Study Protocol logbooks forms submitted study office daily basis locked cabinet confidentiality.",{"entities":[]}],["Youth (YTP) assessment idiographic instrument designed identify monitor youth perspectives youth caregiver11, Strengths Difficulties Questionnaire (SDQ) tool assesses mental health youth ( emotional symptoms, conduct ,Hyperactivity/inattention , peer relationship problems.",{"entities":[[0,45,"ASSESSMENT_TOOL"],[110,157,"ASSESSMENT_TOOL"]]}],["social behavior) Kenya,33.",{"entities":[[17,25,"COUNTRY"]]}],["investigators Patient Health Questionnaire (PHQ-9) screening tool depression.",{"entities":[[14,50,"ASSESSMENT_TOOL"],[66,76,"DISEASE"]]}],["9-item self-report instrument screening, assessing severity depression, examines symptoms two-week period.",{"entities":[[60,70,"DISEASE"]]}],["9 items rated follows: 0 - \"\"not all\"\", 1 - \"\"Several days\"\", 2 - \"\"More days\"\", 3 - \"\"Nearly day\"\".",{"entities":[]}],["Interpretation total scores follows; 0-4 minimal depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, 20-27 severe depression50.",{"entities":[[49,59,"DISEASE"],[65,80,"DISEASE"],[88,107,"DISEASE"],[115,143,"DISEASE"],[151,170,"DISEASE"]]}],["PHQ-9 validated income Sub-Saharan Africa setting49.",{"entities":[[0,5,"ASSESSMENT_TOOL"],[23,41,"LOCATION"]]}],["investigators Generalized Anxiety Disorder 7 ( GAD-7 ) tool assessing generalized anxiety disorder, Kenyan setting.",{"entities":[[14,54,"ASSESSMENT_TOOL"],[70,98,"DISEASE"],[100,106,"COUNTRY"]]}],["item self-report instrument examines symptoms two-week period.",{"entities":[]}],["item rated 4-point scale follows: 0 - \"\"not all\"\", 1 - \"\"Several days\"\", 2 - \"\"More days\"\", 3 - \"\"Nearly day\"\".",{"entities":[]}],["scores sensitivity 89% specificity 82%.51.",{"entities":[]}],["GAD-7 validated income Sub-Saharan Africa setting49.",{"entities":[[0,5,"ASSESSMENT_TOOL"],[23,41,"LOCATION"]]}],["Written tests Peer role plays: Peer mentor PST knowledge competency measured written assessing PST content coded role plays (pre-post training) clinical competency measured Enhancing Assessment Common Therapeutic factors (ENACT) rating scale.",{"entities":[[95,98,"INTERVENTION"],[173,228,"ASSESSMENT_TOOL"]]}],["Kenya assess lay provider competency.26,27 Recording PST sessions: PST sessions recorded assess fidelity PST measured adherence checklist outlining steps PST session (coding analysis below).",{"entities":[[0,5,"COUNTRY"],[53,56,"INTERVENTION"],[67,70,"INTERVENTION"],[105,108,"INTERVENTION"],[154,157,"INTERVENTION"]]}],["Study Procedures Community-Engaged Approach.",{"entities":[]}],["project guided principles community-based participatory engage community stakeholders study18.",{"entities":[]}],["approach helps improve quality, impact, eventual sustainability clinical treatment 19.",{"entities":[]}],["Aligned approach, project developed mental health FHOK.",{"entities":[[36,49,"INTERVENTION"],[50,54,"ORG"]]}],["proposed guided community partners including FHOK leadership, adolescents, MTRH representatives, collaboration Pamoja Mtaani, youth mobilize youth drop-in center.",{"entities":[[45,49,"ORG"],[75,79,"ORG"],[111,124,"ORG"]]}],["investigators stakeholders guide mobilization strategy communications.",{"entities":[]}],["Mobilizing youth key piece ensuring investigators meet target sample size understand reach.",{"entities":[]}],["desired adolescents screen, investigators incorporate activities youth proposed.",{"entities":[]}],["Recruitment.",{"entities":[]}],["investigators recruit FHOK peer-mentors aged 18-24 providers adolescents aged 12-18 coming FHOK drop-in center participants study.",{"entities":[[22,26,"ORG"],[91,95,"ORG"]]}],["peer mentors require attained form 4 education volunteering FHOK minimum 6 months prior recruitment.",{"entities":[[60,64,"ORG"]]}],["5 peer mentors, gender Peer-mentors/Providers.",{"entities":[]}],["Peer mentors FHOK recruited community based willingness volunteer time.",{"entities":[[13,17,"ORG"]]}],["starting FHOK, peer mentors receive one-week training youth friendly services, peer-to-peer engagements clarification.",{"entities":[[9,13,"ORG"]]}],["investigators encourage FHOK peers aged 18-24 school apply peers study flyers, messages, presentations study, word mouth.",{"entities":[[24,28,"ORG"]]}],["Applications consist initial application interview process selecting 8-10 peers attend PST training compensation time.",{"entities":[[87,90,"INTERVENTION"]]}],["training, post-training quiz role-plays select qualified peer mentors deliver intervention consent ethics training final selection.",{"entities":[]}],["Participants.",{"entities":[]}],["eligible adolescents, peer mentors explain study.",{"entities":[]}],["adolescents agree participate, written assent peer mentor verbal phone consent parent/guardian.",{"entities":[]}],["Youth eligible screening aged 12-18 reside 30 minutes travel FHOK center.",{"entities":[[61,72,"ORG"]]}],["screening, eligible treatment report elevated levels mental health remain Eldoret duration treatment.",{"entities":[[74,81,"LOCATION"]]}],["(If remain Eldoret, investigators assist linkage care.) investigators screen Swahili-language version Strengths Difficulties Questionnaire (SDQ), PHQ-9, GAD-7.",{"entities":[[11,18,"LOCATION"],[102,144,"ASSESSMENT_TOOL"],[146,151,"ASSESSMENT_TOOL"],[153,158,"ASSESSMENT_TOOL"]]}],["Treatment: Solving Therapy (PST) investigators apply evidence-based Solving Therapy (PST), transdiagnostic, low-intensity approach improve mental health adolescents demonstrated effectiveness global settings20 21.",{"entities":[[11,32,"INTERVENTION"],[68,89,"INTERVENTION"],[139,152,"CONDITION"],[153,164,"POPULATION"]]}],["PST adolescents 5 session individual treatment demonstrated efficacy delivered lay providers.32 PST theorized function increasing adolescent capacity cope perceived experienced stress problem- emotion- focused coping skills engagement positive, healthy activities.",{"entities":[[0,3,"INTERVENTION"],[4,15,"POPULATION"],[96,99,"INTERVENTION"],[130,140,"POPULATION"]]}],["PST straightforward approach amenable settings focus idiographic problems, session content driven adolescent's causing distress impairment.",{"entities":[[0,3,"INTERVENTION"]]}],["investigators standardized, core steps PST existing manualized protocols including Friendship Bench study protocol Management Plus.21,45 peers deliver PST 5 structured counseling sessions 30-60 minutes 4-6 week period.",{"entities":[[39,42,"INTERVENTION"]]}],["5 core components PST including listing identification, exploration, developing action plan, implementation, follow up.21 components introduced session reviewed iterative process session participants model problems.",{"entities":[[18,21,"INTERVENTION"]]}],["Peer Mentor Training Supervision train supervise peer mentors, investigators employ approaches promising global mental health work.46 procedures iterative collaborative refinements based key delivery stakeholder (e.g., FHOK leadership, mentors) feedback practice pilot studies.",{"entities":[[219,223,"ORG"]]}],["5-day training screening mental health delivering PST, 4 mock cases, 2-observed prior supervised practice.",{"entities":[[25,38,"CONDITION"],[50,53,"INTERVENTION"]]}],["Observed sessions serve opportunity on-site clinician assess peer-providers readiness conduct supervision.",{"entities":[]}],["Supervision.",{"entities":[]}],["Peer-mentors meet led trained Psychologist discuss cases, common challenges, successes.",{"entities":[[0,12,"OCCUPATION"],[30,42,"OCCUPATION"]]}],["step, investigators tapered approach supervision intensity supervision start implementation reduced intensity time.",{"entities":[]}],["implementation, peer- mentor meet weekly.",{"entities":[[16,28,"OCCUPATION"]]}],["month 1 supervision, led trained psychologist.",{"entities":[[33,45,"OCCUPATION"]]}],["month 2, psychologist lead bi-weekly, peer mentors, chosen larger peer-mentors, leading remaining meetings psychologist support phone needed.",{"entities":[[9,21,"OCCUPATION"],[38,50,"OCCUPATION"],[66,78,"OCCUPATION"],[107,119,"OCCUPATION"]]}],["month 3 beyond, led peer-mentors week psychologist support consultation phone needed; 6 weeks psychologist sit peer groups.",{"entities":[[20,32,"OCCUPATION"],[38,50,"OCCUPATION"],[94,106,"OCCUPATION"]]}],["emergencies urgent questions, psychologist consultation phone.",{"entities":[[30,42,"OCCUPATION"]]}],["",{"entities":[]}],["Common mental disorders (CMD) depression anxiety prevalent untreated Kenyan pregnant postpartum women living HIV (PPWH).",{"entities":[[0,29,"CONDITION"],[30,40,"CONDITION"],[41,48,"CONDITION"],[76,101,"POPULATION"],[109,112,"CONDITION"]]}],["CMD lead poor maternal child health outcomes contribute lack HIV care engagement virologic failure PPWH.",{"entities":[[0,3,"CONDITION"],[14,35,"CONDITION"],[61,64,"CONDITION"]]}],["efficacious treatments CMD exist, scaling treatment routine health care low- middle-income (LMIC) settings require stakeholder engagement effectiveness implementation data inform scale sustainability.",{"entities":[[23,26,"CONDITION"]]}],["study team integrated efficacious interventions antenatal (ANC) HIV care Kenya.",{"entities":[[34,47,"INTERVENTION"],[59,62,"INTERVENTION"],[64,67,"CONDITION"],[73,78,"COUNTRY"]]}],["investigators propose integrate proven mental health services collaborative care model, combined intensity evidence-based intervention (problem solving therapy), targeting social determinants HIV-related health PPWH (stigma IPV).",{"entities":[[39,52,"CONDITION"],[192,203,"CONDITION"],[211,215,"POPULATION"]]}],["Building current multidisciplinary approach HIV care Kenya, proposed Collaborative Care Model (CCM) utilize existing peer mentor mothers, non-specialist behavioral care managers, psychiatric nurses; incorporate consultant psychiatrist ANC/HIV care team.",{"entities":[[44,47,"CONDITION"],[53,58,"COUNTRY"],[60,99,"INTERVENTION"],[117,128,"OCCUPATION"],[179,197,"OCCUPATION"],[222,234,"OCCUPATION"]]}],["Guided EPIS (Exploration-Preparation-Implementation-Sustainment) framework, study goal integrate collaborative care perinatal CMD routine ANC/HIV services Kenya, assess costs cost-effectiveness approach, policy decision makers determine key considerations scale-up.",{"entities":[[116,129,"CONDITION"],[138,145,"INTERVENTION"],[155,160,"CONDITION"]]}],["Specifically, Aim 1, investigators identify contextual barriers facilitators refine optimal integration model delivering collaborative care model multimethod data collection (focus providers, in-depth interviews key informants, clinic readiness checklist).",{"entities":[]}],["workshop study Advisory Board comprising county national level stakeholders, investigators translate findings locally relevant CCM.",{"entities":[[127,130,"INTERVENTION"]]}],["Aim 2, investigators CCM antenatal care PPWH hybrid type 2 implementation-effectiveness trial stepped wedge design 15 primary health care facilities southwestern Kenya.",{"entities":[[21,24,"INTERVENTION"],[40,44,"POPULATION"],[149,161,"LOCATION"],[162,167,"COUNTRY"]]}],["investigators introduce CCM care PPWH diagnosed CMD antenatal care.",{"entities":[[24,27,"INTERVENTION"],[33,37,"POPULATION"],[48,51,"CONDITION"]]}],["co-primary health outcomes 12 months postpartum (1) recovery depression anxiety symptoms PPWH, (2) proportion PPWH sustained viral suppression retention HIV care.",{"entities":[[37,47,"CONDITION"],[61,71,"CONDITION"],[72,79,"CONDITION"],[89,93,"POPULATION"],[110,114,"POPULATION"],[153,156,"CONDITION"]]}],["Key implementation outcomes feasibility acceptability.",{"entities":[]}],["Finally, Aim 3, investigators refine CCM implementation strategies cost-effectiveness dissemination research.",{"entities":[[37,40,"INTERVENTION"]]}],["investigators carry costing cost-effectiveness analysis invite policy decision-makers participate nominal technique process elucidate factors scale sustainment CCM approach.",{"entities":[[160,163,"INTERVENTION"]]}],["Findings study guide development scalable model adaptable LMIC settings, contributing global HIV maternal health goals addressing burden untreated CMD.",{"entities":[[93,96,"CONDITION"],[147,150,"CONDITION"]]}],["",{"entities":[]}],["Poor person-centered maternal care (PCMC) contributes maternal mortality morbidity, indirectly, lack of, delayed, inadequate, unnecessary, harmful care.",{"entities":[[5,34,"INTERVENTION"]]}],["proposed R01 effectiveness intervention targets provider stress bias improve PCMC.",{"entities":[[77,81,"INTERVENTION"]]}],["investigators accomplish 3 aims.",{"entities":[]}],["Aim 1: assess effectiveness CPIPE intervention PCMC Kenya Ghana.",{"entities":[[28,46,"INTERVENTION"],[47,51,"INTERVENTION"],[52,57,"COUNTRY"],[58,63,"COUNTRY"]]}],["investigators hypothesize CPIPE improve PCMC women, SES women.",{"entities":[[40,44,"INTERVENTION"]]}],["primary outcome PCMC measured PCMC scale multiple cross-sectional surveys mothers birth preceding 12 weeks study facilities baseline (prior intervention), midline (6 months post-baseline), endline (12 months post-baseline) (N=2000 time point).",{"entities":[[16,20,"INTERVENTION"],[30,34,"INTERVENTION"]]}],["sub-aim 1 assess cost-effectiveness CPIPE.",{"entities":[]}],["Aim 2: examine mechanisms impact CPIPE PCMC.",{"entities":[]}],["investigators assess CPIPE intermediate outcomes provider knowledge, self-efficacy, stress, burnout, bias levels; conduct mediation analysis assess outcomes account CPIPE PCMC.",{"entities":[[165,170,"INTERVENTION"],[171,175,"INTERVENTION"]]}],["Aim 3: assess impact CPIPE intervention distal outcomes including maternal health seeking behavior maternal neonatal health; examine PCMC account effects.",{"entities":[[21,39,"INTERVENTION"],[99,116,"POPULATION"],[133,137,"INTERVENTION"]]}],["",{"entities":[]}],["goal randomized, clinical trial compare placebo vaginal films HIV seronegative adult (18-45 old) persons assigned female sex birth risk acquiring HIV infection, sexual partners evaluable participants.",{"entities":[[40,47,"INTERVENTION"],[48,55,"BODY_PART"],[62,65,"CONDITION"],[79,96,"POPULATION"],[146,159,"CONDITION"],[161,176,"POPULATION"]]}],["Participants recruited sites, sub-Saharan Africa.",{"entities":[[30,48,"LOCATION"]]}],["100 participants randomized (1:1), stratified site, insert placebo vaginal film placebo vaginal film B, shape, monthly months.",{"entities":[[59,66,"INTERVENTION"],[67,74,"BODY_PART"]]}],["Participants refrain sexual activity month resume usual sexual activity month insertion film film assigned month.",{"entities":[]}],["Differences safety, acceptability, usability, social harms benefits, vaginal microenvironment films study phases (i.e., sexual abstinence requirement) assessed.",{"entities":[]}],["addition, participants 30 sexual partners evaluable participants depth interviews assess acceptability, attitudes, experiences film gauge future vaginal films HIV prevention option.",{"entities":[[145,152,"BODY_PART"],[159,162,"CONDITION"]]}],["",{"entities":[]}],["low- middle-income countries, children experience episode Shigella-attributable diarrhea 2 life.",{"entities":[[30,38,"POPULATION"],[58,79,"CONDITION"],[80,88,"CONDITION"]]}],["addition leading diarrhea, enteric bacterium linear growth faltering, precursor stunting.",{"entities":[[17,25,"CONDITION"]]}],["Stunting marker vulnerability childhood infection, decreased vaccine efficacy lifelong morbidity.",{"entities":[[30,39,"POPULATION"]]}],["Currently, promising Shigella vaccines development.",{"entities":[[21,29,"CONDITION"]]}],["Eventual Phase 2b/3 Shigella vaccine trials require consortium potential vaccine trial sites settings incidence Shigella-attributed medically-attended diarrhea, participant retention, laboratory capacity confirm Shigella infection.",{"entities":[[20,28,"CONDITION"],[29,36,"INTERVENTION"],[73,80,"INTERVENTION"],[112,131,"CONDITION"],[151,159,"CONDITION"],[212,220,"CONDITION"]]}],["Enterics Global Health (EFGH) Shigella burden study employ cross-sectional longitudinal study designs establish updated incidence rates document consequences Shigella diarrhea 7 country sites Africa, Asia, Latin America.",{"entities":[[0,22,"ORG"],[30,38,"CONDITION"],[59,93,"STUDY_DESIGN"],[158,175,"CONDITION"],[192,198,"LOCATION"],[200,204,"LOCATION"],[206,219,"LOCATION"]]}],["two-year period, EFGH study enroll 9,800 children (1,400 country site) 6-35 months medically-attended diarrhea.",{"entities":[[17,21,"ORG"],[102,110,"CONDITION"]]}],["multi-country surveillance network, selected EFGH sites ready implement rigorous efficient vaccine trials provide critical data policy makers relative vaccine-preventable disease, accelerating time vaccine availability uptake children Shigella burden settings.",{"entities":[[45,49,"ORG"],[91,98,"INTERVENTION"],[151,170,"INTERVENTION"],[198,205,"INTERVENTION"],[226,234,"POPULATION"],[235,243,"CONDITION"]]}],["Primary Aims 1.",{"entities":[]}],["Determine incidence Shigella-attributed medically-attended diarrhea children 6 35 months age EFGH country sites.",{"entities":[[20,39,"CONDITION"],[59,67,"CONDITION"],[68,92,"POPULATION"],[93,97,"ORG"]]}],["Secondary Aims 1.",{"entities":[]}],["Determine incidence Shigella medically-attended diarrhea serotype, severity definition, laboratory method (culture vs.",{"entities":[[20,28,"CONDITION"],[48,56,"CONDITION"]]}],["qPCR), age, season.",{"entities":[]}],["2.",{"entities":[]}],["prevalence resistance commonly antibiotics Shigella isolates EFGH country site.",{"entities":[[61,65,"ORG"]]}],["3.",{"entities":[]}],["Determine risk death, hospitalization, persistent diarrhea, diarrhea recurrence, linear growth faltering 3 months episode Shigella medically-attended diarrhea.",{"entities":[]}],["4.",{"entities":[]}],["Compare severity definitions ability distinguish Shigella non-Shigella attributable diarrhea ability predict risk death hospitalization subsequent 3 months.",{"entities":[]}],["5.",{"entities":[]}],["Quantify cost incurred families health care systems Shigella morbidity mortality.",{"entities":[]}],["6.",{"entities":[]}],["Identify optimal laboratory methods Shigella culture by: 1.",{"entities":[]}],["comparing isolation rate Shigella transport media rectal swabs (Cary-Blair modified Buffered Glycerol Saline \\\\[BGS\\\\]) 2.",{"entities":[]}],["comparing isolation rate Shigella fecal sample types (rectal swabs stool) subset children produced stool Gambia Bangladesh country sites.",{"entities":[[25,33,"CONDITION"],[105,111,"COUNTRY"],[112,122,"COUNTRY"]]}],["",{"entities":[]}],["Rationale: Meplazumab, erythrocytic stage-macromolecular antibody drug, potential control clinical occurrence falciparum malaria.",{"entities":[[11,21,"DRUG"],[110,128,"CONDITION"]]}],["Meplazumab humanized anti-CD147 immunoglobulin subclass 2 (IgG2) monoclonal antibody strong affinity CD147.",{"entities":[[0,10,"DRUG"],[21,64,"BIOLOGICAL"],[101,106,"BIOLOGICAL"]]}],["CD147 expressed erythrocyte lineage cells erythroid development, including mature erythrocytes target Plasmodium merozoites reorientation subsequent invasion erythrocytes.",{"entities":[[0,5,"BIOLOGICAL"],[16,27,"BIOLOGICAL"],[82,94,"BIOLOGICAL"],[102,112,"BIOLOGICAL"],[113,123,"BIOLOGICAL"],[158,170,"BIOLOGICAL"]]}],["Nonclinical studies demonstrated meplazumab binding CD147 interferes receptor-ligand interaction CD147 rhoptry-associated protein 2 (RAP2) P.",{"entities":[[33,43,"DRUG"],[52,57,"BIOLOGICAL"],[122,140,"BIOLOGICAL"]]}],["falciparum merozoite inhibits formation parasitophorous vacuoles P.",{"entities":[[0,20,"BIOLOGICAL"],[40,64,"BIOLOGICAL"]]}],["falciparum preventing invasion P.",{"entities":[[0,10,"BIOLOGICAL"]]}],["falciparum human erythrocytes.",{"entities":[[0,10,"BIOLOGICAL"],[17,29,"BIOLOGICAL"]]}],["Furthermore, therapeutic prophylactic effects meplazumab demonstrated vivo human erythrocyte chimeric NOG mouse model, considered optimal choice vivo inhibition efficacy study human-hosted P.",{"entities":[[46,56,"DRUG"],[81,92,"BIOLOGICAL"]]}],["falciparum.",{"entities":[[0,10,"BIOLOGICAL"]]}],["Meplazumab studied healthy participants Phase 1 studies evaluated activity 2 completed clinical trials patients diagnosed coronavirus disease 2019 (COVID 19).",{"entities":[[0,10,"DRUG"],[122,146,"CONDITION"],[148,156,"CONDITION"]]}],["safety, tolerability, pharmacokinetics study healthy participants, MPZ I-01, demonstrated prolonged receptor occupancy (RO%) meplazumab CD147.",{"entities":[[125,135,"DRUG"],[136,141,"BIOLOGICAL"]]}],["Phase 2a study designed dose escalation trial assess safety meplazumab target population evaluate meplazumab efficacious treating malaria.",{"entities":[[60,70,"DRUG"],[98,108,"DRUG"],[130,137,"CONDITION"]]}],["data study determine recommended meplazumab dose future Phase 2b 3 efficacy trials.",{"entities":[[33,43,"DRUG"]]}],["Design: Phase 2a multicenter, open-label, dose-finding, dose escalation study.",{"entities":[]}],["study recruit participants confirmed P.",{"entities":[]}],["falciparum infection.",{"entities":[[0,10,"BIOLOGICAL"]]}],["60 participants enrolled 1 3 meplazumab dose levels (20 participants /dose level).",{"entities":[]}],["Participants: 60 participants enrolled 1 3 meplazumab dose levels (20 participants/dose level).",{"entities":[]}],["Intervention Duration: Participants administered single intravenous (IV) infusion dose meplazumab 120±5 minutes Day 0 confined 72 hours dosing (up Day 3) monitor safety tolerability therapy, ensure treatment response.",{"entities":[]}],["confinement, blood sampling safety, pharmacokinetic (PK), pharmacodynamic (PD) testing predefined times collected Schedule Assessment (SoA).",{"entities":[]}],["Furthermore, subset participants/dose level, additional (serial) PD sample collected 1, 2, 4 8 hours post end-of-infusion.",{"entities":[]}],["3 additional samples Day 0-3 serial sample collection period.",{"entities":[]}],["clinically well, participants discharged clinical unit Day 3 Investigator's discretion.",{"entities":[]}],["Participants return study center follow-up visits Days 28±2, 56±7, 84±7 182±7 (End Study) safety, tolerability, PK, PD (RO rate), immunogenicity assessments SoA (Weeks 4, 8, 12 26).",{"entities":[]}],["",{"entities":[]}],["Participants enrolled sites, USA, Kenya, South Africa, 20 site.",{"entities":[[29,33,"COUNTRY"],[34,39,"COUNTRY"],[41,53,"COUNTRY"]]}],["Participants randomized (1:1) receive placebo TAF/EVG vaginal insert randomized (1:1:1) 3 tissue sampling time post-treatment (24hr, 48hr 72hr dose).",{"entities":[]}],["Participants complete 8 study visits clinical behavioral evaluations, subset complete in-depth interview assess acceptability vaginal insert use.",{"entities":[]}],["",{"entities":[]}],["study intends investigate experiences nurses patients specific brand device 'neospot' device county, health centres Kenya.",{"entities":[[38,44,"OCCUPATION"]]}],["study aims finding device rate efficiency nurses facilities.",{"entities":[[42,48,"OCCUPATION"]]}],["study apply cross sectional design, facilities sampling frame urban facilities Nairobi County peri urban rural facility Kajiado county.",{"entities":[[79,86,"LOCATION"],[120,127,"LOCATION"]]}],["participants selected randomly.",{"entities":[]}],["Data total 159 randomly selected patients, nurses duty included participants study team leaders interviewed key informants qualitative data.",{"entities":[[43,49,"OCCUPATION"]]}],["Quantitative data analysed SPSS version 24 descriptive inferential statistics, NVIVO software analyse qualitative data determine themes.",{"entities":[]}],["Study Duration: Data collection, analysis report writing 4 ½ months.",{"entities":[]}],["",{"entities":[]}],["investigators developed mobilization strategy integrating HIV testing multi-disease screening recruit \\\\>2,000 people drinking venues Kenya Uganda invite biomedical HIV prevention eligible (OPAL Aim 1; NCT05862857) uptake biomedical HIV prevention, persons heavy alcohol challenges retention care adherence PrEP/PEP.",{"entities":[[58,61,"CONDITION"],[134,139,"COUNTRY"],[140,146,"COUNTRY"],[165,168,"CONDITION"],[307,315,"DRUG"]]}],["investigators adapted alcohol counseling intervention (Health Living Intervention) reduce alcohol promote antiretroviral therapy (ART) adherence HIV viral suppression persons HIV Kenya Uganda.",{"entities":[[22,29,"SUBSTANCE"],[55,81,"INTERVENTION"],[106,133,"DRUG"],[145,148,"CONDITION"],[175,178,"CONDITION"],[179,184,"COUNTRY"],[185,191,"COUNTRY"]]}],["investigators determine intervention promote retention biomedical prevention PrEP/PEP adherence adults heavy alcohol use.",{"entities":[[109,116,"SUBSTANCE"]]}],["Specific Aims: * Determine efficacy Healthy Living Intervention (HLI) reduce heavy alcohol vs.",{"entities":[[83,90,"SUBSTANCE"]]}],["standard care (control) retention biomedical HIV prevention randomized trial adults heavy alcohol use.",{"entities":[[45,48,"CONDITION"],[90,97,"SUBSTANCE"]]}],["* Determine cost-effectiveness interventions increase biomedical HIV prevention retention adults high-risk HIV attend drinking venues.",{"entities":[[65,68,"CONDITION"],[107,110,"CONDITION"]]}],["proposed address critical intersection alcohol HIV risk SSA, promoting retention biomedical HIV prevention exploring facilitators barriers.",{"entities":[[47,50,"CONDITION"],[56,59,"LOCATION"]]}],["",{"entities":[]}],["Background: Kenya, 17% women unmet family planning (FP) modern contraceptive prevalence rate (mCPR) plateaued 45%, contributing poor reproductive health outcomes.",{"entities":[[12,17,"COUNTRY"],[35,50,"INTERVENTION"],[56,76,"INTERVENTION"]]}],["includes 50% women Kenya report pregnancy unintended, experiencing gender-based violence (GBV), forms intimate partner violence (IPV) reproductive coercion (RC; behaviors reduce women's ability contraception prevent pregnancy), risk.",{"entities":[[32,41,"CONDITION"],[67,94,"PUBLIC_HEALTH_CONCERN"],[102,133,"PUBLIC_HEALTH_CONCERN"],[216,225,"CONDITION"]]}],["LMIC settings, RC IPV highly prevalent Kenya, women seeking FP reproductive health services (\\\\>1/3 female FP clients).",{"entities":[[18,21,"PUBLIC_HEALTH_CONCERN"],[39,44,"COUNTRY"],[46,51,"POPULATION"],[60,62,"INTERVENTION"]]}],["2013, Health Organization (WHO) recommended IPV RC addressed reproductive health services and, 2018, Lancet Commission Sexual Reproductive Health Rights RC IPV contributor unmet FP unintended pregnancy, impacts women girls LMICs.",{"entities":[[6,31,"ORG"],[101,152,"ORG"],[178,180,"INTERVENTION"],[192,201,"CONDITION"],[211,216,"POPULATION"],[217,222,"POPULATION"]]}],["Kenya, Ministry Health (MOH) reduction unintended pregnancy gender-based violence (GBV), adolescents, primary objective.",{"entities":[[0,5,"COUNTRY"],[7,28,"ORG"],[50,59,"CONDITION"],[60,87,"PUBLIC_HEALTH_CONCERN"],[89,100,"POPULATION"]]}],["guidance, clinic-based intervention models U.S.",{"entities":[[10,35,"INTERVENTION"]]}],["(apart one, ARCHES) demonstrated efficacy improve FP uptake/use reduce IPV RC reducing unintended pregnancy.",{"entities":[[12,18,"INTERVENTION"]]}],["Intervention Description: ARCHES (Addressing Reproductive Coercion Health Settings) brief, clinic-based intervention delivered family planning providers aiming to: 1) Increase women's girls' ability family planning reproductive coercion, facilitating women's voluntary family planning uptake continued interference, 2) Provide safe supportive environment IPV disclosure subsequent referral support services, 3) Educate support providers improve quality care family planning counseling, including addressing reproductive coercion intimate partner violence.",{"entities":[[26,83,"INTERVENTION"],[127,142,"INTERVENTION"],[176,189,"POPULATION"],[251,258,"POPULATION"],[355,358,"PUBLIC_HEALTH_CONCERN"],[529,554,"PUBLIC_HEALTH_CONCERN"]]}],["Objective: objective study generate evidence learnings scaling integrated family planning services (including family planning, reproductive coercion, intimate partner violence) public sector health facilities Uasin Gishu County, Kenya adaptation implementation ARCHES, partnership Kenya MOH.",{"entities":[[74,89,"INTERVENTION"],[150,175,"PUBLIC_HEALTH_CONCERN"],[209,227,"LOCATION"],[229,234,"COUNTRY"],[261,267,"INTERVENTION"],[287,290,"ORG"]]}],["Methodology: cluster randomized controlled trial paired concurrent implementation science assessments effectiveness ARCHES model adapted scale Kenya MOH.",{"entities":[[13,42,"STUDY_DESIGN"],[116,122,"INTERVENTION"],[143,148,"COUNTRY"],[149,152,"ORG"]]}],["Female family planning clients aged 15-49 selected sites complete baseline surveys (immediately prior receiving care), post-visit exit surveys, 6-month follow-up surveys.",{"entities":[]}],["Family planning providers trained ARCHES complete pre-training, post-training, 3-month follow-up surveys assess gender-equitable attitudes self-efficacy address issues violence clients.",{"entities":[[0,25,"OCCUPATION"],[34,40,"INTERVENTION"]]}],["Costs scale-up strategy tracked utilized combination effectiveness trial assess total cost cost-effectiveness ARCHES.",{"entities":[]}],["",{"entities":[]}],["multi-center, double-blinded, placebo-controlled, Phase study evaluate safety, tolerability, immunogenicity single dose cAd3-Sudan Ebolavirus vaccine healthy adults 70 age, Uganda Kenya.",{"entities":[[0,48,"STUDY_DESIGN"],[120,149,"INTERVENTION"],[173,179,"COUNTRY"],[180,185,"COUNTRY"]]}],["study enroll 125 eligible participants randomized 4:1 receive cAd3-Sudan Ebolavirus vaccine 1.0 × 10\\\\^11 PU dose placebo (0.9% sodium chloride (NaCl) solution) Day 1, intramuscularly deltoid muscle.",{"entities":[[62,91,"INTERVENTION"],[184,198,"BODY_PART"]]}],["Participants screened eligibility 28 days enrollment.",{"entities":[]}],["Enrollment staggered, starting healthy adults 18 50 age (inclusive).",{"entities":[]}],["enrollment minimum 25 adult participants (sentinel), safety data 7 days post vaccination 25 sentinel participants reviewed independent Data Safety Monitoring Board (DSMB).",{"entities":[[22,27,"POPULATION"],[135,170,"ORG"]]}],["Progression enrollment adults (\\\\>50 70 age) dependent unblinded review DSMB.",{"entities":[[72,76,"ORG"]]}],["Safety immunogenicity assessed Days 1, 8, 15, 29, 85, 169, conclude study visit Day 366.",{"entities":[[7,21,"BIOLOGICAL"]]}],["",{"entities":[]}],["REACH prospective, phase I/II open-label dose escalation trial hydroxyurea children confirmed SCA 3 age.",{"entities":[[19,40,"STUDY_DESIGN"],[63,74,"DRUG"],[75,83,"POPULATION"],[94,97,"CONDITION"]]}],["short-term goal critical pilot data feasibility, safety, benefit hydroxyurea children SCA multiple distinct settings Africa.",{"entities":[[65,76,"DRUG"],[77,85,"POPULATION"],[117,123,"LOCATION"]]}],["Based information, longer-term goal hydroxyurea children SCA Africa, identified SCA expanded newborn screening programs.",{"entities":[[36,47,"DRUG"],[48,56,"POPULATION"],[57,60,"CONDITION"],[61,67,"LOCATION"],[80,83,"CONDITION"]]}],["REACH prospective trial, Original Cohort receive long-term treatment Cohort, treatment continue 4 PK-guided dosing initial 3-month screening period.",{"entities":[]}],["",{"entities":[]}],["Background: urban peri-urban Kenya, Consumption vegetables pyramid (BoP) households, earn \\\\< 3.20 dollars person day.",{"entities":[[29,34,"COUNTRY"]]}],["increase vegetable consumption population, GAIN implement Vegetables program, aims improve access safe fresh vegetables Fit Food Zones (FFZs) generate demand vegetables radio/television campaign FFZ branding.",{"entities":[]}],["main retailers FFZ mama mbogas (vegetable vendors), linked suppliers Agricultural Practices (GAP) compliant.",{"entities":[[19,30,"POPULATION"]]}],["Objective: objectives evaluation are: 1) assess effectiveness GAIN's Vegetables program increasing quantity vegetables consumed improving diet quality BoP consumers 2) conduct process evaluation GAIN's program data support findings impact evaluation.",{"entities":[]}],["Methods: study mixed-methods quasi-experimental design 124 FFZs assigned intervention control Nairobi, Kiambu, Machakos, Mombasa, Nakuru counties.",{"entities":[[94,101,"LOCATION"],[103,109,"LOCATION"],[111,119,"LOCATION"],[121,128,"LOCATION"],[130,136,"LOCATION"]]}],["impacts assessed cross-sectional population-based surveys households women 18-49 child 3-11 62 intervention 62 control FFZs baseline endline (N=1,364 time point).",{"entities":[[17,32,"STUDY_DESIGN"]]}],["Mama mboga surveys conducted 124 sampled FFZs baseline, midline, endline (N=372 time point).",{"entities":[[0,10,"POPULATION"]]}],["Qualitative data collected midline endline.",{"entities":[]}],["In-depth interviews (IDIs) conducted vegetable chain actors stakeholders (N=18 time point).",{"entities":[]}],["Focus discussions (FGDs) conducted mama mbogas (20 FGDs time point) household (20 FGDs time point).",{"entities":[[0,24,"STUDY_DESIGN"],[35,46,"POPULATION"],[51,55,"STUDY_DESIGN"],[82,86,"STUDY_DESIGN"]]}],["analysis performed difference-in-difference estimation (surveys) thematic content analysis methods (qualitative).",{"entities":[[65,90,"STUDY_DESIGN"]]}],["",{"entities":[]}],["Malnutrition forms prevalent resource limited settings driven diet quality, food preparation feeding practices including hygiene.",{"entities":[[0,12,"CONDITION"]]}],["Untreated childhood malnutrition deprives child living potential, increasing susceptibility childhood infections life threatening.",{"entities":[[10,19,"POPULATION"],[20,32,"CONDITION"],[92,101,"POPULATION"]]}],["Insects alleviating malnutrition energy density, protein, vitamins micronutrients (iron, zinc).",{"entities":[[20,32,"CONDITION"]]}],["Crickets positively support growth probiotics (Bifidobacterium animalis) support gut health increasing nutrient absorption reduces systemic inflammation.",{"entities":[[47,62,"BIOLOGICAL"]]}],["Single nutrition interventions confirmed effective reducing malnutrition stunting particular, combination nutrition-specific nutrition-sensitive interventions yielding outcome.",{"entities":[[60,72,"CONDITION"],[73,81,"CONDITION"]]}],["spite recognizing nutritional insects contribution cricket improved gut health, limited evidence benefit cricket based complementary food reducing stunting infants children.",{"entities":[[68,71,"BODY_PART"],[147,155,"CONDITION"],[156,172,"POPULATION"]]}],["study aims determine integrating nutrition interventions (cricket enriched porridge nutrition education) infant child growth (stunting status) gut health rural Kenya; Alego Usonga Sub-County Siaya County.",{"entities":[[58,83,"INTERVENTION"],[105,117,"POPULATION"],[143,146,"BODY_PART"],[160,165,"COUNTRY"],[167,190,"LOCATION"],[191,203,"LOCATION"]]}],["study based 2x2 factorial design infants aged 6 months target assess main combined interventions (nutrition education cricket enriched porridge) infant child's stunting gut health.",{"entities":[[33,40,"POPULATION"],[145,151,"POPULATION"],[152,159,"POPULATION"],[160,168,"CONDITION"],[169,172,"BODY_PART"]]}],["study arms namely: Control arm (CA) study participants receive standard care comprising supercereal Corn Soy Blend (CSB+) amounts adjusted age, Enriched nutrition arm (ENA) receive improved complementary food enriched cricket optimized benefits cricket amounts adjusted age, Nutrition education arm (NEdA) receive nutrition education Combined Nutrition Education enriched nutrition (CEdNA).",{"entities":[[88,121,"INTERVENTION"]]}],["required sample size (based parameters: groups: = 4, size = 0.2, significance level = 0.05, power = 80%) 70 study participants study arm yielding total 280.",{"entities":[]}],["",{"entities":[]}],["Phase 1 dose finding dose verification study determine dose S.",{"entities":[]}],["sonnei 53G induces primary outcome ≥60% Kenyan adult volunteers.",{"entities":[]}],["study occur phases, Phase (dose-finding) 40 volunteers challenged 53G Phase (dose verification) N=30 volunteers planned administered 53G.",{"entities":[]}],["Based published data model, 1,500 colony-forming units (CFU) dose administered cohort.",{"entities":[]}],["Dosing subsequent cohorts depend previous cohort.",{"entities":[]}],["lower-than-expected attack rate (AR) occurs, dose cohort increased 500 CFU.",{"entities":[]}],["Conversely, expected dose cohort decreased 500 CFU.",{"entities":[]}],["Cohorts volunteers continue challenged either; dose reproducibly infection 60% volunteers; safety precludes continuing (\\\\>90% 500 CFU) futility (an 60% unable achieved, 3000 CFU dose).",{"entities":[]}],["3 dose-finding optimal dose primary outcome (shigellosis) achieved ≥60% volunteers total volunteers enrolled phases N=60.",{"entities":[]}],["optimal dose established Phase A, dose carried verification Phase B.",{"entities":[]}],["Phase B, dose verification 30 volunteers (2 cohorts 15 volunteers cohort) conducted verify chosen dose.",{"entities":[]}],["dose finding verification stages staggered fashion dose adjusted, 5 cohorts enrolled time.",{"entities":[]}],["Allocation \"\"first served basis\"\" randomization occurring enrolment cohorts.",{"entities":[]}],["",{"entities":[]}],["adolescent people period crucial life transitions fraught range internal external challenges.",{"entities":[[0,10,"POPULATION"]]}],["people low- middle-income countries (LMICs) vulnerable mental health exposure multiple adverse life experiences.",{"entities":[[55,68,"CONDITION"]]}],["Positive psychological interventions brought social-emotional learning curriculum western countries efficacy supporting salutary effects health wellbeing people.",{"entities":[[9,22,"CONDITION"]]}],["LMICs, access psychologists psychiatrists, models limited application people struggling.",{"entities":[[14,27,"OCCUPATION"],[28,41,"OCCUPATION"]]}],["primary goal project design effects mental health well-being outcomes arts-based train-the-trainer intervention, cultivating gratitude, kindness, hope youth schools informal settlements.",{"entities":[[36,49,"CONDITION"]]}],["central change theory cultivating key strengths, youth experience empowering mind-set shifts prepare navigate past, present, future life challenges, including mental illness.",{"entities":[[159,173,"CONDITION"]]}],["create robustly tested, adaptable, scalable intervention speaks realities people schools informal settlements LMICs, project integrate fields character development, positive psychology, mental health.",{"entities":[[186,199,"CONDITION"]]}],["project support cross-border collaboration bridge rich diverse sectors.",{"entities":[]}],["bring specialists LMICs high-income countries (HICs), mental health character development professionals, youth adult researchers, produce fundamental evidence nexus character development health outcomes.",{"entities":[]}],["project single-blind cluster randomized controlled trial design clusters 60 people schools 30 communities recruited informal settlements Nairobi India.",{"entities":[[8,56,"STUDY_DESIGN"],[137,144,"LOCATION"],[145,150,"COUNTRY"]]}],["evaluation employ mixed methods approach determine impact intervention mental wellbeing people.",{"entities":[]}],["Quantitative data collected survey baseline end-line focus discussions (FGD) conducted end-line.",{"entities":[[28,43,"STUDY_DESIGN"]]}],["analyzed STATA NVivo softwares respectively.",{"entities":[]}],["project proposes that, model evidence generated innovative ways: 1) designed scale low-resource settings takes replicability account start.",{"entities":[]}],["2) intervention's accessibility diverse range youth LMICs, including marginalized, considered start; 3) departs traditional approach testing interventions based individual character strengths weave gratitude, kindness, hope integrated life (past, present, future) approach and; 4) focus people's leadership ability support peers.",{"entities":[]}],["Character strengthening independent critical thinking inherently required developing leaders.",{"entities":[]}],["outcome study ability lead oneself compassion signifies likelihood longer-term impact character strengthening intervention.",{"entities":[]}],["Findings study contribute improving mental health policies programs.",{"entities":[]}],["",{"entities":[]}],["study goal characterize assess implementation enhanced service delivery package providing informed choice pre-exposure prophylaxis (PrEP) products women U.S.",{"entities":[[106,137,"DRUG"]]}],["President's Plan AIDS Relief/U.S.",{"entities":[[17,21,"CONDITION"]]}],["Agency International Development (PEPFAR/USAID) delivery sites Kenya, Lesotho, South Africa, Uganda, Zimbabwe.",{"entities":[[0,32,"ORG"],[33,47,"ORG"],[63,68,"COUNTRY"],[70,77,"COUNTRY"],[79,91,"COUNTRY"],[93,99,"COUNTRY"],[101,109,"COUNTRY"]]}],["study conducted stages, approved oral PrEP PrEP rings offered Stage I, addition CAB PrEP Stage approved regulatory authority country.",{"entities":[[33,42,"DRUG"],[43,47,"DRUG"]]}],["study goal accomplished conducting mixed-methods implementation study involving components: 1.",{"entities":[[35,48,"STUDY_DESIGN"]]}],["Component 1: Prospective cohort study women PEPFAR/USAID delivery sites delivering HIV PrEP, including daily oral PrEP, monthly PrEP rings, bimonthly CAB PrEP 1.",{"entities":[[44,56,"ORG"],[87,91,"DRUG"],[114,118,"DRUG"]]}],["Descriptive nested cohort study evaluate performance characteristics HIV testing strategies participants initiate CAB PrEP 2.",{"entities":[]}],["Descriptive nested cohort study evaluate feasibility validity prevention effective (PEU) measure subset PrEP users 2.",{"entities":[]}],["Component 2: Mixed-methods process evaluation involving implementers key stakeholders 1.",{"entities":[]}],["Nested costing study Lesotho, Uganda, Zimbabwe study sites 2.",{"entities":[[21,28,"COUNTRY"],[30,36,"COUNTRY"],[38,46,"COUNTRY"]]}],["Nested qualitative study understand community acceptance PrEP informed choice PrEP products",{"entities":[]}],["",{"entities":[]}],["Low- middle-income countries (LMIC) bear brunt non-intentional traumatic injury.",{"entities":[[63,79,"CONDITION"]]}],["fact, millions people die injury year, 90% mortality faced LMICs.",{"entities":[]}],["additional 650 people suffer disabilities worldwide.",{"entities":[]}],["expansion emergency medical services (EMS) low- middle-income countries address 45% deaths 36% total disease burden low-income countries.",{"entities":[]}],["However, emergency care, prehospital emergency medical services, priorities LMICs.",{"entities":[]}],["injury leading prehospital condition Africa, 91.3% African population EMS evidence EMS systems 61% African countries.",{"entities":[]}],["Sub-Saharan Africa affected, data emergency care demonstrates current combination patient volume mortality emergency care urgent focus future mortality-reducing interventions, 80% injury deaths occur prehospital setting low-resource settings compared 59% developed settings.",{"entities":[]}],["studies investigating programs training lay responders treat unaddressed traumatic injury burden undertaken mid- late-1990's.",{"entities":[]}],["Subsequent initial studies, Health Organization (WHO) recommended establishing lay responder systems step developing formal emergency medical services 2004.",{"entities":[]}],["However, global uptake guidelines limited, injury leading death people ages 15 45.",{"entities":[]}],["LMICs lack organized EMS systems, ambulances interfacility transport, emergency care vehicles.",{"entities":[]}],["2004 announcement, programs attempted leverage pre-existing networks responders, commercial drivers, lay persons, bystanders, provide proportion prehospital transport occasionally provide aid LMICs.",{"entities":[]}],["such, EMS development incongruous varied, lay responders (LFR) Model demonstrated program success heterogeneous regions.",{"entities":[]}],["Health Organization recommendation studies completed subsequently, aid laypeople victims trauma requires additional programs studies investigating responder training, program scalability, clinical implications trauma patients.",{"entities":[[89,95,"CONDITION"],[210,216,"CONDITION"]]}],["meet needs, primary objectives study evaluate educational efficacy clinical impact Massive Online (MOOC) LFR training international roll-out.",{"entities":[]}],["randomized control trial design arms identically deployed settings: Sierra Leone (Makeni), Nigeria (Lagos), Uganda (Mukono), Kenya (Kakamega).",{"entities":[[68,80,"COUNTRY"],[82,88,"LOCATION"],[91,98,"COUNTRY"],[100,105,"LOCATION"],[108,114,"COUNTRY"],[116,122,"LOCATION"],[125,130,"COUNTRY"],[132,140,"LOCATION"]]}],["control arm, participants assigned validated half-day responder assessed knowledge acquisition clinical skills performance.",{"entities":[]}],["experimental arm, participants assigned half-day MOOC assessed knowledge acquisition clinical skills performance.",{"entities":[]}],["Trainees arms monitored knowledge retention skill usage post-training.",{"entities":[]}],["Outcomes demonstrate relative efficacy MOOC compared traditional in-person training methods, inform LFR program scalability future EMS capacity building efforts.",{"entities":[]}],["",{"entities":[]}],["Limited HIV services risk primary reasons continued HIV transmission sub-Saharan Africa.",{"entities":[[8,11,"CONDITION"],[52,55,"CONDITION"],[69,87,"LOCATION"]]}],["Identifying engaging individuals-particularly 20% people living HIV unaware status-is major challenge met existing service delivery approaches.",{"entities":[[64,67,"CONDITION"]]}],["purchase sex (MPS) priority HIV-infected inherently challenging identify reach HIV services.",{"entities":[[28,40,"CONDITION"],[79,82,"CONDITION"]]}],["proposed project region Kenya HIV prevalence seeks promote engagement HIV testing, prevention, care MPS.",{"entities":[[24,29,"COUNTRY"],[30,33,"CONDITION"],[70,73,"CONDITION"]]}],["Preliminary data demonstrate \"\"secondary distribution\"\" HIV self-tests women sell sex (WSS) sexual partners acceptable, feasible, safe leads male partner testing.",{"entities":[]}],["However, post-self-test services seldom promoted measured secondary distribution model.",{"entities":[]}],["interdisciplinary experienced team Investigators address key gap.",{"entities":[]}],["project stepped wedge trial design innovative, well-targeted HIV self-test secondary distribution intervention promote uptake HIV services MPS.",{"entities":[]}],["Clusters served Ministry Health-supported HIV clinics randomized start time receive secondary distribution intervention.",{"entities":[]}],["investigators recruit WSS key population clinics transactional sex \"\"hot spots.\"\" WSS oral fluid-based HIV self-tests encouraged distribute male transactional sex partners.",{"entities":[]}],["Self-test kits include salient clinic location hours cluster, pilot-tested messaging ART initiation, availability benefits PrEP.",{"entities":[[85,88,"DRUG"],[123,128,"DRUG"]]}],["Aim 1, investigators evaluate programmatic data HIV clinics study clusters objectively determine intervention's impact uptake confirmatory testing, HIV diagnoses, ART initiation PrEP initiation men.",{"entities":[[48,51,"CONDITION"],[148,151,"CONDITION"],[163,166,"DRUG"],[178,182,"DRUG"],[194,197,"POPULATION"]]}],["Aim 2, investigators conduct process evaluation characterize factors influencing intervention effectiveness.",{"entities":[]}],["investigators assess secondary distribution patterns characterize MPS population receiving self-tests quantitative program data follow-up questionnaire enrolled WSS.",{"entities":[[0,13,"OCCUPATION"]]}],["investigators qualitative data in-depth interviews MPS, WSS clinic staff explore pathways contextual factors influencing accessed post-test services.",{"entities":[[0,13,"OCCUPATION"],[60,72,"OCCUPATION"]]}],["Aim 3, investigators compute incremental cost-effectiveness intervention inform decisions broader implementation.",{"entities":[[7,20,"OCCUPATION"]]}],["project potential break ground engage high-risk hard-to-reach populations HIV services.",{"entities":[[74,77,"CONDITION"]]}],["effective, approach adapted settings advance global goals HIV elimination.",{"entities":[[58,61,"CONDITION"]]}],["",{"entities":[]}],["study evaluate effectiveness one-stop PrEP services 12 public health facilities Kenya.",{"entities":[[38,42,"DRUG"],[80,85,"COUNTRY"]]}],["core implementation strategies optimize one-stop PrEP care include training healthcare providers, technical assistance, joint clinic supervision county health officials, abstraction program data PrEP initiations continuations including characteristics PrEP users quality improvement.",{"entities":[[49,53,"DRUG"],[145,168,"OCCUPATION"],[195,199,"DRUG"],[252,256,"DRUG"]]}],["program, study team recruit nested observational cohort detailed complementary individual clinical, behavioral, mental health outcomes (including clients discontinue PrEP).",{"entities":[[35,55,"STUDY_DESIGN"],[166,170,"DRUG"]]}],["",{"entities":[]}],["\\\\[BACKGROUND\\\\] Alcohol common risk factor HIV prevention uptake retention sub-Saharan Africa (SSA).",{"entities":[[17,24,"SUBSTANCE"],[44,47,"CONDITION"],[76,100,"LOCATION"]]}],["Interventions promote biomedical HIV prevention (PrEP PEP) persons heavy alcohol sexual partners urgently needed.",{"entities":[[33,36,"CONDITION"],[49,57,"DRUG"],[73,80,"SUBSTANCE"],[81,96,"POPULATION"]]}],["Alcohol-serving drinking venues play role sites HIV transmission SSA ideal sites engage women increased risk HIV biomedical prevention services.",{"entities":[[48,51,"CONDITION"],[65,68,"LOCATION"],[88,93,"OCCUPATION"],[109,112,"CONDITION"]]}],["\\\\[OVERVIEW\\\\] investigators developed mobilization strategy integrating HIV testing multi-disease screening recruit \\\\>2,000 people drinking venues Kenya Uganda.",{"entities":[[149,154,"COUNTRY"],[155,161,"COUNTRY"]]}],["investigators determine multi-disease mobilization promote uptake HIV prevention adults drinking venues context biomedical prevention options.",{"entities":[]}],["project rigorously innovative interventions Kenya Uganda increase uptake biomedical HIV prevention, assess facilitators, barriers, cost-effectiveness approaches.",{"entities":[]}],["Specific Aims: * Compare effectiveness mobilization strategies increase uptake biomedical HIV prevention adults drinking venues.",{"entities":[]}],["* Determine cost-effectiveness interventions increase biomedical HIV prevention uptake adults high-risk HIV attend drinking venues.",{"entities":[]}],["proposed address critical intersection alcohol HIV risk SSA, promoting reach uptake biomedical HIV prevention exploring facilitators barriers.",{"entities":[[47,50,"CONDITION"],[56,59,"LOCATION"]]}],["",{"entities":[]}],["expansion access Anti-Retroviral Treatment (ART) Middle-Income Countries (LMIC), increase HIV drug resistance.",{"entities":[[17,48,"DRUG"]]}],["recommended 1st-line regimen Tenofovir, Emtricitabine Efavirenz (TEE) drugs genetic barrier resistance.",{"entities":[[29,39,"DRUG"],[40,63,"DRUG"]]}],["result, acquired drug resistance mutations detected majority people TEE regions HIV-1 subtypes.",{"entities":[[68,71,"DRUG"]]}],["steady increase Pre-treatment Drug Resistance (PDR) ART coverage expanded LMIC.",{"entities":[]}],["recommends Dolutegravir (DTG) 1st -, 2nd 3rd-line ART adults adolescents.",{"entities":[[11,23,"DRUG"],[54,60,"POPULATION"],[61,72,"POPULATION"]]}],["Therefore, countries, PLHIV transitioned DTG-based regimen.",{"entities":[[22,27,"CONDITION"],[41,50,"DRUG"]]}],["DTG potent Integrase Strand Transfer Inhibitor (InSTI) efficacy safety profile Efavirenz 1st-line therapy Lopinavir/Ritonavir 2nd-line therapy.",{"entities":[[0,20,"DRUG"],[21,54,"DRUG"],[79,88,"DRUG"],[106,125,"DRUG"]]}],["DTG genetic barrier resistance, resistance ART-naïve individuals treated combination ART rare.",{"entities":[[0,3,"DRUG"],[85,88,"DRUG"]]}],["However, monotherapy, people pre-existing InSTI resistance, DTG risk virologic failure resistance.",{"entities":[[42,47,"DRUG"],[60,63,"DRUG"]]}],["study, investigators aim - 1.",{"entities":[]}],["Identify mutations combinations DTG Drug Resistance Mutations (DRMs).",{"entities":[[32,35,"DRUG"]]}],["2.",{"entities":[]}],["Identify risk factors virologic failure, development InSTI DRMs InSTI drug resistance.",{"entities":[[53,58,"DRUG"],[64,69,"DRUG"]]}],["3.",{"entities":[]}],["Check correlations resistance genotypes phenotypic DTG resistance HIV-1 subtypes.",{"entities":[]}],["Adults (≥18 years) adolescents (10-17 years) virologic failure (viral load ≥1000 copies/mL) DTG-based anti-retroviral treatment (1st-line, 2nd-line 3rd-line) 20-30 clinical sites regions IeDEA cohort recruited study.",{"entities":[[0,6,"POPULATION"],[19,30,"POPULATION"]]}],["study visit participant study observational embedded routine care, additional interventions.",{"entities":[]}],["obtaining informed consent, blood specimen study participants.",{"entities":[]}],["genome sequencing performed Illumina MiSeq platform identify Drug Resistance Mutations.",{"entities":[]}],["addition, DRMs mutation pathways explored viral genome-wide association study conjunctive Bayesian network approaches.",{"entities":[]}],["",{"entities":[]}],["study aims understand spatial analysis methods support assessment prediction geographical variation snakebite risk.",{"entities":[]}],["investigators analyse data collected community health facility surveys conducted geographically, ecologically demographically diverse Kenya Eswatini.",{"entities":[]}],["Data sources comprise existing snakebite incidence data countries prospective data collected adding snakebite questions planned health/demographic survey platforms feasible conducting stand-alone cluster-sampled surveys complement this.",{"entities":[]}],["Selected households invited complete short questionnaires covering sociodemographic details snakebite history.",{"entities":[]}],["Survey data compared health facility data collected locations assess relative bias data sources snakebite risk assessment.",{"entities":[]}],["Data analysed geostatistical techniques, predicted risk mapped sampled locations appropriate.",{"entities":[]}],["findings build knowledge spatial determinants snakebite countries support development risk mapping methodology snakebite.",{"entities":[[46,55,"CONDITION"],[111,120,"CONDITION"]]}],["Identification high-risk locations support advocacy resources guide treatment prevention activities.",{"entities":[]}],["Interviews conducted key stakeholders healthcare fields Kenya understand healthcare decision-making process outputs spatial analysis snakebite data support this.",{"entities":[[56,61,"COUNTRY"],[133,142,"CONDITION"]]}],["Interview aid development recommendations optimal presentation snakebite data support programmatic decision making.",{"entities":[[63,72,"CONDITION"]]}],["",{"entities":[]}],["investigators examine frequent virologic monitoring enhanced communication low-level viremia strategy identify support pregnant postpartum women risk virologic failure.",{"entities":[[119,144,"POPULATION"]]}],["Virologic monitoring reinforce adherence stable patients, frequent monitoring detect potential adherence challenges early.",{"entities":[]}],["Notably, low-level viremia strong predictor subsequent virologic failure, lowest level perinatal transmission known.",{"entities":[]}],["pilot study 6 months 4 Ministry Health facilities Kisumu County, Kenya; 275 participants enrolled.",{"entities":[[50,63,"LOCATION"],[65,70,"COUNTRY"]]}],["Prior pilot study, 125 controls enrolled prospectively, 150 controls abstracted records prior year.",{"entities":[]}],["",{"entities":[]}],["Phase 4 blinded, randomized, active-controlled, non-inferiority trial.",{"entities":[[0,27,"STUDY_DESIGN"]]}],["Persons gender identity eligible.",{"entities":[]}],["Final evaluable population include minimum 596 individuals: 298 persons assigned female sex birth (AFAB) confirmed urogenital chlamydia (CT) 298 persons assigned male birth (AMAB) confirmed rectal chlamydia (CT).",{"entities":[[115,135,"CONDITION"],[190,206,"CONDITION"]]}],["664 participants enrolled achieve minimum 596 participants contribute primary outcome data.",{"entities":[]}],["Randomization stratified study sex birth: 332 persons assigned female sex birth (AFAB) 332 persons assigned male sex birth (AMAB).",{"entities":[[0,24,"STUDY_DESIGN"]]}],["Participants randomized 1:1 3-day regimen doxycycline 7-day regimen doxycycline.",{"entities":[[42,53,"DRUG"],[68,79,"DRUG"]]}],["study blind maintained providing 7 days identical pre-filled blister packs, 3 days active treatment 4 days placebo, 7 days active treatment.",{"entities":[]}],["Participants return 28 days randomization (at day 29), time re-tested chlamydia (CT) laboratory-based chlamydia (CT) nucleic acid amplification (NAAT).",{"entities":[[70,79,"CONDITION"]]}],["primary objective compare efficacy 3-day vs.",{"entities":[]}],["7-day regimen doxycycline treatment urogenital chlamydia (CT) infection persons assigned female sex birth (AFAB) based proportion participants microbiologic cure (negative nucleic acid amplification \\\\[NAAT\\\\] vaginal swab positive nucleic acid amplification (NAAT) vaginal swab study treatment Day 29) Day 29.",{"entities":[[14,25,"DRUG"],[36,56,"CONDITION"]]}],["Also, compare efficacy 3-day vs.",{"entities":[]}],["7-day regimen doxycycline treatment rectal chlamydia (CT) infection persons assigned male sex birth (AMAB) based proportion participants microbiologic cure (negative nucleic acid amplification (NAAT) rectal swab positive nucleic acid amplification (NAAT) rectal swab study treatment Day 29) Day 29.",{"entities":[[43,52,"CONDITION"]]}],["secondary objectives compare efficacy 3-day vs.",{"entities":[]}],["7-day regimen doxycycline treatment rectal CT infection persons AFAB based microbiologic cure.",{"entities":[[14,25,"DRUG"]]}],["Also, compare efficacy 3-day vs.",{"entities":[]}],["7-day regimen doxycycline treatment urethral CT infection persons AMAB based microbiologic cure.",{"entities":[[14,25,"DRUG"],[36,57,"CONDITION"]]}],["addition, compare efficacy 3-day vs.",{"entities":[]}],["7-day regimen doxycycline treatment total CT infection (any anatomic site) persons AFAB AMAB based microbiologic cure.",{"entities":[[14,25,"DRUG"]]}],["Lastly, compare efficacy 3-day vs.",{"entities":[]}],["7-day regimen doxycycline treatment rectal CT infection persons AMAB based microbiologic cure, stratified lymphogranuloma venereum (LGV) status.",{"entities":[[14,25,"DRUG"],[106,136,"CONDITION"]]}],["",{"entities":[]}],["Vincristine effective chemotherapeutic agents pediatric oncology patients.",{"entities":[[0,11,"DRUG"],[22,45,"DRUG"]]}],["However, black African children optimally dosed genetic differences metabolism vincristine.",{"entities":[[79,90,"DRUG"]]}],["study aims optimize dosing regimen vincristine carefully monitoring toxicity.",{"entities":[[35,46,"DRUG"]]}],["prospective cohort study consisting parts: feasibility study rest study.",{"entities":[]}],["feasibility study, 15 children aged 5-14 scheduled receive 2 vincristine administrations included.",{"entities":[[61,72,"DRUG"]]}],["administration vincristine, venous blood samples finger prick blood samples determine vincristine concentrations.",{"entities":[[15,26,"DRUG"],[86,97,"DRUG"]]}],["samples shipped analyzed Netherlands determine vincristine concentration sample.",{"entities":[[25,36,"COUNTRY"]]}],["Based this, dose advise subsequent vincristine administrations.",{"entities":[[35,46,"DRUG"]]}],["cycle repeated maximum 2 times maximum 1 dose advice given.",{"entities":[]}],["Toxicity monitored determination bilirubin, questionnaires physical examination check signs peripheral neuropathy.",{"entities":[[33,42,"BIOLOGICAL"],[92,113,"CONDITION"]]}],["rest study, 85 children included, finger prick samples taken.",{"entities":[]}],["",{"entities":[]}],["multi-center, double-blinded, placebo-controlled, Phase study evaluate safety, tolerability, immunogenicity single dose cAd3-Marburg vaccine healthy adults 70 age, Uganda Kenya.",{"entities":[[0,48,"STUDY_DESIGN"],[93,107,"BIOLOGICAL"],[120,140,"INTERVENTION"],[164,170,"COUNTRY"],[171,176,"COUNTRY"]]}],["study enroll 125 eligible participants randomized 4:1 receive cAd3-Marburg vaccine 1.0 × 10\\\\^11 PU dose placebo (0.9% sodium chloride (NaCl) solution) Day 1, intramuscularly deltoid muscle.",{"entities":[[62,82,"INTERVENTION"],[175,189,"BODY_PART"]]}],["Participants screened eligibility 28 days enrollment.",{"entities":[]}],["Enrollment staggered, starting healthy adults 18 50 age (inclusive).",{"entities":[]}],["enrollment minimum 25 adult participants (sentinel), safety data 7 days post vaccination 25 sentinel participants reviewed independent DSMB.",{"entities":[]}],["Progression enrollment adults (\\\\>50 70 age) dependent unblinded review Data Safety Monitoring Board (DSMB).",{"entities":[]}],["Safety immunogenicity assessed Days 1, 8, 15, 29, 85, 169, conclude study visit Day 366.",{"entities":[]}],["",{"entities":[]}],["Participating study pharmacies 1:1:1:1 randomized either: 1) pharmacy PrEP/PEP services fee (clients pay 250 KES/visit; study team compensates pharmacies 0 KES/visit); pharmacy PrEP/PEP services (clients pay 0 KES/visit; study team compensates pharmacies 250 KES/visit); 3) HTS counselor-supported pharmacy PrEP/PEP services (clients pay 0 KES/visit; study team compensates pharmacies 100 KES/visit); 4) pharmacy referral existing clinic-based PrEP/PEP services (clients pay 0 KES/visit; study team compensates pharmacies 100 KES/visit).",{"entities":[[70,78,"DRUG"],[177,185,"DRUG"],[307,315,"DRUG"]]}],["primary cRCT outcomes PrEP initiation continuation, assessed 60 days clients pharmacy PrEP/PEP visit/referral.",{"entities":[]}],["implement trial 16 months, longer, depending achievement primary study objectives.",{"entities":[]}],["",{"entities":[]}],["Earthen floors damp dusty difficult clean, providing ideal environment faecal pathogens parasites.",{"entities":[[78,97,"BIOLOGICAL"]]}],["Cross-sectional studies revealed associations household flooring health outcomes, robust experimental evidence scant.",{"entities":[]}],["study evaluate impact improved household flooring intervention enteric infections, soil-transmitted helminth (STH) infections, tungiasis implementation cluster-randomised trial rural settings Kwale Bungoma Counties, Kenya.",{"entities":[[83,108,"CONDITION"],[152,176,"STUDY_DESIGN"],[192,197,"LOCATION"],[198,205,"LOCATION"],[216,221,"COUNTRY"]]}],["primary aim study evaluate effectiveness improved flooring intervention reducing burden enteric infections, STH tungiasis participating households implementation randomised controlled trial (RCT) distinct settings rural Kenya.",{"entities":[[108,111,"CONDITION"],[112,121,"CONDITION"],[162,195,"STUDY_DESIGN"],[220,225,"COUNTRY"]]}],["primary objectives quantify impact prevalence enteric infections, STH infections, tungiasis.",{"entities":[[66,80,"CONDITION"],[82,91,"CONDITION"]]}],["Secondary objectives include assessing impact wellbeing caregivers children, self-report gastrointestinal illness children, extent entero-pathogen parasitic contamination floors reduced home.",{"entities":[[131,156,"CONDITION"]]}],["examine differential effects community household contexts (including water, sanitation, hygiene (WASH) infrastructure, animal husbandry, user adherence study site).",{"entities":[]}],["Lastly, deliver process evaluation determine practicality, acceptability, costs, durability improved flooring intervention environmental, installation, factors affect these.",{"entities":[]}],["total, 440 clusters (households) sites allocated control intervention group, low-cost, sealed, washable cement-based floor installed eligible buildings dwelling, floor care guide induction meeting.",{"entities":[[49,69,"STUDY_DESIGN"]]}],["Prevalence enteric infections children 5 assessed stool surveys PCR; prevalence tungiasis infection children 1-14 based clinical exam; prevalence STH infection household 1 assessed Kato-Katz.",{"entities":[[80,89,"CONDITION"],[181,190,"INTERVENTION"]]}],["12-month implementation period final assessments, control households offered improved floors.",{"entities":[]}],["",{"entities":[]}],["pregnant/postpartum women living HIV (PWLWH) resource, HIV prevalence settings, access antiretroviral treatment (ART) increased dramatically mother-to-child transmission (MTCT) HIV decreased substantially, successful outcomes universal.",{"entities":[[0,25,"POPULATION"],[33,36,"CONDITION"],[80,117,"DRUG"]]}],["52% decline HIV infections children 2010-2019, UNAIDS data global targets missed wide margins, estimated 160,000 pediatric HIV infections annually.",{"entities":[]}],["Sub-optimal retention PWLWH major contributor pediatric infections.",{"entities":[]}],["study conducted high-volume, low-resource health facilities Kisumu County, Kenya, priority WLWH HIV burden counties.",{"entities":[[60,73,"LOCATION"],[75,80,"COUNTRY"]]}],["PMTCT programs sub-Saharan Africa (SSA) aim elimination MTCT context decreased funding, geared identifying supporting vulnerable PWLWH tailored interventions implemented resources.",{"entities":[[15,39,"COUNTRY"]]}],["study aims build previous study, Mother Infant Visit Adherence Treatment Engagement Study (MOTIVATE, R01HD080477), develop implement interventions promote proper HIV drugs PWLWH, risk calculator identify women risk treatment failure adapted Management (PM+) intervention geared women identified risk.",{"entities":[[33,46,"POPULATION"]]}],["interventions critical identify vulnerable PWLWH intervene effective targeted interventions improve maternal child health outcomes.",{"entities":[[43,48,"OCCUPATION"]]}],["",{"entities":[]}],["study objectives are: evaluate Chama participation mitigating effects pandemic social gender equity.",{"entities":[]}],["* Impact economic status (assessed Poverty Probability scores) * Impact health service utilization behaviours (assessed enrollment national health insurance scheme, ANC visits attended, facility delivery, maternal death, newborn death, infant death, exclusive breastfeeding, children immunized age 1) * Social attitudes well-being (assessed using, attitude harsh punishment children, level parental stress) * COVID-19 (assessed COVID-19 infection, COVID-19 vaccination, effects COVID restrictions) equity-centered design process narrative approach share findings.",{"entities":[[409,417,"CONDITION"],[448,456,"CONDITION"],[478,483,"CONDITION"]]}],["team intends evaluate women's experiences pandemic mixed method approach participatory action design method.",{"entities":[]}],["focus 3 study cohorts: (1) women participated Chamas pandemic, (2) women left Chamas pandemic, (3) women communities randomized receive Chamas intervention.",{"entities":[[27,32,"POPULATION"],[136,142,"INTERVENTION"]]}],["understand effects Chama participation study outcomes, conduct interviewer-administered survey cohorts women.",{"entities":[[19,24,"INTERVENTION"]]}],["qualitative studies contextualize study findings investigate gender dynamics social processes.",{"entities":[]}],["Focus discussions (FGDs) key informant interviews (KIIs) conducted investigate study cohort's experiences pandemic identify strategies participants mitigate negative effects pandemic restrictions.",{"entities":[[0,24,"INTERVENTION"]]}],["",{"entities":[]}],["Eligible study participants receive propanolol daily initial 12-week period.",{"entities":[]}],["conclusion 12-weeks, response assessed.",{"entities":[]}],["Participants achieve complete partial response continue propanolol additional 6 weeks 12 weeks, respectively.",{"entities":[[56,66,"DRUG"]]}],["",{"entities":[]}],["Basic design: Participants approached/recruited assistants ground designated local markets.",{"entities":[]}],["Potential participants consented agree study time recruitment.",{"entities":[]}],["attendance required participants, product demonstrations conducted study sites, grocery store demonstration, instant flour reconstituted.",{"entities":[]}],["time, consumers attending demonstrations participate study.",{"entities":[]}],["assistants read consent form participants ensure understand it.",{"entities":[]}],["Purdue investigator(s) (one - Torres-Aguilar, Rendall, Hamaker) Eldoret study phases involving consenting data collection.",{"entities":[[64,71,"LOCATION"]]}],["Products produced, distributed weekly basis sites.",{"entities":[]}],["investigators plan introducing \"\"new\"\" product consumers random in-store displays individual locations 2 weeks, continue promote (advertise) sell product period 8 weeks.",{"entities":[]}],["schedules proposed: Weeks 1-2: Product demonstrations sampling consumers Weeks 3-5: Product sold market cost cereal flour products (as active promotion) Weeks 6-10: locations, product sold parity cereal products (with advertising additional promotion, discounts).",{"entities":[]}],["Data collected store managers individual consumers.",{"entities":[]}],["Enumerators trained sales' location morning evening coincide peak shopping times.",{"entities":[]}],["tasked collecting random sample consumers purchasing cereals (1,200 total weeks).",{"entities":[]}],["sample, purchasers non-purchasers FtFF fortified products identified consented.",{"entities":[]}],["Phone collected follow appointment/interview scheduled (600).",{"entities":[]}],["Enumerators coordinate collection data sale managers: 1.",{"entities":[]}],["Total volume/units FtFF fortified product sold 2.",{"entities":[]}],["Total volume/units cereal products sold 3.",{"entities":[]}],["Total FtFF fortified product sold 4.",{"entities":[]}],["TotaI cereal product sold 5.",{"entities":[]}],["Product comments consumers (include returns complaints) 6.",{"entities":[]}],["repeat purchasers Follow interviews consumers conducted private location close centralized market sites original purchase 2 weeks.",{"entities":[]}],["enable follow inconveniencing participant.",{"entities":[]}],["",{"entities":[]}],["43% children under-5 risk attaining developmental potential.",{"entities":[]}],["Parenting interventions recommended improving childhood development earliest life.",{"entities":[[0,23,"INTERVENTION"]]}],["However, limited evidence delivery effectiveness parenting interventions promote child development outcomes Kenya specifically.",{"entities":[[108,113,"COUNTRY"]]}],["cluster-randomized trial aims evaluate effectiveness Moments Matter® (MTM) Program child development caregiving outcomes selected counties western Kenya.",{"entities":[[0,24,"STUDY_DESIGN"],[53,74,"ORG"]]}],["MTM Program implemented Anglican Church Kenya Development Services - Nyanza (ADS-Nyanza), faith-based organization focused supporting integrated community-based programs support health, wellbeing, development vulnerable children families.",{"entities":[[24,39,"ORG"],[40,45,"COUNTRY"],[69,75,"LOCATION"]]}],["stakeholders - including community volunteers, faith leaders, ECD committees - mobilized trained deliver nurturing care ECD services 18-month program period.",{"entities":[[25,45,"OCCUPATION"],[47,60,"OCCUPATION"],[62,76,"OCCUPATION"]]}],["trial enroll primary caregivers children 0-18 months age longitudinally follow study cohort ultimately compare child development caregiving outcomes intervention waitlist-control study arms.",{"entities":[[57,84,"STUDY_DESIGN"]]}],["addition impact evaluation, qualitative implementation evaluation conducted assess quality delivery, identify factors influence program effectiveness, determine program potential sustainability scale-up.",{"entities":[]}],["",{"entities":[]}],["\"\"evaluation\"\" Phase B, SEARCH SAPPHIRE study evaluate effects Dynamic Prevention Dynamic Treatment intervention packages based data Phase (NCT04810650) advances study delivered precision community health model, HIV incidence health outcomes, pair-matched community randomized design.",{"entities":[]}],["Phase precision community health intervention consist intervention: 1) Community-enhanced reach activities 2) Person-centered care delivery; and, 3) Data-enhancement improve precision interventions.",{"entities":[[16,45,"INTERVENTION"],[71,89,"INTERVENTION"],[110,139,"INTERVENTION"]]}],["study hypothesis Phase population level study is: Precision Community Health Model leveraging existing facility-based outreach community health workers, enabled dynamic choice prevention/treatment multi-disease approaches interactive data systems -will reduce HIV infections, deaths improve health.",{"entities":[]}],["Structured stakeholder consultations formally incorporated study design leverage regular ongoing collaborations study team HIV, non-communicable disease health leads Kenya Uganda Ministries Health PEPFAR implementing partners national regional level.",{"entities":[[123,126,"CONDITION"],[128,152,"CONDITION"],[166,171,"COUNTRY"],[172,178,"COUNTRY"],[197,203,"ORG"]]}],["",{"entities":[]}],["INTREPiD two-arm, open-label, parallel-assignment randomized trial strategy 1st trimester screening P.",{"entities":[]}],["falciparum parasites high-sensitivity rapid diagnostic (HS-RDT).",{"entities":[[0,20,"BIOLOGICAL"],[21,63,"INTERVENTION"]]}],["Participants women gravidities antenatal clinics 1st trimester sites endemic P.",{"entities":[]}],["falciparum malaria Kenya Democratic Republic Congo.",{"entities":[[0,18,"CONDITION"],[19,24,"COUNTRY"],[25,35,"COUNTRY"],[36,50,"COUNTRY"]]}],["consent enrollment, women allocated 1:1 usual antenatal care intervention.",{"entities":[[46,73,"INTERVENTION"]]}],["intervention single screening 1st trimester P.",{"entities":[]}],["falciparum infection maternal peripheral blood HS-RDT.",{"entities":[[0,20,"CONDITION"],[21,46,"BIOLOGICAL"],[47,53,"INTERVENTION"]]}],["Women positive P.",{"entities":[]}],["falciparum HS-RDT testing treated single Artemether-Lumefantrine (AL) returned usual antenatal care.",{"entities":[[0,10,"BIOLOGICAL"],[11,17,"INTERVENTION"],[41,69,"DRUG"]]}],["Participants delivery offspring's month life.",{"entities":[]}],["Hypothesis that, compared usual antenatal care, screening women 1st trimester P.",{"entities":[]}],["falciparum treating positive reduce risk adverse pregnancy outcome.",{"entities":[[0,10,"BIOLOGICAL"],[49,58,"CONDITION"]]}],["",{"entities":[]}],["purpose platform study evaluate parasiticidal potential cure anti-malarial agents administered monotherapy and/or combination therapy anti-malarial agents adult adolescent patients uncomplicated Plasmodium falciparum malaria.",{"entities":[[61,81,"DRUG"],[195,224,"CONDITION"]]}],["Additionally, safety, tolerability, pharmacokinetics anti-malarial agents evaluated dose selection future studies.",{"entities":[[53,73,"DRUG"]]}],["",{"entities":[]}],["Guaranteeing access safe drinking water challenge rural households developing countries, unsafe water sources responsible millions deaths world.",{"entities":[]}],["Coupons dilute chlorine solution (i) cost-effective solution targeting water treatment households (ii) effective ameliorating child health reducing diarrhea incidence.",{"entities":[]}],["empirical challenge, however, positive health effects maintained program implemented scale.",{"entities":[]}],["study, investigators conduct randomized controlled trial (RCT) scale study impacts chlorine coupon program implemented health clinics child health, including self-reported diarrhea, fever, cough incidence previous weeks.",{"entities":[[29,62,"STUDY_DESIGN"],[172,180,"CONDITION"],[182,187,"CONDITION"],[189,194,"CONDITION"]]}],["Investigators study pathway impact, self-reported objectively measured chlorine frequency visits health clinics.",{"entities":[[0,13,"OCCUPATION"]]}],["Investigators monitor program's impact Health Demographic Surveillance Systems (HDSS) sites collaboration Kenya Medical Institute (KEMRI).",{"entities":[[0,13,"OCCUPATION"],[39,85,"ORG"],[106,137,"ORG"]]}],["Data collection includes child mortality, verbal autopsies deceased children.",{"entities":[[25,40,"CONDITION"]]}],["Data mortality future meta-analyses pool data multiple studies estimate mortality impact chlorine distribution schemes.",{"entities":[]}],["",{"entities":[]}],["interrupted time series study conducted Moi Teaching Referral Hospital (MTRH) neonatal ward April 2022 June 2023.",{"entities":[[40,77,"ORG"],[78,86,"OCCUPATION"]]}],["study participants comprise newborn patients admitted MTRH period.",{"entities":[[28,35,"POPULATION"],[54,58,"ORG"]]}],["MTRH neonatal ward arranged 8 sub-units comprise comparison sub-groups.",{"entities":[[0,4,"ORG"],[5,13,"POPULATION"]]}],["Newborns admitted April-November 2022 comprise pre-intervention arm exposed neoGuard, receive existing standard-of-care vital sign monitoring.",{"entities":[]}],["December 2022, neoGuard installed 4 sub-units (intervention group), remaining 4 sub-units (comparison group) continued standard-of-care monitoring.",{"entities":[]}],["measurement effectiveness performed levels: (1) device's ability detect abnormal physiological signals provide alerts/alarms notify nurses check patient's status and; (2) alarms/alerts level intervention administered patient (valid alarms), alarms/alerts necessitate intervention (invalid alarms); (3) month-to-month difference newborn complication rates treatment outcomes intervention comparison group.",{"entities":[]}],["Medical staff interact neoGuard participate user surveys intervention period capture user experience perceptions feasibility sustainability.",{"entities":[]}],["",{"entities":[]}],["Primary goals: * Estimate HIV incidence recency testing samples women screen HIV infection, assess HIV incidence prospectively cohort.",{"entities":[]}],["* Assess characteristics women initiate PrEP compared initiate PrEP.",{"entities":[[40,44,"DRUG"],[63,67,"DRUG"]]}],["* Evaluate women's preferences attributes long-acting formulations PrEP, discrete choice experiment.",{"entities":[]}],["* Assess acceptability patient-facing PrEP decision support tool provide women informed choice PrEP options.",{"entities":[]}],["",{"entities":[]}],["western Kenya, HIV prevalence 16% women population, 29% economically constrained women.",{"entities":[]}],["HIV/STI epidemic overlaps broader reproductive health concerns.",{"entities":[[0,7,"CONDITION"]]}],["Menstrual hygiene management (MHM) pervasive low- middle-income countries.",{"entities":[[0,34,"INTERVENTION"]]}],["Phillips-Howards' survey 3,400 women rural Kenya, two-thirds women impoverished settings depend sexual partners provide branded products.",{"entities":[]}],["Economically vulnerable women risk HIV STI uniquely challenged continue sex menses, engage harmful MHM practices, vaginal insertion sponges cotton maintain dryness.",{"entities":[[35,38,"CONDITION"],[39,42,"CONDITION"]]}],["Led co-investigator Phillips-Howard, cluster-randomized study 644 girls aged 14-16 western Kenya compared reusable menstrual cups usual menstrual practice counseling; 9 months, menstrual cup 35% reduction (p=0.034) Bacterial vaginosis (BV) prevalence 56% reduction (p=0.001) STI prevalence compared materials.",{"entities":[[20,35,"ORG"],[37,55,"STUDY_DESIGN"],[91,96,"COUNTRY"],[136,165,"INTERVENTION"],[177,190,"INTERVENTION"],[215,234,"CONDITION"]]}],["431 Kenyan secondary schoolgirls aged 14-21, observed cloth menses 1.72-fold increased odds non-optimal vaginal microbiome (CST-IV vs.",{"entities":[]}],["CST-I: aOR=1.90; 95% CI: 1.03-2.86).",{"entities":[]}],["18 months observation prior COVID-19, girls menstrual cups manage menses 20% occurrence Lactobacillus crispatus dominated CST-I (aRR=1.29; 95% CI: 1.08-1.53, controlling age, baseline STI sexual activity).",{"entities":[[88,111,"BIOLOGICAL"]]}],["Menstrual cups designed intercourse women prevent STIs hygienic menstrual practices avoidance harmful practices maintain vaginal dryness menses.",{"entities":[[0,14,"INTERVENTION"],[36,41,"POPULATION"],[50,54,"CONDITION"],[121,128,"BODY_PART"]]}],["Objective: single-arm interventional trial seeks evaluate preliminary efficacy menstrual cups non-optimal vaginal microbiome (VMB), BV, STIs economically vulnerable women risk STIs HIV, assess safety profile, understand implementation needs.",{"entities":[[136,140,"CONDITION"],[176,180,"CONDITION"],[181,184,"CONDITION"]]}],["Aim 1, evaluate impact menstrual cups VMB, BV, STIs 402 economically vulnerable women semi-urban Kenya.",{"entities":[[23,37,"INTERVENTION"],[80,85,"POPULATION"],[97,102,"POPULATION"]]}],["Aim 2, conduct integrated surveillance enhanced detection safety endpoints, risk cup contamination, mitigating facilitating water, sanitation, hygiene (WASH) factors.",{"entities":[]}],["Aim 3, identify constructs successful MHM program implementation implementation science framework.",{"entities":[]}],["Future Directions: biological protection suggested randomized setting, findings unhygienic cloth non-optimal VMB, menstrual cup increases optimal VMB composition, provide rational justification trial, relevance economically challenged women globally.",{"entities":[]}],["Assessing preliminary efficacy signal conjunction implementation characteristics adverse events, generate comprehensive foundation definitive assessment effectiveness menstrual cups multipurpose intervention MHM, reduce STIs.",{"entities":[]}],["",{"entities":[]}],["Adolescents adults (AYA) living HIV ART adherence, loss follow-up AIDS-related mortality age groups.",{"entities":[[0,11,"POPULATION"],[12,18,"POPULATION"],[20,23,"POPULATION"],[32,35,"CONDITION"],[36,39,"DRUG"]]}],["Innovative approaches address AYA's unique improve adherence retention HIV care.",{"entities":[]}],["evidence peer support mobile messaging healthcare workers (HCW) strategies effective group, evaluation limited interventions combined them.",{"entities":[[39,63,"OCCUPATION"]]}],["2014, youth-run virtual support spontaneously started HIV clinics, mobile social media application WhatsApp.",{"entities":[]}],["valuable studies proposed project develop structured social media intervention combines peer HCW support improve ART adherence retention, guided preferences AYA.",{"entities":[[93,96,"OCCUPATION"]]}],["SPECIFIC AIMS (1) Characterize existing WhatsApp in-depth interviews detailed content analysis group's communications 6-week observation period.",{"entities":[]}],["define elements features desired AYA social media intervention.",{"entities":[]}],["(2) Guided findings Aim 1, behavioral theory, study team's ongoing mobile messaging improve ART adherence, develop refine structured content reproducible WhatsApp intervention incorporates peer HCW interaction.",{"entities":[]}],["(3) Pilot structured intervention 6 months clinic evaluate impact intermediate outcomes ART knowledge, depression stigma.",{"entities":[[103,113,"CONDITION"],[114,120,"CONDITION"]]}],["",{"entities":[]}],["Anemia, condition estimated 613 (33%) women reproductive age worldwide classified moderate severe public health countries, secondary outcome PRiSMA MNH study.",{"entities":[[38,60,"POPULATION"]]}],["current PRiSMA MNH study sites conduct non-invasive continuous hemoglobin monitoring Masimo device (Kenya, Pakistan, Zambia).",{"entities":[[63,73,"BIOLOGICAL"],[100,105,"COUNTRY"],[107,115,"COUNTRY"],[117,123,"COUNTRY"]]}],["Accurate, precise, comparable hemoglobin measurements importance, clinical diagnosing anemia ensuring pregnant women receive treatment.",{"entities":[[30,40,"BIOLOGICAL"],[86,92,"CONDITION"],[102,110,"CONDITION"]]}],["Masimo Total Hemoglobin SpHb® continuous non-invasive handheld device optical sensor finger measures hemoglobin levels pulse oximetry.",{"entities":[[0,29,"ORG"],[101,111,"BIOLOGICAL"],[119,134,"INTERVENTION"]]}],["measurement takes minute require blood samples laboratory testing.",{"entities":[]}],["characteristics promising medical technology low-resource areas.",{"entities":[]}],["Previous studies SpHb accurately detect hemoglobin levels adult patients degree bias standard deviation point-of-care (PoC) invasive method (e.g., HemoCue device) measurements.",{"entities":[[17,21,"ORG"],[40,50,"BIOLOGICAL"],[147,162,"INTERVENTION"]]}],["However, variability bias limits agreements Masimo device study involving pregnant patients.",{"entities":[[74,82,"CONDITION"]]}],["objective study evaluate compatibility hemoglobin measurements SpHb CBC assessed 5-part autoanalyzer pregnancy weeks postpartum.",{"entities":[[39,49,"BIOLOGICAL"]]}],["study nested Pregnancy Risk Stratification Innovation Measurement Alliance (PRiSMA) Maternal Newborn Health (MNH) study.",{"entities":[[13,83,"INTERVENTION"],[84,113,"PUBLIC_HEALTH_CONCERN"]]}],["PRISMA MNH population-based, open-cohort study seeks evaluate pregnancy risk factors associations adverse pregnancy outcomes countries sub-Saharan Africa Southeast Asia.",{"entities":[[0,6,"INTERVENTION"],[7,10,"PUBLIC_HEALTH_CONCERN"],[106,115,"CONDITION"],[135,153,"LOCATION"],[154,168,"LOCATION"]]}],["study sites (located Zambia, Kenya, Pakistan) participate collect hemoglobin data time (\\\\<20 weeks, 20 weeks, 28 weeks, 36 weeks gestation, weeks postpartum).",{"entities":[[21,27,"COUNTRY"],[29,34,"COUNTRY"],[36,44,"COUNTRY"],[66,76,"BIOLOGICAL"]]}],["investigators measure hemoglobin venous blood sample auto-analyzer (gold standard) non-invasive device.",{"entities":[[22,32,"BIOLOGICAL"]]}],["investigators assess agreement Masimo total hemoglobin complete blood count continuous scale Intraclass Correlation Coefficient Bland-Altman Analysis.",{"entities":[]}],["objective assess agreement measures binary scale Positive Percentage Agreement Negative Percentage Agreement, Cohen's Kappa, McNemar Test.",{"entities":[]}],["ordinal scale, agreement measured Weighted Cohen's Kappa Harrel's Concordance Index.",{"entities":[]}],["Lastly, investigators assess factors affect accuracy Masimo total hemoglobin linear mixed models.",{"entities":[[8,21,"OCCUPATION"]]}],["",{"entities":[]}],["Tu'Washindi intervention developed address factors individual, partnership, community levels influence AGYW's response IPV PrEP use.",{"entities":[]}],["factors addressed three-component intervention delivered 6 months: empowerment-based PrEP adherence support club AGYW, PrEP education events couples offered context health fair (\"\"Buddy Days\"",{"entities":[]}],["",{"entities":[]}],["PRIORITY 2-arm, randomized-controlled trial (RCT) implemented 8 sites 7 countries: Bangladesh, Democratic Republic Congo, Guatemala, India (Nagpur Belagavi), Kenya, Pakistan, Zambia.",{"entities":[[16,49,"STUDY_DESIGN"],[83,93,"COUNTRY"],[95,120,"COUNTRY"],[122,131,"COUNTRY"],[133,138,"COUNTRY"],[140,155,"LOCATION"],[158,163,"COUNTRY"],[165,173,"COUNTRY"],[175,181,"COUNTRY"]]}],["team enroll 600 women deliver hospital facility health center delivery services.",{"entities":[[48,79,"PUBLIC_HEALTH_CONCERN"]]}],["Participants randomized receive single-dose IV iron infusion 6 48 hours delivery prior discharge facility oral iron tablets daily 6 weeks.",{"entities":[]}],["assessed staff health facility 6 weeks 6 months post-delivery providing maternal blood sample analyzed determine Hb concentration.",{"entities":[[113,115,"BIOLOGICAL"]]}],["study visit, trained staff measure serum ferritin, serum transferrin receptor, C-reactive protein (CRP) alpha 1 acid glycoprotein (AGP).",{"entities":[[35,49,"BIOLOGICAL"],[51,77,"BIOLOGICAL"],[79,103,"BIOLOGICAL"],[104,135,"BIOLOGICAL"]]}],["Additionally, African sites, rapid diagnostic (RDT) malaria administered admission birthing facility, 6 weeks 6 months postpartum.",{"entities":[[29,51,"INTERVENTION"],[52,59,"CONDITION"]]}],["Edinburgh Postnatal Depression Scale (EPDS), Health Organization Quality-of-Life (QOL) scale, Maternal Fatigue Severity Scale (FSS-5R), Mother-to-infant Bonding Scale (MIBS) 6 weeks 6 months postpartum follow appointments collect data secondary study aims.The study hypothesizes 6 weeks post-delivery, prevalence non-anemic women received single-dose IV iron infusion 6 48 hours delivery prior discharge facility women supply oral iron tablets daily 6 weeks.",{"entities":[[0,43,"INTERVENTION"],[45,92,"INTERVENTION"],[94,134,"INTERVENTION"],[136,173,"INTERVENTION"],[313,323,"CONDITION"],[324,329,"POPULATION"],[351,367,"DRUG"],[426,443,"DRUG"]]}],["Secondary study aims effects postpartum depression maternal quality life, fatigue, breastfeeding initiation retention rates.",{"entities":[[29,50,"CONDITION"],[51,59,"POPULATION"]]}],["Depression risk factor reducing infant-mother bonding.",{"entities":[]}],["PRIORITY RCT include implementation (IR) sub-study complement findings RCT trial provide evidence facilitators, barriers, costs implementation inform global guidelines IV iron postpartum women Low-Middle Income Countries (LMIC).",{"entities":[[168,175,"DRUG"],[176,192,"POPULATION"]]}],["Implementation (IR) sub-study build PRIORITY trial projects assess IV iron conducted Jawaharlal Nehru Medical College team Belagavi, India, Thomas Jefferson University (TJU) Aga Khan University team Pakistan.",{"entities":[[85,117,"ORG"],[133,138,"COUNTRY"],[147,173,"ORG"],[174,193,"ORG"],[199,207,"COUNTRY"]]}],["utilize mixed methods approach, employing quantitative qualitative data collection understand potential barriers facilitators IV iron India Pakistan.",{"entities":[[126,133,"DRUG"],[134,139,"COUNTRY"],[140,148,"COUNTRY"]]}],["implementation harmonized timeline main PRIORITY trial, enabling investigators collect data parallel trial.",{"entities":[]}],["mixed methods study PRIORITY trial India Pakistan guided Consolidated Framework Implementation (CFIR) Proctor's implementation outcomes framework.",{"entities":[]}],["CFIR Proctor's framework complementary provide structure guiding types questions target implementation data collection trial.",{"entities":[]}],["",{"entities":[]}],["purpose study investigate birth companion (BC) intervention implemented increase proportion women accompanied BC labor, childbirth, postpartum Ethiopia, Kenya Nigeria.",{"entities":[[26,59,"INTERVENTION"],[120,130,"CONDITION"],[132,142,"CONDITION"],[143,151,"COUNTRY"],[153,158,"COUNTRY"],[159,166,"COUNTRY"]]}],["baseline data collection, facilities randomized 3:1 ratio; facilities receive BC intervention, facility serve control facility.",{"entities":[[78,93,"INTERVENTION"]]}],["randomization, months, intervention facilities start preparing introduce BC intervention facilitate presence BC labor delivery, control facilities continue provide local standard routine care.",{"entities":[[73,88,"INTERVENTION"]]}],["intervention components: 1) Orient facilities providers benefits BC; 2) Develop/update formal standard operating procedures (SOP) implementing BC develop plans implement SOP; 3) Assess data required implementation audit feedback cycle tracking coverage; 4) Assess carry modest structural facilities facilitate BC; 5) human centered design develop materials/resources distinguish/recognize BC, account common barriers misconceptions; 6) Prepare providers integrate BC care team; 7) Orient antenatal care (ANC) clients BC rationale selection; 8) Prepare BCs support women; 9) Iterate model track intervention/policies.",{"entities":[[65,67,"INTERVENTION"],[310,312,"INTERVENTION"],[389,391,"INTERVENTION"],[464,466,"INTERVENTION"],[552,555,"INTERVENTION"]]}],["Investigators mixed methods approach address implementation questions exit interviews, health facility register data extraction, in-depth interviews, focus discussions, key informant interviews.",{"entities":[]}],["Investigators collect quarterly quantitative qualitative data week each, total data collection periods including baseline.",{"entities":[]}],["",{"entities":[]}],["Aim #1 Train Kenyan health practitioners software developers HCD.",{"entities":[[41,60,"OCCUPATION"]]}],["accomplished implementing HCD curriculum three-day workshop Kenyan collaborators.",{"entities":[[26,29,"OCCUPATION"]]}],["Drs.",{"entities":[]}],["Wyche, Olson Holtz, travelled Nairobi, Kenya, September 28 October 5 conduct three-day training workshop.",{"entities":[]}],["collaborators LakeHub (in Kisumu) flew Nairobi.",{"entities":[[26,32,"LOCATION"],[39,46,"LOCATION"]]}],["collaborators-from DMI-are based Kenya's capital city.",{"entities":[]}],["held workshop Ngong Hills Hotel Nairobi.",{"entities":[[14,25,"LOCATION"],[32,39,"LOCATION"]]}],["Aim #2 HCD build prototype intervention adolescents Kenya T1D.",{"entities":[[7,10,"OCCUPATION"]]}],["accomplished aim conducting interviews; analyzing data; holding design workshops; developing initial version diary; conducting pilot evaluation diary; iterating diary's design.",{"entities":[]}],["project outcomes include personal diary.",{"entities":[]}],["April 2022, Dr.",{"entities":[]}],["Jennifer Olson, collaborators DMI ROA, interviewed 24 youth T1D sites Kenya (Vihiga County Nairobi); 12 participants site.",{"entities":[[77,90,"LOCATION"],[91,98,"LOCATION"]]}],["interviewed parents/caregivers (n=22), key stakeholders (e.g., doctors, teachers, community health workers).",{"entities":[]}],["Interviews digitally recorded (with participants' consent).",{"entities":[]}],["time, youth digital camera engage photovoice exercise (i.e., participants photographs, reflecting reasons, emotions experiences motivated photos).",{"entities":[]}],["hired translators-fluent Kiswahili English-to translate transcribe interviews.",{"entities":[]}],["collected participants' photographs.",{"entities":[]}],["Drs.",{"entities":[]}],["Olson Wyche analyzed transcribed interviews photographs May-June 2022.",{"entities":[]}],["objective deepen understanding youth managed T1D identify technology interventions.",{"entities":[[45,48,"CONDITION"]]}],["finding developing mobile phone application support youths' existing practices.",{"entities":[]}],["participants allowed mobile phones school.",{"entities":[]}],["Further, participants, living rural areas, access smart phone.",{"entities":[]}],["July 2022, Drs.",{"entities":[]}],["Wyche Olson travelled Kenya.",{"entities":[]}],["held two, two-day design workshops (between July 3 July 7).",{"entities":[]}],["held Sosa Cottages (Majengo); held Ngong Hills Hotel (Nairobi).",{"entities":[]}],["youth caregivers, Dr.",{"entities":[]}],["Olson interviewed April, attended workshops.",{"entities":[]}],["Workshop objectives included: learning youth T1D; brainstorming design interventions youth manage disease.",{"entities":[[45,48,"CONDITION"]]}],["sessions, participants discussed experiences managing T1D; talked photographs.",{"entities":[[54,57,"CONDITION"]]}],["activities include brainstorming exercises.",{"entities":[]}],["Participants ideas included posters educate people T1D, calendar youth track doctors' appointments, diary supported T1D-related activities.",{"entities":[[51,54,"CONDITION"],[116,127,"CONDITION"]]}],["conclusion workshops Drs.",{"entities":[]}],["Wyche Olson determined diary promising intervention.",{"entities":[]}],["diary youth track sugar levels, ate activity levels.",{"entities":[]}],["diary include effectively manage T1D (e.g., inject insulin, healthy meals, properly store insulin).",{"entities":[[33,36,"CONDITION"],[51,58,"DRUG"],[90,97,"DRUG"]]}],["designed LakeHub develop initial version diary.",{"entities":[]}],["September 2022, design team printed 60 initial copies diary.",{"entities":[]}],["time, Drs.",{"entities":[]}],["Wyche Olson returned Kenya share diaries doctors, collaborators (at DMI ROA), youth caregivers.",{"entities":[]}],["Dr.",{"entities":[]}],["Wyche met Drs.",{"entities":[]}],["Karakezi Ngugi (DMI) review diary.",{"entities":[]}],["held two, daylong workshops-one Vihiga Nairobi-to introduce diary youth parents.",{"entities":[]}],["objective preliminary feedback improve diary's design.",{"entities":[]}],["Outcomes interviews workshops included insights improve diary (e.g., modifying text, changing images, adding information).",{"entities":[]}],["Aim #3 final phase HCD process implementation, project's formative evaluation phase.",{"entities":[[19,22,"OCCUPATION"]]}],["September 2022, prototype diary youth, caregivers, stakeholders contributed development (e.g., doctors, community health workers).",{"entities":[[37,49,"OCCUPATION"],[95,102,"OCCUPATION"],[104,128,"OCCUPATION"]]}],["objective validate intervention's feasibility increase adolescents' knowledge T1D management disease.",{"entities":[[78,81,"CONDITION"]]}],["achieve goal, conducted focus assess youth's initial reactions diary, (e.g., blood glucose monitoring page), solicited feedback diary's strengths weaknesses.",{"entities":[]}],["administered short survey assess diary one-month period.",{"entities":[]}],["Participants' feedback positive.",{"entities":[]}],["commented diary's professional appearance inclusion images context (e.g., illustrations foods ate).",{"entities":[]}],["received feedback improve diary.",{"entities":[]}],["included adding properly store insulin-when access refrigerator-as guidance inject insulin.",{"entities":[]}],["Survey data suggested frequent diary (i.e., day).",{"entities":[]}],["",{"entities":[]}],["IMPALA randomized, open-label, multicenter, interventional study 540 virologically suppressed (\\\\<200 c/mL) HIV-1 infected adults (18 older) history sub-optimal adherence daily oral ART and/or engagement HIV care.",{"entities":[]}],["IMPALA seeks demonstrate non-inferior antiviral effectiveness switching acting injectable rilpivirine (RPV LA) acting injectable cabotegravir (CAB LA) 2 months (Q2M CAB + RPV LA) compared continuation first-line daily oral ART 2 nucleoside reverse transcriptase inhibitor (NRTIs) integrase strand transfer inhibitor (INSTI; dolutegravir \\\\[DTG\\\\]).",{"entities":[[90,101,"DRUG"],[102,110,"DRUG"],[129,141,"DRUG"],[143,149,"DRUG"],[171,177,"DRUG"],[229,279,"DRUG"],[280,315,"DRUG"],[317,322,"DRUG"],[324,336,"DRUG"],[340,345,"DRUG"]]}],["providing written informed consent, participants evaluated eligibility screening period.",{"entities":[]}],["Participants viremic (HIV VL \\\\>200 c/mL) time screening virologically suppressed (for \\\\>3 months) regimen 2 NRTIs DTG prior randomization.",{"entities":[[110,115,"DRUG"],[116,119,"DRUG"]]}],["Day 1 virologically suppressed (\\\\<200 c/mL 3 months) individuals randomized 1:1 continue daily oral ART (2 NRTI + DTG, control arm), switch Q2M CAB + RPV IM, intervention arm.",{"entities":[[101,104,"DRUG"],[108,112,"DRUG"],[115,118,"DRUG"],[141,144,"DRUG"],[145,148,"DRUG"],[151,154,"DRUG"]]}],["randomized intervention arm offered optional oral lead-in (OLI) 1 month daily oral CAB RPV direct injection (DTI) approach.",{"entities":[[83,86,"DRUG"],[87,90,"DRUG"]]}],["decision dose OLI Phase determined study participant informed consent discussion investigator.",{"entities":[]}],["total duration study 24 months.",{"entities":[]}],["participant received single dose CAB + RPV discontinues regimen reason Month 24 start suppressive daily oral ART 2 months injection.",{"entities":[[33,36,"DRUG"],[39,42,"DRUG"],[109,112,"DRUG"]]}],["optional real-world extension phase, regimen deemed non-inferior Month 12 24.",{"entities":[]}],["",{"entities":[]}],["SEARCH CAB-LA (Cabotegravir Injectable Suspension) dynamic choice HIV prevention study randomized extension study person-centered Dynamic Choice HIV Prevention model delivering existing evidence-based biomedical prevention interventions vs.",{"entities":[[15,27,"DRUG"]]}],["standard care (SOC).",{"entities":[]}],["study conducted 3 settings rural Western Uganda Kenya: antenatal (ANC) clinics, outpatient department (primary care clinics), community settings.",{"entities":[]}],["Participants randomized Dynamic Choice HIV Prevention SOC re-consented remain initial randomized arm.",{"entities":[]}],["extension, Dynamic Choice HIV Prevention intervention offers participants choices biomedical prevention product (oral Pre-Exposure Prophylaxis (PrEP), oral post-exposure prophylaxis (PEP), Cabotegravir Injectable Suspension (CAB-LA) ongoing basis option switch products time based participant preference perceived risk.",{"entities":[[118,142,"DRUG"],[156,181,"DRUG"],[189,201,"DRUG"]]}],["primary endpoint proportion time covered biomedical prevention product 48 weeks; secondary endpoints are: i) incident HIV infection 48 weeks; and, ii) proportion time participant reports risk HIV infection covered biomedical prevention product 48 weeks.",{"entities":[]}],["Participants intervention arm reconsented 48 weeks implementation evaluation 96 weeks.",{"entities":[]}],["",{"entities":[]}],["study pilots implementation intervention (AYA PrEP peer mentors) increasing knowledge, reducing stigma increasing uptake adherence PrEP AYA.",{"entities":[]}],["middle income countries, peer mentor interventions improve health behaviors supported evidence, extensively AMPATH programs practice.",{"entities":[]}],["examining implementation (e.g.",{"entities":[]}],["training, reach, acceptability) effectiveness intervention.",{"entities":[]}],["study approved IU IRB Moi University Institutional Ethics Committee.",{"entities":[]}],["intervention engage PrEP focused peer-mentors, stationed Moi Teaching Referral Hospital Reproductive Health Clinic; Lesbian, Gay, Bisexual, Transgender, Queer (LGBTQ) community, tertiary institutions Eldoret, Kenya (Eldoret Medical Training College, University Eldoret, Eldoret Polytechnic) focus college students.",{"entities":[[57,87,"ORG"],[116,123,"POPULATION"],[125,128,"POPULATION"],[130,138,"POPULATION"],[140,151,"POPULATION"],[153,158,"POPULATION"],[160,165,"POPULATION"],[216,248,"ORG"],[250,268,"ORG"],[270,289,"ORG"]]}],["peer mentors paid monthly stipend, roles to: (1) Hold discussions target AYA PrEP; (2) hold discussions PrEP target AYA; (3) champion PrEP promotion provision healthcare workers; (4) outreach-work, adherence support clinic reminders PrEP.",{"entities":[]}],["Peer mentors received PrEP peer mentor training adapted existing USAID curriculum, training procedures.",{"entities":[[65,70,"ORG"]]}],["Peer mentors complete pre-and post-training survey measure efficacy knowledge HIV PrEP.",{"entities":[[78,81,"CONDITION"],[82,86,"DRUG"]]}],["EHR aspect study involve extraction data peer mentor intervention.",{"entities":[]}],["data extraction include de-identified visits PrEP initiation PrEP maintenance AYA Uasin Gishu County.",{"entities":[[82,100,"LOCATION"]]}],["collect socio-demographic clinical data PrEP initiation maintenance visits AYA aged 15-24 years.",{"entities":[]}],["qualitative data aspects involve FGDs 1) PrEP focused peer mentors, 2) PrEP AYA initiators, 3) Healthcare workers.",{"entities":[]}],["FGDs explore acceptability, feasibility adaption AYA PrEP peer mentor program.",{"entities":[]}],["quantitative data include PrEP peer mentors completing tracking form describes characteristics outreach interaction, including total # people, topics discussed, risk (e.g.",{"entities":[]}],["LGBTQ, pregnant/parenting, discordant relationship).",{"entities":[[0,5,"POPULATION"]]}],["personal identifiers identifiable characteristics individuals collected, waiver informed consent granted.",{"entities":[]}],["data analysis effectiveness, visits PrEP initiation maintenance 3 month period intervention starts compared visits PrEP initiation intervention.",{"entities":[[36,40,"DRUG"],[115,119,"DRUG"]]}],["De-identified EHR data used.",{"entities":[]}],["qualitatively examine intervention stigma barriers, FGDs conducted AYA, healthcare workers, peer mentors intervention.",{"entities":[]}],["examine implementation intervention, (1) participants overall, (2) total interactions/outreach, (3) total interactions/outreach include HIV risk groups, (4) topics outreach interaction tracked charts.",{"entities":[]}],["",{"entities":[]}],["Background: Adolescent substance prevalent Kenya US, negative health social outcomes.",{"entities":[]}],["adolescents regions limited access substance treatment services costly scarce.",{"entities":[]}],["Substance screening Intervention (SBI) delivered primary health care peer-mentors, represents promising strategy overcoming barriers substance treatment adolescents.",{"entities":[[0,32,"INTERVENTION"]]}],["Objective: aim study pilot study procedures data intervention acceptability, fidelity preliminary efficacy, determine feasibility definitive randomized controlled trial (RCT) efficacy peer-delivered substance SBI adolescents attending out-patient clinic Kenya.",{"entities":[[209,212,"INTERVENTION"]]}],["Design: study qualitative quantitative methods meet objectives Intervention: SBI includes single session screening Alcohol, Smoking \\\\& Substance Involvement Screening Youth questionnaire (ASSIST-Y), intervention (20-30 minutes motivational interviewing) moderate risk substance use.",{"entities":[[77,80,"INTERVENTION"],[115,198,"INTERVENTION"]]}],["peers trained days deliver SBI.",{"entities":[[27,30,"INTERVENTION"]]}],["peer-mentors receive regular supervision study implementation process.",{"entities":[]}],["Outcomes: SBI feasibility defined extent fidelity SBI maintained preliminary effects SBI substance quality life outcomes.",{"entities":[[10,13,"INTERVENTION"],[50,53,"INTERVENTION"]]}],["SBI acceptability evaluated perspective adolescents qualitative interviews guided Sekhon's theoretical framework acceptability.",{"entities":[]}],["Feasibility conducting future full-scale RCT explored measuring outcomes study participation rate, willingness randomized, study completion rates ability measure effectiveness outcomes.",{"entities":[]}],["Investigating team future plans: study conducted team including faculty Moi Teaching Referral Hospital, faculty Indiana University, team National Authority Campaign Alcohol drug abuse (NACADA).",{"entities":[[72,102,"ORG"],[112,130,"ORG"],[137,192,"ORG"]]}],["team experience implementing scaling peer-led substance SBIs adolescent populations.",{"entities":[]}],["SBI delivery feasible acceptable plan partner government conduct full-scale multi-site RCT Kenya Indiana.",{"entities":[]}],["",{"entities":[]}],["Performance feasibility photoplethysmograph (PPG)-derived clinical measurement tools (medical device smartphone-based screening technologies) primary care providers assessed type 2 hybrid design conduct mixed methods diagnostic accuracy implementation study.",{"entities":[[0,49,"INTERVENTION"]]}],["diagnostic accuracy study consist 3 components achieve primary secondary objectives: 1) usability assessment observed user-product interactions usability score, 2) measurement multimodal PO device performance comparison reference standard, 3) caregiver/provider acceptability semi-structured interviews.",{"entities":[]}],["observational implementation (OI) study consists 3 components achieve primary secondary objectives: 1) human-centered design workshop, 2) observational study evaluate feasibility implementing approved multimodal PO device clinical care, 3) semi-structured in-depth interviews assess provider caregiver acceptability adaptation.",{"entities":[]}],["interventions study PPG-derived clinical measurement tools measure oxygen saturation (SpO2), pulse rate, respiratory rate, and/or temperature.",{"entities":[]}],["interventions compared reference standard clinical measurements",{"entities":[]}],["",{"entities":[]}],["Background simple affordable rapid diagnostic antigen detection tests (Ag-RDT) expand access Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) testing incorporated national Coronavirus Disease 2019 (COVID-19) response plans, including Cameroon Kenya.",{"entities":[[46,78,"INTERVENTION"],[93,140,"CONDITION"],[142,152,"CONDITION"],[184,208,"CONDITION"],[210,218,"CONDITION"],[246,254,"COUNTRY"],[255,260,"COUNTRY"]]}],["Ag-RDT expensive, highly sensitive, provide faster results, require technical support diagnose SARS-CoV-2 infection.",{"entities":[[0,6,"INTERVENTION"],[95,115,"CONDITION"]]}],["Targeting populations risk COVID-19 severe outcomes, risk transmitting infection vulnerable populations potential mitigate propagation effects SARS-CoV-2 pandemic.",{"entities":[[27,35,"CONDITION"],[143,153,"CONDITION"]]}],["high-risk populations include pregnant women, people living HIV, patients tuberculosis.",{"entities":[[30,38,"CONDITION"],[46,63,"POPULATION"],[74,86,"CONDITION"]]}],["Data SARS-CoV-2 infection populations Africa integration Ag-RDT testing Maternal Neonatal Child Health (MNCH), HIV, TB clinics limited.",{"entities":[[5,15,"CONDITION"],[111,114,"CONDITION"],[116,118,"CONDITION"]]}],["Objectives main objective study evaluate effectiveness integration SARS-CoV-2 Ag-RDT MNCH, HIV TB clinics Cameroon Kenya SARS-CoV-2 testing routine service delivery compared baseline.",{"entities":[[67,77,"CONDITION"],[91,94,"CONDITION"],[95,97,"CONDITION"],[106,114,"COUNTRY"],[115,120,"COUNTRY"],[121,131,"CONDITION"]]}],["Investigators facility individual factors SARS-CoV-2 infection cascade care clinical outcomes post -integration period.",{"entities":[[42,52,"CONDITION"]]}],["Methods pre- post-implementation evaluation design implemented countries compare COVID-19 testing Ag-RDT integration.",{"entities":[[81,89,"CONDITION"],[98,104,"INTERVENTION"]]}],["study conducted 61 purposively selected facilities (31 Kenya 30 Cameroon).",{"entities":[[55,60,"COUNTRY"],[64,72,"COUNTRY"]]}],["population include attendees MNCH, HIV TB clinics 61 facilities.",{"entities":[[35,38,"CONDITION"],[39,41,"CONDITION"]]}],["SARS-CoV-2 screening performed attendees testing offered meet eligibility criteria MOH supported COVID-19 response.",{"entities":[[0,10,"CONDITION"],[97,105,"CONDITION"]]}],["study consist abstraction/extraction routine facility service delivery records secondary analysis program data only.",{"entities":[]}],["specific sample size investigators estimate \\\\>10,000 clinic attendees screened.",{"entities":[]}],["Study Outcome evidence generated evaluation support policy recommendations improving COVID-19 testing, isolation, treatment solutions existing health platforms.",{"entities":[[85,93,"CONDITION"]]}],["evaluation dissemination subsequent adoption proven models integration decentralization COVID testing multiple countries.",{"entities":[[88,93,"CONDITION"]]}],["",{"entities":[]}],["Current diarrhea management strategies low- middle-income countries (oral rehydration solution, ReSoMal zinc) focus management dehydration micronutrient replacement negligible impact preventing future diarrheal episodes improving nutritional outcomes.",{"entities":[[8,16,"CONDITION"],[69,94,"DRUG"],[96,103,"DRUG"],[104,108,"DRUG"]]}],["Lactoferrin lysozyme milk-derived nutritional supplements reduce risk diarrheal episodes accelerate nutritional recovery treating preventing underlying enteric infections and/or improving enteric function.",{"entities":[[0,11,"BIOLOGICAL"],[12,20,"BIOLOGICAL"]]}],["Children moderate severe wasting high-risk death, diarrhea recurrence, nutritional deterioration diarrheal episode.",{"entities":[]}],["factorial, double-blind, placebo-controlled, randomized trial aims determine efficacy lactoferrin lysozyme supplementation decreasing diarrhea incidence improving nutritional recovery children convalescing diarrhea wasting.",{"entities":[[86,97,"BIOLOGICAL"],[98,106,"BIOLOGICAL"]]}],["explore interventions improve outcomes reducing enteric pathogens, improving enteric function and/or increasing hemoglobin concentrations children.",{"entities":[]}],["study aims enroll 600 Kenyan children aged 6-24 months facilities Western Kenya.",{"entities":[[66,73,"LOCATION"],[74,79,"COUNTRY"]]}],["Enrolled children randomized 16-weeks lactoferrin, lysozyme, combination two, placebo 24 weeks total, bi-weekly visits community health workers clinic visits 4, 10, 16, 24 weeks.",{"entities":[[38,49,"BIOLOGICAL"],[51,59,"BIOLOGICAL"]]}],["study inform management strategies children moderate/severe wasting risk mortality, morbidity, nutritional deterioration diarrhea.",{"entities":[]}],["Aim 1: determine 16-week lactoferrin, lysozyme combination shortens time WHO-defined recovery wasting (MUAC ≥12.5cm) reduces incidence moderate-to-severe diarrhea subsequent 6-months presentation health facility diarrhea children moderate/severe childhood wasting (MUAC \\\\<12.5 time screening).",{"entities":[[38,46,"BIOLOGICAL"]]}],["Hypothesis: Children randomized lactoferrin, lysozyme, combination experience incidence moderate-to-severe diarrhea earlier recovery wasting (increased MUAC) subsequent 6-months placebo-treated children.",{"entities":[[32,43,"BIOLOGICAL"],[45,53,"BIOLOGICAL"]]}],["Combination therapy provide synergistic benefit reducing diarrhea improving nutritional recovery.",{"entities":[]}],["Aim 2: explore 16-week lactoferrin, lysozyme combination therapy improves secondary clinical, nutritional, enteric pathogen, enteric function outcomes.",{"entities":[]}],["Hypothesis: Children randomized lactoferrin, lysozyme, combination experience hospitalizations deaths, improved linear growth, reduced prevalence specific enteric bacteria linear growth failure (Campylobacter, LT-ETEC, EAEC, typical EPEC and/or Shigella), improved markers enteric dysfunction (myeloperoxidase, alpha antitrypsin, neopterin, lactulose:rhamnose ratio) improved hemoglobin, compared placebo-treated children.",{"entities":[[45,53,"BIOLOGICAL"],[195,208,"BIOLOGICAL"],[245,253,"BIOLOGICAL"],[294,309,"BIOLOGICAL"],[311,328,"BIOLOGICAL"],[330,339,"BIOLOGICAL"],[341,350,"BIOLOGICAL"],[351,359,"BIOLOGICAL"]]}],["Aim 3: evaluate acceptability, adherence cost-effectiveness lactoferrin and/or lysozyme Kenya.",{"entities":[]}],["Hypothesis: therapies highly acceptable caregivers health workers.",{"entities":[]}],["Adherence therapies participants (≥ 95%).",{"entities":[]}],["Lactoferrin lysozyme, combination, cost-effective interventions reducing moderate-to-severe diarrhea short-term compared standard-of-care.",{"entities":[]}],["",{"entities":[]}],["study aims improve integrated delivery PrEP women seeking health services maternal child health clinics piloting evaluating strategies bundles strategies optimized PrEP delivery.",{"entities":[[39,43,"DRUG"],[164,168,"DRUG"]]}],["Strategies tested include packages strategies identified stakeholders.",{"entities":[]}],["",{"entities":[]}],["Background: start COVID-19 pandemic, SARS-CoV-2 variants concern emerged, dominant including B.1.1.7 (alpha), B.1.617 (delta) B.1.1.529 (omicron).",{"entities":[[18,26,"CONDITION"],[37,47,"CONDITION"]]}],["clinical implications variants unvaccinated vaccinated persons adequately characterized.",{"entities":[]}],["detailed understanding interplay variants, vaccine immune responses disease severity scarce.",{"entities":[]}],["Study objectives: objectives are: * collect data and/or biological material COVID-19 in-patients diverse setting 12 clinics 11 countries 4 continents * analyse clinical COVID-19 in-patients relation viral characteristics * analyse clinical COVID-19 in-patients relation vaccines vaccination schedules * deliver recommendations optimized clinical management treatment special consideration viral characteristics vaccines Specific objectives are: * patterns clinical symptoms, therapeutic interventions clinical outcome patients hospitalized 12 hospitals/clinics, 11 countries 4 continents.",{"entities":[[76,84,"CONDITION"],[169,177,"CONDITION"],[240,248,"CONDITION"]]}],["* assess impact viral variants / viral sequences clinical outcome measured all-cause in-hospital mortality, non-invasive mechanical ventilation/high-flow nasal oxygen, mechanical ventilation, admission intensive care unit, time intensive care hospitalization.",{"entities":[]}],["* assess impact vaccines vaccination schedules clinical outcome measured all-cause in-hospital mortality, non-invasive mechanical ventilation/high-flow nasal oxygen, mechanical ventilation, admission intensive care unit, time intensive care hospitalization.",{"entities":[]}],["* assess impact viral variants / sequences response treatment interventions clinical outcome * assess impact vaccines vaccination schedules response treatment interventions clinical outcome * provide WP2 EuCARE biological material studies viral characteristics immune responses * provide WP5 EuCARE data studies artificial intelligence",{"entities":[]}],["",{"entities":[]}],["Aim 1, investigators conduct cluster RCT Kisumu, Kenya determine nurse-navigators PrEP initiation, persistence, adherence AGYW seeking contraception pharmacy-based PrEP delivery model.",{"entities":[[41,47,"LOCATION"],[65,81,"OCCUPATION"]]}],["study randomize 20 retail pharmacies offering PrEP (10 pharmacies randomization arm) enroll 1900 AGYW seeking contraception.",{"entities":[]}],["participants enrolled purchase contraceptive method, offered PrEP (daily oral PrEP DPV-VR) months.",{"entities":[]}],["study quantify compare PrEP initiation, persistence, adherence pharmacy-level randomization arms, addition secondary exploratory outcomes.",{"entities":[]}],["Pharmacy selection cluster RCT (Aim 1): investigators conducted landscape analysis pharmacies Kisumu, Kenya team's ongoing pharmacy-based PrEP delivery studies.",{"entities":[]}],["analysis, investigators gathered types customers attend pharmacies, types services offered (e.g., HIV testing) products purchased (e.g., contraceptive methods) pharmacies, availability separate private consultation room.",{"entities":[]}],["investigators select 20 pharmacies based provide PrEP national guidelines, separate consultation HIV testing PrEP counseling, provide range contraceptives AGYW clients (including EC, OCP, injectables, implants, condoms).",{"entities":[]}],["Randomization (Aim 1): pharmacies receive standard pharmacy-based PrEP delivery randomized receive (n=10 pharmacies) receive (n=10 pharmacies) nurse-navigator assist PrEP delivery.",{"entities":[[66,70,"DRUG"],[166,170,"DRUG"]]}],["ensure balance randomization arms terms key characteristics, sites categorized AGYW volume (i.e., monthly purchases AGYW clients) distribution frequency contraceptive methods purchased (based pharmacy log data) restricted randomization (cluster) allocation intervention control arms.",{"entities":[]}],["Specifically, randomizations distribute sites factors (AGYW client volume distribution contraceptive methods) 2 study arms generated, combination selected random generator.",{"entities":[]}],["Randomization allocation performed biostatistician UW CFAR Biometrics Core, knowledge sites variables included restricted randomization process, Study Statistician, received MPH Biostatistics UW, supervise randomization process.",{"entities":[[151,163,"OCCUPATION"]]}],["assigned, randomization allocation unblinded.",{"entities":[]}],["randomization occur pharmacy level, impossible blind study team participants randomization assignments.",{"entities":[]}],["However, procedures minimize influence unblinded nature study outcomes implemented.",{"entities":[]}],["Ongoing data monitoring include study endpoints disaggregated study arm.",{"entities":[]}],["study statistician review data study endpoints study arm facility.",{"entities":[]}],["",{"entities":[]}],["Background: burden critically patients growing middle income countries (LMICs), resources assist patients limited.1 Critical care established rapidly evolving service Kenya.2 Yet, patient epidemiological characteristics, patterns ICU management patient outcomes Kenyan ICUs remain scarcely investigated.3,6,7 ICU registry: Kenyan Critical Care Registry started December 2020 receiving ethical approval November 2020, involves units 6 Hospitals.",{"entities":[]}],["registry launched collaboration Network Intensive Care Systems Training (NICST) Mahidol Oxford Unit (MORU).",{"entities":[[32,79,"ORG"],[80,107,"ORG"]]}],["countries, Kenyan Critical Care registry aims play increasingly pivotal role evaluating treatment outcomes, benchmarking services providing opportunities service forecasting.",{"entities":[]}],["Dedicated data collectors registry perform real-time data collection.",{"entities":[]}],["registry data housed stored securely national server located Kenyan soil.",{"entities":[]}],["entered electronically password-protected computers participating facilities, automatically encrypted leaves institution visualization loop ring-fenced server NICST, unencrypted aggregated automated visualization.",{"entities":[[159,164,"ORG"]]}],["NICST healthcare standard GDP HIPAA standards.",{"entities":[[0,5,"ORG"],[30,35,"ORG"]]}],["processed data re-encrypted transferred national server, automatically unencrypted review authorized personnel, secure step log - process navigated Kenyan teams.",{"entities":[]}],["audit trail created time registry accessed, logged it, when, data retrieved modified.",{"entities":[]}],["Study aims: study aim patient epidemiological characteristics, basic management outcomes critically patients Kenya COVID-19 pandemic, leveraging newly-implemented Kenya Critical Care Registry housed Critical Care Society Kenya (CCSK).",{"entities":[[163,191,"ORG"],[199,226,"ORG"]]}],["Study outcomes include clinico-demographic characteristics patients admitted critical care units Kenya Critical Care Registry network, primary management process measures short-term critical care outcomes.",{"entities":[]}],["Patients: patients admitted participating critical care units day registry onset day database analysis included.",{"entities":[]}],["secure, non-proprietary, real-time, cloud-based platform designed NICST, adapted participating facilities registry began, data entry management.",{"entities":[]}],["critical care minimum dataset (CCMDS) variables employed investigators, consultation critical care team participating facilities.",{"entities":[]}],["Ethical Considerations: Ethical clearance Aga Khan University Institutional Ethics Review Committee (IERC) registry creation November 2020 (Ref:2019/IERC-89) NACOSTI licence secured.",{"entities":[[42,61,"ORG"],[62,99,"ORG"],[158,165,"ORG"]]}],["approvals NACOSTI-accredited ethical committees and/or administrative clearance participating institutions prior commencement.",{"entities":[[10,28,"ORG"]]}],["Ethical/administrative national regulatory approvals study sought manner, prior study commencement.",{"entities":[]}],["Benefits: direct benefit patients outset.",{"entities":[]}],["expected improvement critical care processes outcomes enabled registry data analysis potential benefit future critically patients Kenya.",{"entities":[]}],["addition gathered admission, patient flow, occupancy acuity essential helping Kenyan administrative management team plan future critical care resource provision, optimising critical care resource utilisation cost effectiveness.",{"entities":[]}],["study provide context specific COVID-19 case-mix outcome data clinicians, administrators policy makers ongoing pandemic.",{"entities":[[31,39,"CONDITION"]]}],["Confidentiality: Access electronic registry restricted personnel authorized leadership participating facilities, unique login password purpose.",{"entities":[]}],["person access registry signed data protection agreement, indicating share login details else, share contents registry unauthorized personnel.",{"entities":[]}],["ICU registries, identifiable patient data restricted hospital staff authorized access critical care registry administration individual facilities.The data extraction analysis concern de-identified data.",{"entities":[]}],["",{"entities":[]}],["Study context 31 March 2020, confirmed country, total 20144 confirmed 877 deaths (case fatality rate (4.4%) line-listed 27th February 2022.",{"entities":[]}],["Kiambu ranks cumulative confirmed Coronavirus-19 cases.",{"entities":[[0,6,"LOCATION"],[34,48,"CONDITION"]]}],["Kiambu county major gaps Coronavirus-19 management inadequate resources limiting response capacity detecting, investigating, contact tracing follow facilities community.",{"entities":[[0,6,"LOCATION"],[25,39,"CONDITION"]]}],["county reported spikes Coronavirus-19 participation mass gathering events political rallies, markets, churches, burials, etc.",{"entities":[[23,37,"CONDITION"]]}],["county tertiary institutions identified transmission hotspots.",{"entities":[]}],["Kiambu county implements Coronavirus-19 guidelines stipulated ministry health guidelines (hand washing, social distancing, masks etc), non-compliance Coronavirus-19 protocols learning institutions public Bus parks, markets supermarkets.",{"entities":[[0,13,"LOCATION"],[25,39,"CONDITION"],[150,164,"CONDITION"]]}],["Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) supporting Ministry Health (MOH) Kenya accelerate effective Coronavirus-19 response solutions increase access quality diagnostics therapeutics Unitaid-funded Catalysing Coronavirus-19 Action (CCA) project.",{"entities":[[0,50,"ORG"],[62,83,"ORG"]]}],["project, EGPAF supporting decentralizing testing integration severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) antigen rapid diagnostic (Ag RDT) Maternal Newborn Child Health, Tuberculosis HIV clinics 31 facilities Kiambu county.",{"entities":[[95,108,"CONDITION"],[110,120,"CONDITION"],[187,199,"CONDITION"]]}],["project enhances linkage care treatment including therapeutics hub spoke model.",{"entities":[]}],["EGPAF civil society organizations key stakeholders Kiambu county increase demand SARS-CoV-2 testing care treatment.",{"entities":[[0,5,"ORG"],[51,64,"LOCATION"],[81,91,"CONDITION"]]}],["study build programmatic components CCA project explore effectiveness SARS-CoV-2 AgRDT mass testing volume community venues detect SARS-CoV-2 infections.",{"entities":[[70,80,"CONDITION"],[131,141,"CONDITION"]]}],["CCA project implemented October 2021 testing Ag-RDT January 2022 Kiambu county.",{"entities":[[65,78,"LOCATION"]]}],["observed clients attending facilities services offered testing, community vaccination campaigns, people possibility tested.",{"entities":[]}],["Study Rationale 14 March 2022, 28.8% adults vaccinated Kenya 4.",{"entities":[]}],["vaccines widespread availability, testing isolation methods control disease spread national level.",{"entities":[]}],["simple, rapid, affordable Ag-RDT expand access SARS-CoV-2 testing incorporated national Coronavirus-19 responses.",{"entities":[[47,57,"CONDITION"],[88,102,"CONDITION"]]}],["Targeting volume community venues potential screen lot people limited time determine contributing community transmission.",{"entities":[]}],["Data acceptability mass SARS-CoV-2 Ag-RDT testing community settings Africa limited.",{"entities":[[24,34,"CONDITION"],[35,41,"INTERVENTION"]]}],["current programs screen strategy identify symptomatic infection risk exposure limited availability costs broader testing.",{"entities":[]}],["However, strategy identify asymptomatic infection contribute spread SARS-CoV-2 infection.",{"entities":[[68,78,"CONDITION"]]}],["Data inform evolving SARS-CoV-2 testing guidelines provide MOH feasible costed testing models address national strategies.",{"entities":[[21,31,"CONDITION"]]}],["study generate evidence determine SARS-CoV-2 detection rate proportion asymptomatic symptomatic infections detected volume community venues SARS-CoV-2 Ag-RDTs.",{"entities":[[34,44,"CONDITION"],[140,150,"CONDITION"],[151,158,"INTERVENTION"]]}],["Additionally, genome sequencing positive MoH determining circulating genomic strains Kenya real time contribute national guidance.",{"entities":[]}],["Study Aim: aim study generate evidence evaluating Ag-RDTs community identification SARS-CoV-2 infections gathering venues, ultimately determine mass testing venues feasible approach.",{"entities":[[83,93,"CONDITION"]]}],["Primary Objective: 1.To estimate SARS-CoV-2 detection rate (number SARS-CoV-2 infections detected 100 individuals tested) volume community venues SARS-CoV-2 Ag-RDT, disaggregated venue type.",{"entities":[[33,43,"CONDITION"]]}],["Secondary Objectives: determine proportion venue attendees SARS-CoV-2 testing cascade: people offered Ag-RDT, accept testing, receive results, positive, determine proportion people positive SARS-CoV2 RDT symptomatic, referred polymerase chain reaction (PCR) testing confirmed PCR, referred home-based isolation care, identify factors SARS-CoV-2 infection, age, venue, exposure history vaccination status.",{"entities":[[226,257,"BIOLOGICAL"],[276,279,"BIOLOGICAL"]]}],["SARS-CoV-2 variants SARS-CoV-2 positive attendees determine costs implementation SARS-CoV-2 Ag-RDT community settings.",{"entities":[[0,10,"CONDITION"],[20,30,"CONDITION"],[81,91,"CONDITION"]]}],["investigators hypothesize introduction SARS-CoV-2 mass testing high-exposure venues community, individuals access testing services, individuals accept SARS-CoV-2 RDT, symptomatic asymptomatic SARS-CoV-2 infections diagnosed, individuals diagnosed SARS-CoV-2 linked care treatment services.",{"entities":[[39,49,"CONDITION"],[151,161,"CONDITION"],[192,202,"CONDITION"]]}],["lead isolation SARS-CoV-2 infected individuals, quarantining contacts, medical treatment requiring it.",{"entities":[]}],["Study Design community-based cross-sectional study.",{"entities":[[13,50,"STUDY_DESIGN"]]}],["study conducted population Kiambu County, central Kenya, attending specific high-volume community venues identified community-based transmission.",{"entities":[[27,40,"LOCATION"],[50,55,"COUNTRY"]]}],["high-volume community venues be: Venues identified individuals diagnosed SARS-CoV-2 infection subset CCA-supported facilities Kiambu County.",{"entities":[]}],["CCA questionnaire, participants identify crowded participants days prior positive SARS-CoV-2 test.",{"entities":[]}],["provide opportunity staff identify market places, worship, schools, venues SARS-CoV-2 transmission occur communities.",{"entities":[]}],["study, testing activities conducted health facilities.",{"entities":[]}],["Venues identified collaboration department public health Coronavirus-19 response team county transmission hotspots.",{"entities":[]}],["approaches above, investigators identify venues Kiambu county people congregate propose mass testing.",{"entities":[]}],["Variant surveillance population Individuals positive SARS-Cov-2 Ag-RDT negative symptoms Coronavirus-19 provide sample confirmatory PCR testing genome sequencing variant surveillance.",{"entities":[]}],["participants care Coronavirus-19 participant wait PCR result.",{"entities":[]}],["Based national guidelines management Coronavirus-19 Kenya, person meets clinical epidemiological criteria suspected SARS-CoV-2.",{"entities":[[37,51,"CONDITION"],[52,57,"COUNTRY"],[116,126,"CONDITION"]]}],["participant assessed based severity symptoms participant referred treatment centre symptoms managed.",{"entities":[]}],["person mild symptoms referred based care.",{"entities":[]}],["study team transport hospitalized hospital.",{"entities":[]}],["Kiambu county 5 treatment centres isolation centres.",{"entities":[]}],["secondary sample collection routine national surveillance, purposes, investigators perform study activity voluntarily agree study administration written informed consent.",{"entities":[]}],["sample community venue written consent/assent transported testing laboratory standard operating procedures.",{"entities":[]}],["Inclusion criteria variant surveillance: Venue attendee positive result SARS-Cov-2 Ag-RDT Venue attendee negative Ag-RDT, Coronavirus-19 symptoms Provide written informed consent collect sample Community mobilization recruitment describes activities conducted Kiambu County Coronavirus-19 response team start study activities.",{"entities":[[72,82,"CONDITION"],[122,136,"CONDITION"],[274,288,"CONDITION"]]}],["Mobilizing community ensure response rate priority successful study implementation Kiambu County Coronavirus-19 response team engaged initial stages ensure security coordination mechanisms informed.",{"entities":[]}],["mass testing, meetings held community leaders explain study opportunity discuss potential concerns, including preventing dissemination false information.",{"entities":[]}],["meetings coordinated public health department county strong collaboration EGPAF team.",{"entities":[]}],["Depending venue, key stakeholders include social workers, community health volunteers, local community leaders (chiefs, chiefs), county sub- county health management teams, including public health department, county Coronavirus-19 response manager, county education department, school principals, religious leaders, others.",{"entities":[]}],["Ongoing dialogue stakeholders maintain community engagement study implementation.",{"entities":[]}],["days start testing campaign, community health volunteers visit selected attendance venues poster announcing community testing activity distributed display venue prior scheduled testing intervention.",{"entities":[]}],["Trained community health volunteers mobilizers venue pre-agreed day(s) actual testing day mobilize community.",{"entities":[]}],["channels community, Facebook, social media mobilize community.",{"entities":[]}],["church leaders association pastors, messages testing posted church websites available.",{"entities":[]}],["Megaphones caravans community mobilization deemed appropriate.",{"entities":[]}],["Data Collection day testing, individuals accessing venue informed SARS-CoV-2 testing participants tested.",{"entities":[[66,76,"CONDITION"]]}],["anonymous screening log completed individuals offered testing, include age, sex, testing accepted not, reported reasons choosing test.",{"entities":[]}],["capture description population venue documentation testing refusal rate.",{"entities":[]}],["opt testing, MoH staff provide routine procedure performing (see testing procedure).",{"entities":[]}],["consenting process, study objectives procedures client questions.",{"entities":[]}],["agree undergo 2- 5-minutes interview.",{"entities":[]}],["data interview recorded data collection tool entered study database.",{"entities":[]}],["individuals tested positive negative referred PCR Coronavirus-19 symptoms, investigators collect final PCR result, result sequencing obtaining written informed consent.",{"entities":[[46,49,"INTERVENTION"],[50,64,"CONDITION"],[103,106,"INTERVENTION"]]}],["PCR/whole genome sequencing (WGS) surveillance: Kenya Medical Institute-Wellcome Trust Laboratory Kilifi laboratory tasked Ministry Health SARS-CoV-2 genome sequencing Kenya.",{"entities":[[48,86,"ORG"],[98,104,"LOCATION"],[139,149,"CONDITION"]]}],["laboratory operates compliance Clinical Laboratory Practice (GCLP) standards.",{"entities":[]}],["study, Coronavirus-19 sequencing sample manifest form (QMS-F238- Annex 5) completed required swabs Kenya Medical Institute-Wellcome Trust Laboratory.",{"entities":[]}],["Laboratory staff communicate study team unique identifiers above; study team update study database.",{"entities":[]}],["Costs estimated health systems perspective micro-costing method, combining top-down bottom-up approaches resource costs item.",{"entities":[]}],["project costs converted 2022 U.S.",{"entities":[]}],["dollars (US$) prevailing exchange rate adjusted inflation U.S.",{"entities":[]}],["consumer price needed.",{"entities":[]}],["",{"entities":[]}],["Background: annual global HIV infections adults remained unchanged decade fuelled key populations people inject drugs (PWID).",{"entities":[[98,117,"POPULATION"],[119,123,"POPULATION"]]}],["Key populations Kenya account one-third HIV infections 18.3% PWID country living HIV.",{"entities":[[61,65,"POPULATION"]]}],["Drug substance increase country, close 4 Kenyans reporting substance lifetime including injectable drugs fueling spread HIV.",{"entities":[]}],["Pre-Exposure Prophylaxis (PrEP) effective prevention HIV transmission PWID 70.0% correctly.",{"entities":[[70,74,"POPULATION"]]}],["However, uptake, adherence, scale-up use, coverage retention remain limited.",{"entities":[]}],["Thus, effective interventions enhance uptake PrEP PWID sexual injecting partners prevent HIV transmission.",{"entities":[[50,54,"POPULATION"],[55,80,"POPULATION"]]}],["Objectives Study: Broadly, investigators aim determining PrEP uptake barriers facilitators adherence study participants sequel theory-guided behavioral intervention model (PrEP-UP) uptake PrEP study participants.",{"entities":[]}],["Specifically, investigators aim determining: (1) PrEP knowledge levels, attitudes, practices user experiences study participants(2) socio-demographic, behavioural structural factors hindering uptake PrEP study participants; (3) theory-guided behavioural intervention (PrEP-UP) utilizing peer outreach navigation uptake PrEP study participants.",{"entities":[]}],["Methods: investigators conduct study months (1st July 2021 30th June 2022) implementation study pre-post design assess 256 participants' self-reported PrEP uptake retention exposure theory-guided behavioural intervention (PrEP-UP) utilizing navigators peer outreach 128 'cases' PrEP Pamphlet list health facilities offering PrEP Nairobi County 128 'control' members.",{"entities":[]}],["investigators study sites Githurai, Kawangware, Ngara Pangani PWID's hotspots Nairobi City.",{"entities":[[26,34,"LOCATION"],[36,46,"LOCATION"],[48,53,"LOCATION"],[54,61,"LOCATION"],[78,90,"LOCATION"]]}],["targeted study participants PWID's sexual injecting partners ages 18 above.",{"entities":[[28,32,"POPULATION"],[35,60,"POPULATION"]]}],["investigators recruit 256 study participants study peers social workers University Washington's Needle Syringe Program (NSP) sites Githurai, Kawangware, Ngara Pangani.",{"entities":[[72,93,"LOCATION"],[96,123,"ORG"],[131,139,"LOCATION"],[141,151,"LOCATION"],[153,158,"LOCATION"],[159,166,"LOCATION"]]}],["investigators collect baseline data recruitment interventions offered maximum 5 contact sessions investigators follow-up participants investigators weeks 4, 8 12 establish study participants PrEP week 12 post-intervention data collected.",{"entities":[]}],["Lastly, participants' self-reported PrEP retention documented investigators 18 weeks HIV tests conducted participants investigators (optional) OraQuick antibody HIV tests.",{"entities":[]}],["investigators analyze: quantitative data Statistical Package Social Sciences (SPSS) version 24 and: qualitative data flow chart matrices establish divergence convergence themes.",{"entities":[]}],["Significance Study: study, investigators contribute global reduction HIV infections PWIDs sexual injecting partners.",{"entities":[]}],["study inform investigators effectiveness-implementation science interventions recommend PrEP scale-up approaches addition contributing global scientific knowledge.",{"entities":[]}],["",{"entities":[]}],["three-part, multicenter, Phase 2/3 study orally administered osivelotor participants sickle cell disease (SCD).",{"entities":[[85,111,"CONDITION"]]}],["evaluate safety, tolerability, efficacy osivelotor adult participants SCD determine optimal dose.",{"entities":[[70,73,"CONDITION"]]}],["evaluate efficacy osivelotor placebo adult adolescent participants SCD 48 weeks.",{"entities":[[18,28,"DRUG"],[29,36,"INTERVENTION"],[37,42,"POPULATION"],[43,53,"POPULATION"],[67,70,"CONDITION"]]}],["evaluate pharmacokinetics (PK) safety single multiple doses (MD) open-label single arm osivelotor administered pediatric participants.",{"entities":[]}],["",{"entities":[]}],["scheduled visits study.",{"entities":[]}],["screening vaccination visit (Day 0) additional study visits Day 28 Day 180 post-vaccination.",{"entities":[]}],["study, participants/parent/guardian encouraged contact study team participant unwell study team additionally maintain contact study participants.",{"entities":[]}],["participant parent/guardian contacted telephonically Day 90 enquire participant's health occurrence adverse events (SAEs).",{"entities":[]}],["Active surveillance vaccine reactogenicity conducted reactogenicity cohort time vaccination (Day 0) Day vaccination.",{"entities":[]}],["Unsolicited collected study participants Day 28 post vaccination.",{"entities":[]}],["SAEs collected participants study (to Day 180).",{"entities":[]}],["",{"entities":[]}],["Background: Genital Human Papilloma Virus (HPV) infections occur rapidly sexual debut, immunosuppressed individuals risk incident persistent infection.",{"entities":[[12,41,"CONDITION"],[43,46,"CONDITION"]]}],["HPV vaccine virus-like particles (VLP), highly immunogenic induce robust humoral response demonstrated confer term protection HPV infection disease HIV-uninfected individuals.",{"entities":[[0,3,"CONDITION"],[4,32,"BIOLOGICAL"]]}],["magnitude type-specific vaccine induced neutralizing HPV antibody responses diminished HIV-infected compared uninfected individuals.",{"entities":[[53,56,"CONDITION"]]}],["established minimum level antibody predicts protection HPV infection disease, impact antibody titers HIV infected individuals vaccine efficacy unknown.",{"entities":[]}],["risk HPV exposure persists person's sexual life duration protection, vaccine adolescent period critical vaccine effectiveness.",{"entities":[]}],["lasting memory characterized memory cells long-lived plasma cells QHPV booster dose demonstrated anamnestic response HIV-infected adolescents.",{"entities":[]}],["HPV efficacy effectiveness data HIV-uninfected individuals informed current Health Organization (WHO) two-dose vaccine schedule.",{"entities":[[76,100,"ORG"]]}],["field lacks data effectiveness dose two-dose HIV-infected adolescents.",{"entities":[]}],["current on-going single dose schedules urgency determination long-term efficacy HPV vaccine 231 doses HIV-infected adolescent.",{"entities":[]}],["Investigators recall HIV-infected girls boys vaccinated ages 9-14 doses quadrivalent vaccine (QHPV) 2014 evaluated vaccine immunogenicity.",{"entities":[]}],["Method: participants assessed genital warts genital HPV infection.",{"entities":[]}],["Type specific HPV DNA assessed genital swabs genital warts assessed physical examination sexually active participants enrollment, month 6 \\\\&12.",{"entities":[]}],["sexually active, decline genital exam, self-collected swab requested.",{"entities":[]}],["sub-set 30 participants, receive booster dose QHPV, subset, Peripheral Blood Mononuclear Cells (PBMC) plasma samples collected enrollment, month 1 month 12 evaluate memory cell responses.",{"entities":[[60,101,"BIOLOGICAL"]]}],["total duration study follow 12 months.",{"entities":[]}],["",{"entities":[]}],["mainstay cervical cancer (CC) prevention low- middle-income counties (LMIC) single-visit approach screen-and-treat (SVA-SAT) method, visual inspection acetic acid (VIA) ablative treatment cryotherapy manage precancerous lesions.",{"entities":[]}],["low-cost screening approach minimizes loss follow-up compared traditional cytology.",{"entities":[]}],["Kenya, extremely fidelity SVA-SAT.",{"entities":[]}],["Thermal ablation (TA) effective alternative cryotherapy ablation precancerous lesions, recommended Health Organization (WHO) 2019.",{"entities":[[99,124,"BIOLOGICAL"]]}],["Preliminary data investigative team demonstrated safety, effectiveness, acceptability women delivered nurses Zambia Kenya.",{"entities":[[109,115,"COUNTRY"],[116,121,"COUNTRY"]]}],["portable device charged electricity, batteries solar panels, ideal low-resource settings.",{"entities":[]}],["Successful implementation scale-up TA SVA-SAT approach optimize prevention.",{"entities":[]}],["five-year prospective, stepped-wedge, cluster randomized trial implement SVA-SAT+TA reproductive health (RH) clinics central Kenya.",{"entities":[]}],["study mixed-methods evaluation based RE-AIM (Reach, Effectiveness, Adoption, Implementation Maintenance) framework assess intervention's impact.",{"entities":[[37,43,"INTERVENTION"],[44,104,"INTERVENTION"]]}],["collaboration multi-level (clinic, county, national) stakeholders project develop sustainable D\\\\&I strategy leverage trial implementation include costing budget impact analysis.",{"entities":[]}],["objective develop evaluate locally contextualized dissemination implementation (D\\\\&I) strategy SVA-SAT TA (SVA-SAT+TA) inform national scale-up.",{"entities":[]}],["hypothesis TA enhance feasibility, adoption, sustainability prevention services SVA-SAT, compared standard care cryotherapy.",{"entities":[]}],["Design: Prospective, stepped-wedge, cluster randomized trial implement SVA-SAT+TA reproductive health (RH) clinics central Kenya.",{"entities":[]}],["Population: Mixed population: Reproductive health care workers, health manager's, women seeking services cervical cancer screening women screen positive pre-cancerous lesions cervix.",{"entities":[]}],["Objective 1: Develop dissemination implementation strategy introduce SVA-SAT+TA effectively accounts heterogeneity client, provider, inputs.",{"entities":[]}],["Approach: project qualitative interviews women seeking prevention services, reproductive health (RH) providers, RH managers, key program stakeholders identify actionable barriers facilitators SVA-SAT+TA uptake.",{"entities":[]}],["data stakeholder workshop synthesize contextualize strategies effectively introduce intervention provide guidance scale up.",{"entities":[]}],["Objective 2: Deliver SVA-SAT+TA intervention scale RH clinics evaluate implementation RE-AIM framework.",{"entities":[]}],["Approach: SVA-SAT+TA introduced RH clinics stepped-wedge study design RE-AIM framework process rigorously evaluated effective disseminated implemented.",{"entities":[]}],["Key endpoints include: 1.",{"entities":[]}],["(REACH) Proportion clinics reached, providers trained; 2.",{"entities":[]}],["(EFFECTIVENESS) Intervention SVA-SAT process measures: screen positive women identified month, treatment completion rate compared pre-intervention, patient-level TA fidelity implementation assessed testing Human Papillomavirus (HPV) clearance 3.",{"entities":[]}],["(ADOPTION) Proportion clinics incorporating TA routine care 4.",{"entities":[]}],["(IMPLEMENTATION) drivers success/failure Consolidated Framework Implementation (CFIR) 5.",{"entities":[]}],["(MAINTENANCE) Proportion clinics continue provide sustain SVA-SAT+TA services post intervention implementation.",{"entities":[]}],["Objective 3: Compare cost budget impact SVA-SAT+TA SVA-SAT cryotherapy.",{"entities":[]}],["Approach: micro-costing techniques quantify programmatic costs SVA-SAT cryotherapy TA.",{"entities":[]}],["",{"entities":[]}],["study set response international outbreak Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2).",{"entities":[[91,101,"CONDITION"]]}],["aim study answer questions impact coronavirus pregnant women infants.",{"entities":[]}],["investigators aim sero-epidemiology burden COVID-19 disease pregnant women, impact maternal neonatal health, collecting epidemiological data collecting samples pregnancy, labour delivery neonatal period.",{"entities":[[43,51,"CONDITION"]]}],["Data study pooled 5 countries; Malawi, Uganda, Mozambique, Gambia, Kenya provide robust generalisable evidence regions sub-Saharan Africa.",{"entities":[[31,37,"COUNTRY"],[39,45,"COUNTRY"],[47,57,"COUNTRY"],[59,65,"COUNTRY"],[67,72,"COUNTRY"],[119,137,"LOCATION"]]}],["investigators hope information, contribute evidence base recommendations, guidance policy decisions clinical management public health response protect pregnant women infants.",{"entities":[]}],["",{"entities":[]}],["AIM 1: conduct cluster-randomized trial evaluating effectiveness SAIA control (usual procedures) increasing HIV counseling, testing, linkage care, screening linkage PrEP FP clients returning AGYW clients.",{"entities":[[15,39,"STUDY_DESIGN"]]}],["Quantitative qualitative data analyzed RE-AIM framework (21).",{"entities":[]}],["1a) Reach: Proportion intervention arm health facility clients' reached intervention 1b) Effectiveness: Compare effectiveness SAIA vs.",{"entities":[]}],["control increasing rates HIV counseling, testing, linkage care, screening linkage PrEP FP clients returning AGYW clients 1c) Adoption: Proportion clinics adopting SAIA; adoption determinants identified Implementation Logic Model (IRLM) (22) Organizational Readiness Implementing Change (ORIC) scale (23) 1d) Implementation: Proportion FP clinics implementing SAIA fidelity 12 months 24 months; barriers facilitators implementation scale County DOH personnel explored constructs Consolidated Framework Implementation (CFIR) IRLM (24) 1e) Maintenance: Proportion FP clinics maintaining SAIA 12 months 24 months introduction AIM 2: estimate incremental cost budget program impacts SAIA County DOH perspective.",{"entities":[]}],["conduct activity-based costing develop budget impact scenarios based SAIA's adoption.",{"entities":[]}],["",{"entities":[]}],["Rationale: simple, rapid affordable antigen-detecting rapid diagnostic tests (Ag-RDT) expand access SARS-CoV-2 testing incorporated national COVID-19 response plans including Cameroon Kenya.",{"entities":[]}],["Targeting populations risk COVID-19 disease, severe outcomes, onward transmission vulnerable populations pregnant women, people living HIV, patients TB potential mitigate adverse effects SARS-CoV-2 pandemic.",{"entities":[]}],["Data SARS-CoV-2 infection populations Africa feasibility integrating Ag-RDT MNCH, HIV, TB services limited.",{"entities":[]}],["current programs screen strategy identify symptomatic infection risk exposure limited availability costs broader testing.",{"entities":[]}],["However, strategy identify asymptomatic infection contribute spread SARS-CoV-2 infection.",{"entities":[[68,78,"CONDITION"]]}],["Design: conduct pragmatic cluster randomized trial determine SARS-CoV-2 detection rate facilities randomized standard \"\"screen test\"\" model SARS-CoV-2 Ag-RDT compared \"\"test all\"\" model SARS-CoV-2 Ag-RDT MNCH, HIV TB clinics.",{"entities":[[140,150,"CONDITION"],[151,157,"INTERVENTION"],[186,196,"CONDITION"],[197,203,"INTERVENTION"],[214,216,"CONDITION"]]}],["clinical outcomes SARS-CoV-2 infection determine feasibility costs model.",{"entities":[]}],["country, propose randomly allocate purposively chosen facilities \"\"test all\"\" arm standard care arm 1:1 ratio.",{"entities":[]}],["plan enroll 6000 patients arm.",{"entities":[]}],["Screening testing data individuals attending MNCH, TB HIV clinics recorded clinic records captured electronic database accessed study.",{"entities":[]}],["SARS-CoV-2 positive patients prospectively determine SARS-CoV-2 cascade testing, ascertainment disease status, linkage care, disease progression, treatment outcomes hospitalized non-hospitalized patients.",{"entities":[]}],["Disease progression outcome data collected phone interviews patients hospitalized interview medical record extraction hospitalized patients.",{"entities":[]}],["SARS-CoV-2 positive study participants contact tracing testing forms contacts, capture anonymous testing data contacts access Ag-RDT testing health facility.",{"entities":[[0,10,"CONDITION"],[126,132,"INTERVENTION"]]}],["feasibility models integration captured structured questionnaire administered health care workers collection time-motion data determine provider patient time required conduct Ag-RDT testing.",{"entities":[[175,181,"INTERVENTION"]]}],["service delivery costs model (such personnel, training, equipment, tests, documentation) determined.",{"entities":[]}],["Outcomes: Primary outcomes include SARS-CoV-2 detection rates number/ proportion contacts tested diagnosed SARS-CoV-2 infection.",{"entities":[]}],["Secondary outcomes include testing rates, linkage care, disease progression, treatment final outcome SARS-CoV-2 infected patients feasibility cost integration models.",{"entities":[]}],["primary analysis summarize SARS-CoV-2 detection rates 95% confidence intervals facility.",{"entities":[]}],["identification rates arm estimated inverse variance weighted method combine rates facilities.",{"entities":[]}],["intervention 95% confidence intervals estimated Poisson regression expressed relative risk.",{"entities":[]}],["95% confidence interval limit 1 increase detection rates \"\"test all\"\" intervention.",{"entities":[]}],["Additional analyses examine effects \"\"test all\"\" intervention clinics countries.",{"entities":[]}],["account potential clustering outcomes health facility, estimate robust standard errors regression models.",{"entities":[]}],["Duration: anticipated study enrolment 4 months additional 1 month complete study follow-up, 3-4 months data analysis reporting.",{"entities":[]}],["",{"entities":[]}],["project evaluate innovative, theoretically-motivated economic intervention reduce men's engagement transactional sex risky behaviors.",{"entities":[]}],["Leveraging innovations mobile financial services savings behavior low-income countries, investigators propose intervention seeks motivate high-risk, income-earning western Kenya reduce spending risky behaviors save disposable income local bank accounts.",{"entities":[]}],["bank accounts include additional incentives save form lottery-based rewards linked amounts saved.",{"entities":[]}],["intervention encourage participants develop savings goals strategies, provide periodic reminders saving regularly.",{"entities":[]}],["direct economic mechanism (incentives shift expenditures future) psychological mechanism (increasing future orientation), investigators hypothesize intervention result increased savings, reduced spending transactional sex alcohol, risky sexual behavior, reduced risk HIV sexually transmitted infections (STIs).",{"entities":[[267,270,"CONDITION"],[271,309,"CONDITION"]]}],["investigators conduct randomized controlled trial risk HIV STI infection determine effects savings intervention health economic outcomes.",{"entities":[]}],["Specific aims project follows.",{"entities":[]}],["Aim 1: Determine impact intervention savings investment behavior, self-reported sexual behavior, incidence HIV/STIs.",{"entities":[[107,115,"CONDITION"]]}],["Aim 2: Quantitatively qualitatively assess mechanisms behavior change participants sample female partners.",{"entities":[]}],["",{"entities":[]}],["two-year study consist qualitative approaches intervention development, mixed methods pilot study assess newly developed intervention's acceptability, usability, preliminary efficacy (Aim 1).",{"entities":[]}],["conduct focus discussions (FGDs) family caregivers identify acceptable approaches strengthen supportive roles (Aim 2).",{"entities":[[8,32,"INTERVENTION"]]}],null,null,["intervention designed increase awareness stigma HIV pregnancy, improve disclosure self-efficacy skills, facilitate enlistment family social support allies.",{"entities":[]}],["goal intervention enhance uptake services prevention mother-to-child transmission HIV (PMTCT).",{"entities":[[87,92,"CONDITION"]]}],["single pre-post intervention quasi-experimental design, study assess usability, acceptability, preliminary improvements stigma disclosure measures.",{"entities":[]}],["mixed method approach (i.e., quantitative qualitative data collection) evaluate intervention.",{"entities":[]}],["participants receive intervention.",{"entities":[]}],["adolescents included pilot study female, living HIV, pregnant, unmarried, ages 15-19 include rural urban youth.",{"entities":[[0,11,"POPULATION"],[48,51,"CONDITION"],[53,61,"CONDITION"]]}],["contacts study participants.",{"entities":[]}],["contact, participants consented complete baseline quantitative survey.",{"entities":[]}],["contact, participants receive one-on-one intervention session.",{"entities":[]}],["intervention session, mobile phone internet access, guided access digital intervention, receive guided tour website, questions answered.",{"entities":[]}],["tour, explore complete specific tasks staff assistance (e.g., actively engage selected modules).",{"entities":[]}],["exploring website, participants \"\"think aloud\"\" share questions arise.",{"entities":[]}],["qualitative data participants' session audio recorded field staff notes written.",{"entities":[]}],["completion intervention tasks, participants return mobile phone staff complete quantitative survey assessing intervention's acceptability usability.",{"entities":[]}],["contact, weeks intervention session, collect follow survey data assess maintenance/persistence intervention effects short duration exposure.",{"entities":[]}],["Survey measures baseline two-week follow include demographics, stigma HIV pregnancy, disclosure self-efficacy HIV pregnancy, disclosure HIV pregnancy caregivers.",{"entities":[[70,73,"CONDITION"],[74,83,"CONDITION"],[110,113,"CONDITION"],[114,123,"CONDITION"]]}],["Descriptive analyses conducted quantitative data time-related patterns assess clinically meaningful improvements measures.",{"entities":[]}],["",{"entities":[]}],["two-part, phase 2 trial evaluating safety tolerability one-time subcutaneous (SC) administration monoclonal antibody (MAb) L9LS healthy Kenyan children aged 5 months years, protective efficacy doses L9LS naturally occurring Plasmodium falciparum (Pf) infection Kenyan children aged 5 59 months enrollment, setting perennial transmission.",{"entities":[[224,245,"BIOLOGICAL"]]}],["1 age de-escalation dose-escalation study.",{"entities":[]}],["stepwise fashion, children aged 5-10 receive 5 mg/kg L9LS placebo 3 months assess tolerability safety.",{"entities":[[53,65,"INTERVENTION"]]}],["acceptable tolerability safety profiles met 1-week post-injection, 5 mg/kg dose L9LS placebo administered children aged 5-59 months enrolling cohort children aged 5-10 dose mg/kg L9LS placebo.",{"entities":[[80,92,"INTERVENTION"],[179,191,"INTERVENTION"]]}],["1 week, mg/kg dose safe children aged 5-10 5 mg/kg dose safe children aged 5-59 months, 20 mg/kg dose L9LS placebo administered children aged 5-10 mg/kg dose L9LS placebo children aged 5-59 months.",{"entities":[[102,114,"INTERVENTION"],[158,170,"INTERVENTION"]]}],["Finally, doses safe 1 week, 20 mg/kg dose L9LS placebo administered children aged 5-59 months.",{"entities":[[42,54,"INTERVENTION"]]}],["tolerability safety doses acceptable children aged 5-59 months, 2 trial begin.",{"entities":[]}],["Dosing 1 study weight-based doses administered double-blinded fashion.",{"entities":[]}],["12 participants age-dose enrolled 3:1 ratio L9LS placebo, participants total 3 months.",{"entities":[]}],["2 efficacy study.",{"entities":[]}],["Children 5-59 months age randomized receive 10-19 mg/kg dose L9LS placebo administration.",{"entities":[]}],["L9LS cohorts, 5-17 months age 18-59 months age, constitute L9LS arm.",{"entities":[]}],["placebo arm composed children 5-59 months age.",{"entities":[]}],["12 months monthly blood smear microscopy polymerase chain reaction (PCR) twice-monthly symptomatology careseeking behavior questionnaires.",{"entities":[[41,71,"BIOLOGICAL"]]}],["Dosing based weight bands; doses administered fixed doses 75 L9LS, 150 L9LS, 225 L9LS, range 10-19 mg/kg double-blinded fashion.",{"entities":[]}],["Blood drawn assess antibody titers baseline, additional time 12 months establish pharmacokinetics (PK).",{"entities":[[81,99,"BIOLOGICAL"]]}],["Participants L9LS arm randomized 1:1 baseline receive L9LS injection placebo injection evaluate additional efficacy dose administered 6 months dose.",{"entities":[]}],["(Those placebo arm receive injection placebo.) Participants additional 6 months injection monthly blood smear microscopy PCR, blood draw month 11 assess L9LS PK.",{"entities":[]}],["",{"entities":[]}],["dissemination study objective explore effectiveness, acceptability, scalability Shamiri intervention implemented large-scale naturalistic dissemination study Kenyan secondary schools.",{"entities":[[80,87,"ORG"]]}],["Specifically, study broad goals: 1) effectiveness Shamiri mental health psychosocial outcomes delivered naturalistically scale centralized de-centralized (train trainers) administration, 2) examine measure outcomes large-scale dissemination models.",{"entities":[[50,57,"ORG"],[58,71,"CONDITION"]]}],["goal 1, participants receive Shamiri Shamiri team implementation partner.",{"entities":[[29,36,"ORG"],[37,44,"ORG"]]}],["investigators measure mental health psychosocial outcomes determine outcomes compare reported prior RCTs Shamiri.",{"entities":[[105,112,"ORG"]]}],["investigators hypothesize participants receiving Shamiri experience improvements mental health psychosocial outcomes reported previous RCTs.",{"entities":[[49,56,"ORG"],[81,94,"CONDITION"]]}],["investigators priori hypothesis mode participants receive intervention affect intervention outcomes.",{"entities":[]}],["achieve goal 2, investigators measure implementation outcomes: intervention fidelity, cost, sustainment, acceptability, penetration, cost-effectiveness.",{"entities":[]}],["investigators hypothesize Shamiri intervention achieve ratings intervention outcomes.",{"entities":[]}],["",{"entities":[]}],["Online PrEP overcome patient- provider-level barriers facility-delivered PrEP.",{"entities":[]}],["patient-level, online PrEP increase privacy convenience enabling patients receive PrEP location time choice.",{"entities":[[22,26,"DRUG"],[82,86,"DRUG"]]}],["Additionally, expanding options PrEP delivery, patients select model fits preferences.",{"entities":[[32,36,"DRUG"]]}],["delivery PrEP couriers decrease time patients spend (and costs with) traveling waiting health facilities, stigma visiting HIV clinics PrEP care.",{"entities":[[9,13,"DRUG"],[134,138,"DRUG"]]}],["provider-level, online PrEP decrease crowding facilities increase time providers spend patients seeking treatment services.",{"entities":[[23,27,"DRUG"]]}],["Additionally, shifting PrEP delivery responsibilities lower-paid couriers cost saving health system.",{"entities":[]}],["Together, advantages online PrEP increase PrEP continuation individuals risk HIV.",{"entities":[[28,32,"DRUG"],[42,46,"DRUG"]]}],["MYDAWA, Kenya's licensed online pharmacy (https://mydawa.com), uniquely positioned support online PrEP delivery applying technology deliver essential medicines health supplies local communities.",{"entities":[[0,6,"ORG"]]}],["goal study generate data support relevant policy decisions broader adoption online PrEP delivery region.",{"entities":[]}],["investigators plan develop evaluate feasibility online delivery model support PrEP initiation continuation individuals risk HIV acquisition Kenya.",{"entities":[[78,82,"ORG"],[124,127,"CONDITION"],[140,145,"COUNTRY"]]}],["model deliver once-daily oral tenofovir/emtricitabine (TDF/FTC).",{"entities":[[30,53,"DRUG"],[55,62,"DRUG"]]}],["evaluate feasibility model Kenya, investigators propose testing uptake \"\"minimally viable\"\" model, understanding characteristics online PrEP clients acceptability model clients, evaluating costs model.",{"entities":[]}],["Specific objectives 1.",{"entities":[]}],["develop pilot model online PrEP delivery PrEP initiation continuation outcomes individuals risk HIV acquisition Kenya.",{"entities":[[27,31,"DRUG"],[41,45,"DRUG"]]}],["2.",{"entities":[]}],["evaluate acceptability, appropriateness, feasibility, costs online PrEP delivery model Kenya.",{"entities":[[67,71,"DRUG"],[87,92,"COUNTRY"]]}],["Hypothesis investigators hypothesize online PrEP delivery model address patient- provider-level barriers clinic-delivered PrEP result PrEP initiation continuation (compared facility-based models), acceptable providers clients, low-cost.",{"entities":[[11,24,"OCCUPATION"]]}],["",{"entities":[]}],["African countries, worm disease schistosomiasis, bilharzia, health people.",{"entities":[[32,47,"CONDITION"],[49,58,"CONDITION"]]}],["estimated 50 pre-school children sub-Saharan Africa affected, excluded routine preventive chemotherapy praziquantel suitable preparation age group.",{"entities":[[33,51,"LOCATION"],[103,115,"DRUG"]]}],["result, public-private Pediatric Praziquantel Consortium, led pharmaceutical company Merck, developed Levo-Praziquantel 150 mg, child-friendly dosage tolerability taste.",{"entities":[[33,45,"DRUG"],[102,119,"DRUG"]]}],["European \\\\& Developing Countries Clinical Trials Partnership (EDCTP) programme, Global Health Innovation Technology Fund (GHIT), funding conduct implementation study \"\"ADOPT - Adoption Levo-Praziquantel 150mg Schistosomiasis endemic countries\"\" prepare introduction Levo-Praziquantel partner countries Kenya, Côte d'Ivoire Uganda, schistosomiasis endemic.",{"entities":[[0,69,"ORG"],[81,123,"ORG"],[186,203,"DRUG"],[210,225,"CONDITION"],[267,284,"DRUG"],[303,308,"COUNTRY"],[310,323,"COUNTRY"],[324,330,"COUNTRY"],[332,347,"CONDITION"]]}],["study protocol describes social science implementation project (Work Package 1).",{"entities":[]}],["aims provide insights local conditions knowledge, perceptions management schistosomiasis population study countries, parents children health workers.",{"entities":[[73,88,"CONDITION"]]}],null,null,null,["phase, semi-structured Key Informant Interviews (KIIs) conducted health workers stakeholders Neglected Tropical Diseases (NTD) sector local health workers study regions.",{"entities":[[93,125,"CONDITION"]]}],["addition, parents/families children interviewed focus interviews (FGD) socio-demographic questionnaires.",{"entities":[]}],null,null,null,null,null,null,null,["Background: Rabies fatal viral disease transmitted humans domestic dogs.",{"entities":[[12,18,"CONDITION"]]}],["neglected zoonosis underserved populations limited access health care.",{"entities":[[10,18,"CONDITION"]]}],["year, rabies estimated kill 59,000 people globally, children 15 Africa Asia.",{"entities":[[6,12,"CONDITION"],[64,70,"LOCATION"],[71,75,"LOCATION"]]}],["development effective vaccines rabies humans, dogs.",{"entities":[[22,30,"INTERVENTION"],[31,37,"CONDITION"]]}],["rabies fatal clinical signs manifest, disease preventable timely treatment exposure rabies virus.",{"entities":[[0,6,"CONDITION"],[84,96,"CONDITION"]]}],["Health Organization (WHO) recommend bite patients receive wound cleaning soap water 15 minutes, administration anti-rabies vaccine day bite, additional injections month.",{"entities":[[0,25,"ORG"]]}],["Bite patients multiple severe bites head upper trunk, infiltration rabies immunoglobulin wound added.",{"entities":[[67,73,"CONDITION"],[74,88,"BIOLOGICAL"]]}],["Poor availability rabies vaccines, lack access anti-rabies vaccine deviations recommendations delays seeking anti-rabies vaccine incomplete courses vaccine increases risk clinical rabies death.",{"entities":[[18,24,"CONDITION"],[25,33,"INTERVENTION"],[109,128,"INTERVENTION"],[180,186,"CONDITION"]]}],null,null,["Objective: assess SMS reminders compliance five-dose Essen rabies vaccine regimen determine factors compliance dog-bite patients.",{"entities":[[53,73,"INTERVENTION"]]}],["Methods: investigators employed single arm before-after field trial patients dog bites Makueni County Referral Hospital October 2018 March 2019.",{"entities":[[87,119,"ORG"]]}],["study participants allocated groups: 1: bite patients enrolled January - March 2019 received medical card day visiting health facility indicating return subsequent dose, SMS reminders day dose anti-rabies vaccine.",{"entities":[]}],["SMS messages written English local dialect, Kamba; 2: bite patients recruited study October December 2018 SMS reminder introduced, designated control group.",{"entities":[]}],["bite patient routinely receives medical card indicating return subsequent dose.",{"entities":[]}],["collect data factors completion adherence doses anti-rabies vaccine, phone interview completed study participants month bite time.",{"entities":[]}],["",{"entities":[]}],["achievements reducing child mortality, neonatal deaths remain high, accounting 46% deaths children 5 worldwide.",{"entities":[]}],["Addressing neonatal mortality demands efforts focused proven interventions at-risk neonates families.",{"entities":[]}],["mHealth interventions potential improve neonatal care healthcare seeking caregivers.",{"entities":[]}],["Impact interventions maximized ensuring healthcare workers accurately triage messages caregivers respond appropriately messages urgent medical question.",{"entities":[]}],["study adds current knowledge testing natural language processing (NLP) tool detect urgent messages.",{"entities":[]}],["investigators' knowledge, tool developed empirically tested \"\"real-world\"\" implementation.",{"entities":[]}],["Moreover, NLP tools developed high-resource languages; investigators aware tools developed detecting urgency Swahili Luo languages.",{"entities":[]}],["study's overarching hypothesis development adaptive variant Mobile WACh SMS platform automatically detects prioritizes urgent messages feasible acceptable nurses end-users, reduce time message receipt HCW response.",{"entities":[]}],["Broad Objectives study's overarching aim implement NLP model Mobile WACh SMS platform acceptability impact HCW response time.",{"entities":[]}],["Aim: Pilot adapted Mobile WACh (AI-NEO) evaluate acceptability nurse response time.",{"entities":[]}],["pregnant women enrolled receive AI-NEO SMS intervention.",{"entities":[]}],["Women enrolled \\\\>=28 weeks gestation receive automated SMS neonatal health enrollment 6 weeks postpartum, ability interactively message study nurses.",{"entities":[]}],["Participant messages automatically categorized urgency.",{"entities":[]}],["Intervention acceptability recommended improvements evaluated clients nurses quantitative qualitative data collection study exit (quantitative questionnaires client participants qualitative interviews 4 nurses).",{"entities":[]}],["Nurse response time urgent non-urgent participant messages compared AI-NEO pilot vs.",{"entities":[[0,5,"OCCUPATION"]]}],["ongoing Mobile WACh NEO trial, non-adapted Mobile WACh used.",{"entities":[]}],["",{"entities":[]}],["Rationale: TBM devastating illness risk mortality severe neurologic morbidity.",{"entities":[]}],["data dose increases RIF improve outcomes TBM, mortality remains high, enhanced treatment strategies needed.",{"entities":[]}],["addition, limited data guide treatment duration adults TBM.",{"entities":[[55,58,"CONDITION"]]}],["goal Phase II, randomized, open-label trial assess PK, safety, longitudinal treatment outcomes optimized 6-month regimen high-dose RIF, high-dose INH, LZD, PZA 9-month SOC regimen treatment TBM.",{"entities":[[146,149,"DRUG"],[151,154,"DRUG"],[156,159,"DRUG"],[190,194,"CONDITION"]]}],["Primary objective: determine regimen high-dose RIF, high-dose INH, LZD, PZA improves functional outcomes measured modified Rankin Scale (mRS) 48 weeks compared SOC treatment TBM.",{"entities":[]}],["Design: Participants definite, probable, TBM randomized study arms randomization stratified HIV status stage disease defined modified BMRC criteria.",{"entities":[[41,44,"CONDITION"]]}],["Arm A: RIF 35 mg/kg + INH 15 mg/kg + LZD 1200 + PZA 25 mg/kg 2 weeks, RIF 35 mg/kg + INH mg/kg + LZD 1200 + PZA 25 mg/kg 6 weeks, RIF 35 mg/kg INH mg/kg 16 weeks, total 24 weeks study treatment.",{"entities":[[7,19,"DRUG"],[22,34,"DRUG"],[37,45,"DRUG"],[48,60,"DRUG"],[70,82,"DRUG"],[85,94,"DRUG"],[97,105,"DRUG"],[108,114,"DRUG"],[130,142,"DRUG"],[143,155,"DRUG"]]}],["Arm B: SOC: RIF mg/kg + INH 5 mg/kg + EMB 20 mg/kg + PZA 25 mg/kg 8 weeks, RIF mg/kg INH 5 mg/kg 28 weeks, total 36 weeks study treatment.",{"entities":[[12,21,"DRUG"],[24,35,"DRUG"],[38,50,"DRUG"],[53,65,"DRUG"],[75,84,"DRUG"],[85,96,"DRUG"]]}],["15 mg/kg maximum 900 daily oral RIF permitted arm clinician's discretion.",{"entities":[]}],["participants Arms receive pyridoxine, receiving INH, adjunctive corticosteroids disease severity 6 weeks.",{"entities":[[26,36,"DRUG"],[48,51,"DRUG"]]}],["participants Arms randomization week 72.",{"entities":[]}],["Procedures: Study visits include interval history, blood collection laboratory testing, peripheral neuropathy screening, visual acuity, color vision, contrast sensitivity visual testing monitor AEs.",{"entities":[[88,109,"CONDITION"]]}],["Lumbar puncture performed assessments CSF microbiology, LAM biomarkers.",{"entities":[[0,15,"INTERVENTION"]]}],["Optional collection storage blood storage remaining CSF future testing occur.",{"entities":[]}],["Urine LAM assessment.",{"entities":[]}],["Plasma CSF assessments performed.",{"entities":[]}],["Participants undergo assessment functional status DAS 2.0.",{"entities":[]}],["Participants assessed neurocognitive battery depression questionnaire (PHQ-9).",{"entities":[[71,76,"CONDITION"]]}],["",{"entities":[]}],["Purpose: primary objective examine health impact implementing social accountability interventions communities served public-sector healthcare facilities Western Kenya.",{"entities":[[161,166,"COUNTRY"]]}],["aim assess impact social accountability approaches contraceptive use.",{"entities":[]}],["aim assess impact approaches community empowerment, agency, quality care.",{"entities":[]}],["aim assess scalability approaches additional settings.",{"entities":[]}],["study carried Kisumu county, Kenya.",{"entities":[[14,27,"LOCATION"],[29,34,"COUNTRY"]]}],["study design three-arm cluster-randomized controlled experiment 149 public healthcare facilities county randomized study arms: 1.",{"entities":[[13,63,"STUDY_DESIGN"],[104,114,"STUDY_DESIGN"]]}],["Community Score Card treatment, 2.",{"entities":[]}],["Citizen Report Card treatment 3.",{"entities":[]}],["control.",{"entities":[]}],["implementing treatments, individual- facility-level pre- postintervention surveys conducted.",{"entities":[]}],["individual-level surveys conducted representative sample women reproductive age (ages 15 49), stratified study arm cluster, establish primary outcome, modern contraceptive use, study arms, pre- post-treatment.",{"entities":[]}],["individual-level surveys measure multiple linking constructs community empowerment quality care.",{"entities":[]}],["facility-level surveys conducted census public-sector facilities located Kisumu county measure quality family planning service delivery negative provider behaviors informal payments, provider absenteeism, client mistreatment.",{"entities":[[73,86,"LOCATION"]]}],["facility-level surveys, family planning service quality negative provider behaviors measured interviews providers, depending total staff 149 facilities.",{"entities":[]}],null,null,["149 facilities Kisumu receive unannounced visits mystery client visits.",{"entities":[[15,21,"LOCATION"]]}],null,null,null,null,["In-depth interviews undertaken health care providers community assess potential scale-up interventions.",{"entities":[[31,52,"OCCUPATION"]]}],null,null,null,null,null,null,null,null,null,null,["Family planning providers target facilities meet determine barriers quality family planning service delivery.",{"entities":[[0,25,"OCCUPATION"],[76,108,"INTERVENTION"]]}],["Providers decide priority suggestions improving service delivery.",{"entities":[]}],["Providers derive list issues/indicators community.",{"entities":[]}],["Step 4: Connecting patients providers determining action plan.",{"entities":[]}],["Family planning patients providers - community leaders process facilitators - findings jointly determine priority develop action plan.",{"entities":[[0,34,"OCCUPATION"]]}],["action plan, agreed responsibilities assigned timeline communicated.",{"entities":[]}],["Step 5: Implementing action plan continuous monitoring.",{"entities":[]}],["final stage, action plan carried period months, community service providers charge monitoring implementation progress.",{"entities":[[48,75,"OCCUPATION"]]}],null,null,null,null,["PI consult Kisumu County Health Director confirm geographic coverage citizen report card.",{"entities":[[11,24,"LOCATION"],[25,40,"OCCUPATION"]]}],["PI collaborate staff county health office develop post-survey publicity strategy.",{"entities":[[0,2,"OCCUPATION"]]}],["strategy include community dialogues, radio call-in shows, television, newspaper coverage.",{"entities":[]}],["Step 2: Designing CRC survey.",{"entities":[]}],["intervention, focus conducted (two family planning clients stratified women service providers).",{"entities":[]}],["identify key service challenges inform content CRC questionnaire allowing citizens articulate prioritize relevant indicators monitoring reporting service provider performance.",{"entities":[]}],["Focus service providers elicit suggestions type feedback improving service delivery.",{"entities":[[6,23,"OCCUPATION"]]}],null,null,null,null,null,null,null,null,null,null,null,["study include 520 adult adolescent participants (≥ 12 age) SCD.",{"entities":[[59,62,"CONDITION"]]}],["participants receive inclacumab 30 mg/kg administered intravenously 12 weeks.",{"entities":[[21,40,"DRUG"]]}],null,["Improved outcomes epilepsy treatment depend continuous supply daily adherence anti-seizure medications (ASMs).",{"entities":[[18,26,"CONDITION"],[78,109,"DRUG"]]}],["Kilifi County, treatment gap includes diagnostic adherence gap, 70% investigators interruption supply ASMs peripheral clinics, distance clinic lack availability ASMs, barriers adherence.",{"entities":[[0,13,"LOCATION"],[102,106,"DRUG"],[161,165,"DRUG"]]}],["Nairobi County, factors environment hazards, lack social amenities correlates poverty preponderant slums, prevalence epilepsy studied settings consequently, adherence gap remains unknown.",{"entities":[[0,14,"LOCATION"],[117,125,"CONDITION"]]}],["Innovative mobile Health (mHealth) strategies including messages delivered mobile phones ensure adequate supply drugs health centres, daily mobile messages improved adherence medication Human Immunodeficiency Virus (HIV) programs, example.",{"entities":[[11,34,"INTERVENTION"],[186,220,"CONDITION"]]}],["messaging requires patient access mobile phone understand message.",{"entities":[]}],["Multimedia messaging, simple pictures, improve understanding necessity medication, people illiterate, explore avenue improve uptake.",{"entities":[]}],["investigators plan randomize 1200 people epilepsy site, defined Kilifi Nairobi County, Kenya.",{"entities":[[41,49,"CONDITION"],[64,70,"LOCATION"],[71,85,"LOCATION"],[87,92,"COUNTRY"]]}],["divided 300 each, receive SMS, graphic SMS, graphic SMS public health promotion epilepsy e.g.",{"entities":[[80,88,"CONDITION"]]}],null,["investigators aim i) perceptions perspectives people epilepsy caregivers graphic SMS reminders improve adherence ASMs, ii) compare effectiveness graphic messaging service improving adherence people epilepsy engage County Departments Health current ongoing training capacity building studies maintain supply ASMs peripheral clinics iii) identify factors improvement adherence, improved QoL reduction stigma people epilepsy family iv) conduct cost-effectiveness assessment roll intervention.",{"entities":[[53,61,"CONDITION"],[413,421,"CONDITION"]]}],["medication-related messages, messages, previous community-based feedback, selected address stigmatization improve quality life.",{"entities":[]}],null,null,null,["Meeting reproductive health women living HIV (WLWH) essential women prevent unintended pregnancies, safely conceive, eliminate mother-to-child HIV transmission (MTCT).",{"entities":[[28,51,"POPULATION"],[127,142,"POPULATION"]]}],["Reproductive life planning complex WLWH, faced decisions antiretroviral treatment selections potential drug interactions contraceptive methods, planning safe conception, planning prevent sexually transmitted infections.",{"entities":[[35,39,"POPULATION"]]}],["family planning (FP) WLWH, discontinuation FP common women desire pregnancy prevention, driver unmet FP subsequent risk unintended pregnancy adverse maternal child health outcomes.",{"entities":[[0,15,"INTERVENTION"],[17,19,"INTERVENTION"],[21,25,"POPULATION"],[43,45,"INTERVENTION"],[101,103,"INTERVENTION"],[149,157,"POPULATION"],[158,163,"POPULATION"]]}],["programs sub-Saharan Africa integrate FP service delivery routine HIV care, HIV care providers challenges implementing models care.",{"entities":[[9,27,"LOCATION"]]}],["HIV care providers equipped ensure WLWH receive high-quality, rights' based reproductive health counseling services lack time, training, resources, skills.",{"entities":[[35,39,"POPULATION"]]}],["Prior studies integrating FP services HIV care consistently cite implementation challenges.",{"entities":[[26,28,"INTERVENTION"]]}],["Mobile health technology provide cost solution augment counseling services, strengthen health care systems, alleviate demands HIV providers.",{"entities":[]}],["investigators hypothesize providing comprehensive counseling two-way SMS communication, 1) improve delivery integrated HIV reproductive health care services, 2) reduce contraceptive discontinuation rates, 3) acceptable feasible implement, 4) cost-effective contribute prevention MTCT efforts.",{"entities":[[168,181,"INTERVENTION"]]}],["investigators adapt unique two-way SMS platform (Mobile WACh) combines automated bulk SMS messaging dialogue health care provider population, environment, outcomes long-term impact.",{"entities":[[49,60,"INTERVENTION"]]}],["Mobile WACh platform customized provide continuous reproductive life planning counseling WLWH.",{"entities":[[0,11,"INTERVENTION"]]}],null,null,["Aim 1, investigators determine Mobile WACh Empower intervention FP discontinuation, dual method use, unmet FP 2 years.",{"entities":[[31,42,"INTERVENTION"]]}],["Aim 2, investigators evaluate acceptability, feasibility, scalability implementing Mobile WACh Empower real-world settings, WLWH provider perspectives focus discussions.",{"entities":[[83,94,"INTERVENTION"]]}],["Aim 3, investigators construct mathematical model measure health economic impacts Mobile WACh Empower, including cost-effectiveness intervention pregnancy MTCT averted.",{"entities":[[145,154,"CONDITION"]]}],["trial evaluate intervention address crucial gap provision integrated reproductive health HIV care, potential contribution global goals universal access FP elimination MTCT.",{"entities":[[89,92,"CONDITION"]]}],null,null,null,null,null,null,null,["STUDY OVERVIEW: investigator conduct cluster randomized controlled trial 20 Ministry Health HIV clinics Kisumu Kenya, recruiting 580 patients randomized 2 conditions investigate effectiveness intensive intervention aimed smoking cessation.",{"entities":[[104,110,"LOCATION"],[111,116,"COUNTRY"]]}],null,null,["BACKGROUND Kenya fourth largest burden HIV globally close 1.5 people living HIV, prevalence age 45-54 years.",{"entities":[[39,42,"CONDITION"],[76,79,"CONDITION"]]}],["PLHIV live wider access ART, increasingly aging population PLHIV.",{"entities":[[0,5,"POPULATION"],[59,64,"POPULATION"]]}],["current Kenya National Guidelines Health Organization guidelines recommend TDF/3TC/DTG preferred first-line regimen adults.",{"entities":[[8,53,"ORG"],[75,86,"DRUG"]]}],["regimen efficacious, single-tablet regimen, tolerated, reasonable safety profile, populations.",{"entities":[]}],["Managing populations challenging presence multiple comorbidities including cardiovascular disease, renal disease bone disease.",{"entities":[[75,97,"CONDITION"],[99,112,"CONDITION"],[113,125,"CONDITION"]]}],["TDF renal insufficiency osteoporosis/osteopenia, recommended patients pre-existing renal disease osteoporosis.",{"entities":[[0,3,"DRUG"],[4,23,"CONDITION"],[24,47,"CONDITION"],[83,96,"CONDITION"],[97,109,"CONDITION"]]}],["Guidelines recommend measurement renal function initiation TDF ongoing monitoring renal function, potential barrier rapid antiretroviral therapy (ART) initiation feasible resource limited settings.",{"entities":[[59,62,"DRUG"],[122,144,"DRUG"],[146,149,"DRUG"]]}],["Measurement bone mineral density expensive routinely carried resource-limited settings osteoporosis detected fracture.",{"entities":[]}],["Elderly patients contraindications TDF identifying contraindications costly and/or result delay treatment.",{"entities":[[35,38,"DRUG"]]}],["current alternative TDF countries abacavir (ABC), increased risk cardiovascular events concern elderly patients, disadvantage treat hepatitis virus (HBV) co-infection.",{"entities":[[20,23,"DRUG"],[34,42,"DRUG"],[44,47,"DRUG"],[132,152,"CONDITION"]]}],["RATIONALE Tenofovir alafenamide (TAF) pro-drug TDF pharmacokinetics dosing reduced renal bone toxicity compared TDF, approved treat HBV.",{"entities":[[10,31,"DRUG"],[33,36,"DRUG"],[47,50,"DRUG"],[112,115,"DRUG"],[132,135,"CONDITION"]]}],["Switch TDF TAF improvement bone mineral density reversion osteoporosis.",{"entities":[[7,10,"DRUG"],[11,14,"DRUG"],[27,31,"BODY_PART"],[58,70,"CONDITION"]]}],["Bictegravir highly efficacious integrase inhibitor non-inferior DTG naïve patients virally suppressed DTG/3TC/ABC.",{"entities":[[64,67,"DRUG"],[102,113,"DRUG"]]}],["Clinical trials rates drug-related adverse events B/F/TAF compared DTG/3TC/ABC compared regimen comprising DTG, emtricitabine (FTC) TAF (DTG+FTC/TAF).",{"entities":[[50,57,"DRUG"],[67,78,"DRUG"],[107,110,"DRUG"],[112,125,"DRUG"],[127,130,"DRUG"],[132,135,"DRUG"],[137,148,"DRUG"]]}],["B/F/TAF single-tablet once-daily pill INSTI co-formulated pills, attractive patients.",{"entities":[[0,7,"DRUG"],[38,43,"DRUG"]]}],["advantages B/F/TAF PLHIV elderly population.",{"entities":[[11,18,"DRUG"],[19,24,"POPULATION"],[25,43,"POPULATION"]]}],["emerging data increased weight gain TAF, BIC DTG, raise concerns potential increase cardiovascular risk development type 2 diabetes PLHIV treated BFTAF.",{"entities":[[36,39,"DRUG"],[41,44,"DRUG"],[45,48,"DRUG"],[84,98,"CONDITION"],[132,137,"POPULATION"]]}],["TDF lipid-lowering effects association increasing lipid parameters switch TDF TAF, difference change total cholesterol high-density lipoprotein (HDL) ratio.",{"entities":[[0,3,"DRUG"],[74,77,"DRUG"],[78,81,"DRUG"],[119,143,"CONDITION"]]}],["retrospective cohort analysis switching virally suppressed PLHIV TDF TAF increase atherosclerotic cardiovascular disease (ASCVD) risk score, change total cholesterol HDL ratio.",{"entities":[[59,64,"POPULATION"],[65,68,"DRUG"],[69,72,"DRUG"],[82,128,"CONDITION"],[154,169,"CONDITION"]]}],["major limitation study include comparison non-switchers analysis adequately controlled age-determined increase ASCVD risk.",{"entities":[[111,116,"CONDITION"]]}],["retrospective cohort analysis switching PLHIV TDF TAF increase lipid parameters increase low-density lipoprotein HDL ratio; ASCVD risk score analyzed.",{"entities":[[40,45,"POPULATION"],[46,49,"DRUG"],[50,53,"DRUG"],[124,129,"CONDITION"]]}],["post-hoc analysis prospective trial comparing PLHIV initiated TDF TAF-containing regimens increase ASCVD risk scores TAF arm week 96, difference risk categories.",{"entities":[[62,65,"OCCUPATION"],[99,104,"CONDITION"],[117,120,"DRUG"]]}],["ADVANCE trial, ARV-naïve PLHIV randomized receive TAF/FTC+DTG, TDF/FTC+DTG combination TDF, FTC efavirenz (EFV), risk cardiovascular disease (based Framingham QRISK scores) week 48 TAF/FTC+DTG compared TDF/FTC/EFV, statistically difference risk TAF TDF DTG arms.",{"entities":[[50,61,"DRUG"],[63,74,"DRUG"],[87,90,"DRUG"],[92,105,"DRUG"],[107,110,"DRUG"],[118,140,"CONDITION"],[181,192,"DRUG"],[202,213,"DRUG"]]}],["study participants treated TAF/FTC+DTG risk developing type 2 diabetes participants treated TDF/FTC+DTG (based QDiabetes risk scores).",{"entities":[[27,38,"DRUG"],[62,70,"CONDITION"],[92,103,"DRUG"]]}],["aware clinical trial powered compare ARV regimens increasing population elderly PLHIV, study evaluating potential change lipid parameters, cardiovascular risk risk type 2 diabetes regimen switch BFTAF elderly population.",{"entities":[[37,40,"DRUG"],[80,85,"POPULATION"],[139,153,"CONDITION"],[171,179,"CONDITION"],[201,219,"POPULATION"]]}],["propose conduct open-label non-inferiority switch trial elderly PLHIV address knowledge gap.",{"entities":[[64,69,"POPULATION"]]}],null,["Switch virologically suppressed HIV-1 infected elderly adults (≥ 60 years) prior confirmed treatment failure B/F/TAF non-inferior continuing current ARV regimen, determined risk developing virological failure 48 weeks 2.",{"entities":[[32,37,"DRUG"],[109,116,"DRUG"],[149,152,"DRUG"]]}],["Switch B/F/TAF result increased lumbar spine BMD relative remaining current ARV regimen elderly population PRIMARY OBJECTIVES 1.",{"entities":[[7,14,"DRUG"],[32,44,"BODY_PART"],[76,79,"DRUG"],[88,106,"POPULATION"]]}],["evaluate non-inferiority switching B/F/TAF, compared maintaining current ARV regimen, virologically suppressed HIV-1 positive elderly adults (≥ 60 years) prior confirmed virological failure, determined HIV-1 RNA polymerase chain reaction (PCR) ≥ 50 copies/ml week 48 2.",{"entities":[[35,42,"DRUG"],[73,76,"DRUG"],[111,116,"DRUG"],[208,211,"BIOLOGICAL"],[212,237,"BIOLOGICAL"],[239,242,"BIOLOGICAL"]]}],["evaluate B/F/TAF relative maintaining current ARV regimen percentage change lumbar spine bone mineral density (BMD) 48 weeks measured dual-energy X-ray absorptiometry (DXA) STUDY DESIGN phase IV, multi-center, two-arm, open-label, randomized trial 48 weeks, describing efficacy safety switching current ARV regimen B/F/TAF virally suppressed HIV-1 infected elderly adults (≥ 60 years) ART 24 weeks achieved virological suppression (HIV-1 RNA \\\\< 50 copies/ml) 12 weeks, prior confirmed virological failure.",{"entities":[[303,306,"DRUG"],[315,322,"DRUG"],[385,388,"DRUG"]]}],["Participants randomized baseline remain pre-enrollment ARV regimen switch B/F/TAF.",{"entities":[[55,58,"DRUG"],[74,81,"DRUG"]]}],["study sites Kenya: Kenyatta National Hospital (KNH, largest teaching referral hospital Kenya), Jaramogi Oginga Odinga Teaching Referral Hospital (JOOTRH, largest teaching referral hospital Nyanza region Kenya).",{"entities":[[12,17,"COUNTRY"],[19,45,"ORG"],[47,50,"ORG"],[95,144,"ORG"],[146,152,"ORG"],[189,195,"LOCATION"],[203,208,"COUNTRY"]]}],["outpatient HIV clinics sites provide ART 15,000 PLHIV combined, including 1,000 elderly patients ART (85% TDF/3TC NRTI backbone combined DTG EFV; patients TAF BIC).",{"entities":[[37,40,"DRUG"],[48,53,"POPULATION"],[106,113,"DRUG"],[114,118,"DRUG"],[137,140,"DRUG"],[141,144,"DRUG"],[155,158,"DRUG"]]}],["Study visits screening, baseline, weeks 4, 12, 24, 36, 48 (with 4-week extension required confirming HIV-1 RNA levels FDA snapshot window).",{"entities":[[107,110,"BIOLOGICAL"]]}],["HIV-1 RNA viral load performed screening weeks 4, 12, 24 48.",{"entities":[]}],null,null,["DXA lumbar spine total hip performed baseline weeks 24 48 BMD monitoring population.",{"entities":[[4,16,"BODY_PART"],[23,26,"BODY_PART"]]}],["routine study investigations include cluster differentiation 4 (CD4) count, complete blood count, serum creatinine (Cr), alanine aminotransferase (ALT), aspartate aminotransferase (AST), HBsAg, fasting lipids, fasting glucose patient satisfaction questionnaires (HIVTSQ).",{"entities":[[64,67,"BIOLOGICAL"],[76,96,"BIOLOGICAL"],[98,114,"BIOLOGICAL"],[121,145,"BIOLOGICAL"],[153,179,"BIOLOGICAL"],[187,192,"BIOLOGICAL"],[202,208,"BIOLOGICAL"],[218,225,"BIOLOGICAL"]]}],["Participants randomized baseline 1:1 ratio computer-generated randomization sequence continue current ARV regimen switch B/F/TAF.",{"entities":[[102,105,"DRUG"],[121,128,"DRUG"]]}],["STUDY POPULATION Participants Participant Selection anticipated sample size 516 participants (258 study arm) started study treatment patients ARV therapy 24 weeks prior virological failure (defined consecutive HIV-1 RNA viral loads ≥ 50 copies/ml separated 2 weeks), viral load \\\\< 50 copies/ml 12 weeks, aged 60 above.",{"entities":[[142,145,"DRUG"]]}],["Patients prior history changing ARV regimens reasons treatment failure participate study meet eligibility criteria.",{"entities":[]}],null,null,null,["estimated enrollment study is: KNH, 330; JOOTRH, 190.",{"entities":[[31,34,"ORG"],[41,47,"ORG"]]}],["Participants enrolled KNH enter BMD monitoring population (after excluding participants pre-existing conditions decrease validity BMD estimates).",{"entities":[[22,25,"ORG"]]}],null,null,["Eligible participants provide written informed consent undergo screening laboratory investigations (HIV-1 RNA viral load, complete blood count, AST, ALT, serum Cr, HBsAg).",{"entities":[[106,109,"BIOLOGICAL"],[122,142,"BIOLOGICAL"],[144,147,"BIOLOGICAL"],[149,152,"BIOLOGICAL"],[154,162,"BIOLOGICAL"],[164,169,"BIOLOGICAL"]]}],null,["enrollment visit, participants randomized 1:1 ratio continue current ARV regimen switch B/F/TAF.",{"entities":[[69,72,"DRUG"],[88,95,"DRUG"]]}],["Participants enrol study KNH constitute BMD monitoring population (after excluding participants pre-existing conditions decrease validity BMD estimates), baseline total hip lumbar spine DXA performed.",{"entities":[[169,172,"BODY_PART"],[173,185,"BODY_PART"]]}],null,["Anemia continues disproportionately affect marginalized women resource-poor countries.",{"entities":[[0,6,"BIOLOGICAL"]]}],["Africa/SE Asia, 270 women reproductive age anemic.",{"entities":[[10,14,"LOCATION"]]}],["Iron deficiency anemia 18% maternal deaths worldwide.",{"entities":[[0,22,"CONDITION"]]}],["Multiprong approaches reduce prevalence anemia negative impact family health.",{"entities":[[40,46,"CONDITION"]]}],["menstrual cycle, women lose 14 19 iron; iron anemic women lead healthier lives.",{"entities":[[40,51,"CONDITION"]]}],["relationships iron loss menstruation, absorption dietary intake iron, storing iron, impacts hematologic parameters complex, levels menstrual blood loss hemoglobin values.",{"entities":[[14,36,"CONDITION"],[64,68,"BIOLOGICAL"],[78,82,"BIOLOGICAL"],[92,103,"BIOLOGICAL"],[152,162,"BIOLOGICAL"]]}],["levonorgestrel intrauterine highly effective contraceptive product reduces menstrual blood loss.",{"entities":[[0,14,"DRUG"],[45,58,"DRUG"]]}],["spanning decades, product consistently raises hemoglobin levels increases iron stores broad populations women, women heavy menstrual bleeding.",{"entities":[[46,56,"BIOLOGICAL"],[123,141,"CONDITION"]]}],null,["potential tool alleviate anemia, levonorgestrel intrauterine adequately tested.",{"entities":[[33,47,"DRUG"]]}],["Previous focused anemic women, proper scientific approaches determine product increase hemoglobin iron levels reducing menstrual blood loss.",{"entities":[[17,23,"CONDITION"],[87,97,"BIOLOGICAL"]]}],["goal proposed anemic women Kenya opportunity levonorgestrel intrauterine improved scientific approaches, measure impact hemoglobin iron stores.",{"entities":[[120,130,"BIOLOGICAL"],[131,135,"BIOLOGICAL"]]}],["randomized trial, comparison product oral contraceptives iron supplement pills.",{"entities":[[0,16,"STUDY_DESIGN"],[37,56,"DRUG"],[57,78,"DRUG"]]}],["levonorgestrel intrauterine hypothesized, product tool alleviate anemia reproductive-aged women, healthier living healthier pregnancy desired.",{"entities":[[0,14,"DRUG"],[15,27,"BODY_PART"],[65,71,"CONDITION"],[124,133,"CONDITION"]]}],null,["Kenya, neonatal mortality rate 22.6 1000 live births, ranking countries neonatal deaths (\\\\~40,000 year).",{"entities":[[0,5,"COUNTRY"],[7,15,"POPULATION"],[72,80,"POPULATION"]]}],["Community health volunteers (CHVs) cadre lay health workers role promote access preventative care treatment resource-limited settings.",{"entities":[[0,27,"OCCUPATION"],[29,33,"OCCUPATION"]]}],["Kenya, CHVs conduct monthly visits pregnant postpartum women provide education screen complications.",{"entities":[[7,11,"OCCUPATION"],[35,43,"CONDITION"],[44,60,"POPULATION"]]}],["counties Kenya digital community health toolkit (dCHT) supports CHV workflow tracking clients, managing tasks, guiding visits.",{"entities":[[9,14,"COUNTRY"]]}],["so, concentrated risk neonatal illness weeks life potential rapidly deteriorate monthly visits leave mothers neonates on-demand support.",{"entities":[[101,108,"POPULATION"],[109,117,"POPULATION"]]}],null,null,["overarching goal project integrate NEO interactive SMS existing digital infrastructure supporting CHV workflow Western Kenya (dCHT) enable remote communication mothers CHVs visits.",{"entities":[[98,101,"OCCUPATION"],[111,124,"LOCATION"],[160,167,"POPULATION"],[168,172,"OCCUPATION"]]}],["cluster-randomized control trial consisting 20 facility clusters (10 control, intervention) Western Kenya.",{"entities":[[0,32,"STUDY_DESIGN"],[92,105,"LOCATION"]]}],null,["AIM 2: a) Evaluate CHV-NEO's impact neonatal mortality, b) clinic visit attendance, caregiver provision essential newborn care (cord care, thermal care initiation breastfeeding), pragmatic cluster-randomized trial.",{"entities":[[189,213,"STUDY_DESIGN"]]}],null,null,["study constructed inform vaccine regimen, combination enhanced HIV care, serve public health model effective cost-efficient approach preventing SARS-CoV-2 disease, prolonged viral shedding, emergence VOCs population.",{"entities":[[144,154,"STUDY_DESIGN"]]}],null,["study enroll 15,600 adults clinics Eastern Southern Africa.",{"entities":[[35,58,"LOCATION"]]}],null,null,null,["organized people living HIV people evidence prior SARS-CoV-2 infection blood.",{"entities":[[50,60,"CONDITION"]]}],["1 includes people living HIV 3 includes people living HIV.",{"entities":[[54,57,"CONDITION"]]}],["people 1 3 evidence prior SARS-CoV-2 infection blood.",{"entities":[[26,36,"CONDITION"]]}],null,null,["people 2 4 evidence prior SARS-CoV-2 infection blood.",{"entities":[[26,36,"CONDITION"]]}],null,null,null,null,null,null,null,["pilot carried 40 pregnant women divided 2 (n=20 intervention group, n=20 control group).",{"entities":[[17,31,"POPULATION"]]}],null,null,null,null,null,null,["estimated median monthly income informally employed sectors retail trade food service Kenya (estimated 15,000 30,000 Kenyan shillings monthly rural urban respectively).",{"entities":[[86,91,"COUNTRY"]]}],["investigators expect participants meet basic late pregnancy period exclusive breastfeeding women unable maintain gainful employment.",{"entities":[[0,13,"OCCUPATION"],[50,59,"CONDITION"]]}],null,null,null,null,null,["SPECIFIC AIMS: Aim 1: types treatments administered patients diagnosed participating AfrECC sites, including chemotherapeutic regimens, radiation therapy, chemo-radiotherapy, esophageal stenting, esophagectomy, basic supportive care.",{"entities":[[136,153,"INTERVENTION"],[155,173,"INTERVENTION"],[175,194,"INTERVENTION"],[196,209,"INTERVENTION"],[211,232,"INTERVENTION"]]}],null,null,null,null,null,null,null,null,null,["Therefore, investigators implement empirical data collection study cities Kenya collects broad variety socioeconomic, behavioral, spatial, child health, zoonotic vector health, environmental contamination, behavioral, climate data neighborhoods representing infectious disease transmission potential.",{"entities":[[74,79,"COUNTRY"]]}],null,["objective epidemiological study evaluate city (Nairobi, Kisumu) neighborhood socioeconomic development level (low middle income): 1.",{"entities":[[47,54,"LOCATION"],[56,62,"LOCATION"]]}],null,null,null,["include low-income middle income neighborhood cities Kisumu Nairobi.",{"entities":[[53,59,"LOCATION"],[60,67,"LOCATION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["geotrackers remain overnight, caregiver chooses remove infant sleeping, device reach infant replace device infant wakes.",{"entities":[[85,91,"POPULATION"],[107,113,"POPULATION"]]}],null,null,null,null,null,null,["Day 5, enumerators return retrieve diaper feces, check diarrhea calendar completion, encourage caregiver continue diapers collect infant stool.",{"entities":[[55,63,"CONDITION"],[137,142,"BIOLOGICAL"]]}],["Day 8, enumerators return retrieve fourth diaper feces check diarrhea calendar completion.",{"entities":[[61,69,"CONDITION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,["DNA RNA extracted parallel Zymobiomics Miniprep kit stored ultralow freezer use.",{"entities":[[0,3,"BIOLOGICAL"],[4,7,"BIOLOGICAL"]]}],null,["DNA RNA analyzed TaqMan Array card primers probes array enteric pathogens, including limited Norovirus GII, adenovirus 40/41, SARS-Cov2, Rotavirus, Salmonella enterica, Shigella spp., Campylobacter jejuni/coli, Listeria monocytogenes, Clostridium difficile, enterotoxigenic Escherichia coli (ETEC) LT/ST, enteropathogenic Escherichia coli (EPEC), enteroaggregative Escherichia coli (EAEC), Shiga-like toxin-producing E.",{"entities":[[0,3,"BIOLOGICAL"],[4,7,"BIOLOGICAL"],[126,135,"CONDITION"],[148,167,"BIOLOGICAL"],[169,182,"BIOLOGICAL"],[184,209,"BIOLOGICAL"],[211,233,"BIOLOGICAL"],[235,256,"BIOLOGICAL"],[258,290,"BIOLOGICAL"],[292,296,"BIOLOGICAL"],[305,338,"BIOLOGICAL"],[347,381,"BIOLOGICAL"],[390,400,"BIOLOGICAL"]]}],null,null,null,null,null,null,null,["portion primary enrichment transferred selective secondary enrichment media isolation Salmonella Shigella spp., Listeria monocytogenes, Campylobacter jejuni, Escherichia coli.",{"entities":[[86,105,"BIOLOGICAL"],[112,134,"BIOLOGICAL"],[136,156,"BIOLOGICAL"],[158,174,"BIOLOGICAL"]]}],["Selective media undergo hours incubation 37 41C, Campylobacter media, plating aliquots differential selective media.",{"entities":[[49,62,"BIOLOGICAL"]]}],["Incubation C.",{"entities":[]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Eligible infants identified recruited quarterly surveillance reports Community Health Volunteers (CHV), employees Kenyan Ministry Health (MOH) Kenya, age location infants living demographic surveillance area.",{"entities":[[69,96,"OCCUPATION"],[98,101,"OCCUPATION"],[114,136,"ORG"]]}],null,null,null,["African Population Health Center (APHRC) CHVs selected neighborhoods Kisumu Nairobi monitor records monthly update age-eligible children.",{"entities":[[0,32,"ORG"],[34,39,"ORG"],[41,45,"OCCUPATION"]]}],null,null,["CHVs APHRC team approach households caregivers eligible children verify age national identity card determine participating.",{"entities":[[5,10,"ORG"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["PI Baker notify University Iowa IRB committee seek advice response.",{"entities":[[32,35,"ORG"]]}],null,null,null,["Investigators minimize risk Covid-19 transmission regular, rigorous screening staff symptoms prior engagement community testing warranted, limiting staff closely interacting participants, requiring masks and/or shields hygiene PPE data collection, social distancing 2 meters data collection, sterilizing materials transmitted subject's household, provision masks subjects surveys own.",{"entities":[[28,36,"CONDITION"]]}],null,null,null,null,["Paper forms collected field staff submitted supervisors data collection day, stored locked cabinet secure office rural office transport APHRC.",{"entities":[[136,141,"ORG"]]}],["Hardcopy forms stored locked cabinet locked office APHRC, destroyed.",{"entities":[[51,56,"ORG"]]}],["Electronic files stored encrypted password protected database secure server APHRC University Iowa.",{"entities":[[76,81,"ORG"],[82,97,"ORG"]]}],null,null,null,null,null,["Paper/hard records (hard surveys, questionnaires, report forms, pictures, etc.) - database manager APHRC periodically print lists eligible infants contact recruitment purposes follow 14 day period time subjects enrolled.",{"entities":[[99,104,"ORG"]]}],["retained APHRC supervisors study completed, destroyed shredding.",{"entities":[[9,14,"ORG"]]}],["Consent forms collected hardcopy forms stored locked file cabinets locked offices APHRC.",{"entities":[[82,87,"ORG"]]}],["Similarly, 14 day diarrhea calendars identified random household ID, stored collection locked office APHRC.",{"entities":[[18,26,"CONDITION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,["Biologic samples - stool samples collected households, labeled randomly selected barcode ID, linked individual households scanning barcode tablet based file linked subject's identifying information.",{"entities":[[19,32,"BIOLOGICAL"]]}],null,null,null,null,null,null,["approved human subjects review boards University Iowa, African Population Health Center, AMREF NACOSTI.",{"entities":[[38,53,"ORG"],[55,87,"ORG"],[89,94,"ORG"],[95,102,"ORG"]]}],null,null,["HIV-uninfected non-pregnant cisgender women randomly assigned 1 3 dosing frequencies observed therapy (DOT) TAF-FTC PrEP, differentiate poor modest perfect adherence.",{"entities":[[108,115,"DRUG"],[116,120,"DRUG"]]}],null,["safety TAF-FTC-based PrEP HIV-uninfected cisgender women.",{"entities":[[7,20,"DRUG"],[21,25,"DRUG"]]}],null,["define cisgender women-specific expected blood concentrations dose-proportionality TFV-DP DBS PBMCs observed TAF-FTC therapy 2, 4, 7 doses week.",{"entities":[[83,89,"DRUG"],[109,116,"DRUG"]]}],null,["establish model predict adherence rate TAF-FTC level TFV-DP DBS cisgender women.",{"entities":[[39,46,"DRUG"],[53,59,"DRUG"],[64,79,"POPULATION"]]}],["study define TAF-FTC-based PrEP adherence-blood concentration thresholds African cisgender women, priority population HIV prevention.",{"entities":[[13,26,"DRUG"],[27,31,"DRUG"],[73,96,"POPULATION"]]}],["findings guide accurate interpretation safety, adherence, efficacy planned ongoing HIV prevention trials African women.",{"entities":[[105,118,"POPULATION"]]}],["",{"entities":[]}],["STUDY BACKGROUND East Central Africa (ECA) region represents unique environment investigate RVF virus maintenance transmission reported largest RVF epidemics.",{"entities":[[92,101,"CONDITION"]]}],["studies identified hotspots characterized continuous levels human livestock virus infections inter-epidemic periods (IEPs).",{"entities":[]}],["sheep risk severe disease, virus-host interactions animal species research.",{"entities":[]}],["Seroprevalence incidence studies wildlife, livestock, human interface understanding nature cross-species transmission.",{"entities":[]}],["study investigate public health threat posed RVFV IEPs determining burden human livestock diseases, degree sustained viral transmission animal species cryptic cycles.",{"entities":[[45,49,"CONDITION"]]}],null,["Understanding virus maintenance environment, vectors wildlife populations aid identifying potential risk factors RVFV infection prevent future outbreaks.",{"entities":[[113,117,"CONDITION"]]}],["disease occurrence animals frequently unnoticed inadequate animal surveillance systems levels animal abortion, human disease indication RVF virus amplification occurring levels region .",{"entities":[[136,145,"CONDITION"]]}],null,null,null,["enhance global efforts preparing for, preventing, spread RVF disease regions.",{"entities":[[57,60,"CONDITION"]]}],["RVF under-diagnosed febrile illness ECA region occurrence unknown undiagnosed infectious diseases.",{"entities":[[0,3,"CONDITION"]]}],null,null,null,["HYPOTHESIS OBJECTIVES Hypothesis Goal hypothesis RVF virus, maintained cryptic vertebrate-mosquito cycling inter-epidemic periods substantial public health burden.",{"entities":[[49,52,"CONDITION"]]}],["goal determine public health threat posed RVF virus IEPs East Central Africa region identify potential opportunities prevention control strategies reduce likelihood major outbreaks.",{"entities":[[42,45,"CONDITION"]]}],["Primary objectives (i) Determine low-level RVF virus transmission disease animals humans occurs inter-epidemic periods (IEPs) (ii) Conduct detailed niche modelling RVF risk risk ecologies determine ecological risk factors persistence RVF virus recurrence outbreaks animals humans (iii) Investigate impact climate change RVF permissive ecologies RVF virus transmission Secondary objective (iv) Conduct pathogen discovery human, livestock, wildlife samples collected ECA countries identify circulating emerging infectious pathogens epidemic pandemic potential.",{"entities":[[43,46,"CONDITION"],[164,167,"CONDITION"],[234,237,"CONDITION"],[345,348,"CONDITION"]]}],["DESIGN METHODOLOGY conduct field studies countries listed below, understanding emerging RVF hotspots region added.",{"entities":[[88,91,"CONDITION"]]}],["(i) Tana river, Marsabit, Isiolo Murangá counties Kenya (ii) Kabale, Rubanda Isingiro districts Uganda (iii) North South Kivu provinces DRC (iv) 4 countries emerging RVF hotspot STUDY PROCEDURES 1.",{"entities":[[4,14,"LOCATION"],[16,24,"LOCATION"],[26,32,"LOCATION"],[33,40,"LOCATION"],[50,55,"COUNTRY"],[61,67,"LOCATION"],[69,76,"LOCATION"],[77,85,"LOCATION"],[96,102,"COUNTRY"],[109,125,"LOCATION"],[136,139,"COUNTRY"]]}],null,["sample size 707-1,500 human participants recruited 2 site, based assumptions RVFV seroprevalence.",{"entities":[[77,81,"CONDITION"]]}],["health facility, longitudinal acute febrile illness (AFI) surveillance established.",{"entities":[[30,51,"CONDITION"],[53,56,"CONDITION"]]}],null,null,["However, percent samples patients positive malaria rapid diagnostic blood smear included study common risk factors malaria RVF infection.",{"entities":[[123,126,"CONDITION"]]}],null,["Consenting patients enrolled, serum collected tested RVFV RNA, IgM IgG antibodies.",{"entities":[[53,57,"CONDITION"],[58,61,"BIOLOGICAL"],[63,66,"BIOLOGICAL"],[67,70,"BIOLOGICAL"]]}],["Convalescent serum collected 4 weeks enrolment RVFV antibodies.",{"entities":[[47,51,"CONDITION"]]}],["addition, individual contacted provide blood specimen 24 months enrolment analysis peripheral blood mononuclear cells (PBMCs).",{"entities":[[83,117,"BIOLOGICAL"],[119,124,"BIOLOGICAL"]]}],["specimens tested etiology acute febrile illness including brucellosis, q-fever, coronaviruses emerging pathogens molecular methods.",{"entities":[[58,69,"CONDITION"],[71,78,"CONDITION"]]}],null,null,null,null,["livestock sample size, assuming average RVF seroprevalence 4%, precision 2%, confidence level 95%, power 80% 369 animals survey.",{"entities":[[40,43,"CONDITION"]]}],null,null,null,null,["Marsabit site, camels included.",{"entities":[[0,8,"LOCATION"]]}],null,null,null,["Livestock blood samples collected tested RVFV RNA, anti-viral IgM IgG antibodies.",{"entities":[[41,45,"CONDITION"],[46,49,"BIOLOGICAL"],[51,61,"BIOLOGICAL"],[62,65,"BIOLOGICAL"],[66,69,"BIOLOGICAL"]]}],["household selected field sites included seroprevalence (and sero-conversion) study, link animal, vector human infection.",{"entities":[[40,54,"BIOLOGICAL"],[97,103,"BIOLOGICAL"]]}],null,null,null,null,["Slaugther house studies: Sampling cattle goats performed slaughter houses Goma.",{"entities":[[74,78,"LOCATION"]]}],null,["Sheep rarely slaughtered Goma sampled available.",{"entities":[[25,29,"LOCATION"]]}],null,["samples analysed serological molecular techniques detection anti-RVFV antibodies RVFV nucleic acid.",{"entities":[[60,80,"BIOLOGICAL"],[81,85,"CONDITION"],[86,98,"BIOLOGICAL"]]}],null,["Wildlife sampling: Convenient wildlife sampling carried field sites nearby national conservation Kenya, Uganda, Tanzania DRC.",{"entities":[[97,102,"COUNTRY"],[104,110,"COUNTRY"],[112,120,"COUNTRY"],[121,124,"COUNTRY"]]}],null,null,["samples tested RVF RNA antibodies, pathogen discovery detect circulating emerging pathogens.",{"entities":[[15,18,"CONDITION"],[19,33,"BIOLOGICAL"],[35,43,"BIOLOGICAL"],[82,91,"BIOLOGICAL"]]}],null,["Vector studies: approach investigating role vectors cryptic cycles IEPs guided proportion mosquitoes infected, epidemics.",{"entities":[[90,100,"BIOLOGICAL"]]}],["Therefore, identify presence infected mosquitoes interpret acute RVFV infections (presence viral RNA) measure presence infected mosquitoes mosquito-to-vertebrate transmission.",{"entities":[[38,48,"BIOLOGICAL"],[65,69,"CONDITION"],[97,100,"BIOLOGICAL"],[128,138,"BIOLOGICAL"]]}],["acute RVFV infection collect mosquito pools community grazing households livestock sampling, identify species RVFV RNA.",{"entities":[[6,10,"CONDITION"],[29,37,"BIOLOGICAL"],[110,114,"CONDITION"],[115,118,"BIOLOGICAL"]]}],null,null,null,null,null,null,null,null,null,null,null,null,["RVF modelling studies: Modelling studies support RVFV transmission IEPs RVF epidemics.",{"entities":[[0,3,"CONDITION"],[49,53,"CONDITION"]]}],null,null,null,null,null,null,null,null,null,null,["Tana river Kenya Kabale district Uganda), virus circulation evident epidemics occurred (e.g.",{"entities":[[11,16,"COUNTRY"],[17,23,"LOCATION"],[33,39,"COUNTRY"]]}],["Udzungwa Mountains Tanzania) understand differences transmission dynamics.",{"entities":[[0,18,"LOCATION"],[19,27,"COUNTRY"]]}],null,null,["data collected field studies published literature include vector species/vector density/vector RVFV positivity, animal presence/animal density/animal RVFV positivity, human-animal contact, population density/population positivity, spectrum disease presentation severity, co-circulation arboviruses, genetic characterization RVFV areas.",{"entities":[[95,99,"CONDITION"],[150,154,"CONDITION"],[324,328,"CONDITION"]]}],null,["Testing archived samples: approach utilised DRC samples collected studies: Study A: cross-sectional study including outpatient acute febrile syndromes children adults, November 2015 June 2016 Kinshasa, DRC: 342 patients, aged 2 68 years, included.",{"entities":[[192,200,"LOCATION"],[202,205,"COUNTRY"]]}],null,["sampes analysed serological molecular techniques detection anti-RVF antibodies RVFV nucleic acid.",{"entities":[[59,78,"BIOLOGICAL"],[79,83,"CONDITION"],[84,96,"BIOLOGICAL"]]}],["Study B: Archived samples collected cattle goats Goma abattoirs, cattle farms North-Kivu province 2017.",{"entities":[[49,53,"LOCATION"],[78,97,"LOCATION"]]}],["animals originated neighboring countries provide materials assess risk RVFV circulation region.",{"entities":[[71,75,"CONDITION"]]}],null,["Study C: Archived samples collected wild animals Virunga Park Veterinary Laboratory Goma screened presence anti-RVF antibodies RVFV nucleic acid.",{"entities":[[49,83,"ORG"],[84,88,"LOCATION"]]}],null,null,null,["adaptive phase II/III clinical trial evaluate Safety Efficacy Single Day 3-day Single Dose ALBENDAZOLE-IVERMECTIN Coformulation ALBENDAZOLE Treatment Soil-Transmitted Helminth Infections.",{"entities":[[91,113,"DRUG"],[128,139,"DRUG"]]}],null,null,["Phase component (Kenya only) Unicentric, 3-arm, parallel, open-label, individually randomised, phase trial determine weight groups, safety ALBENDAZOLEIVERMECTIN Co-formulation Single Day 3-day Single Dose regimen treatment Trichuris trichiura children adult aged 5 18 years.",{"entities":[[139,160,"DRUG"],[223,242,"BIOLOGICAL"]]}],null,["* 3 (50 participants): body weight 15-23 receive 391-600 µg/Kg IVM (FDC 400mg-9mg) ALB.",{"entities":[]}],["FDC stands Fixed Dose Co-formulation ALB stands Albendazole.",{"entities":[[48,59,"DRUG"]]}],["Then, participants allocated study arms unequal probability (ALB: p=0.2, n=26; FDCx1: p=0.4, n=50; FDCx3: p=0.4, n=50) starting 1.",{"entities":[]}],["* Treatment Arm 1: Single dose tablet ALBENDAZOLE 400 (active control arm).",{"entities":[[38,49,"DRUG"]]}],["* Treatment Arm 2: Single dose tablet ALBENDAZOLEIVERMECTIN Co-formulation.",{"entities":[[38,59,"DRUG"]]}],["* Treatment Arm 3: Daily dose tablet ALBENDAZOLE-IVERMECTIN Co-formulation 3 consecutive days.",{"entities":[[37,59,"DRUG"]]}],["Phase III Component multi-centre, 3-arm, parallel, open-label, randomised, phase III trial compare safety efficacy active control arm (current standard care) 2 experimental arms treatment T.",{"entities":[]}],["trichiura, hookworm S.",{"entities":[[0,9,"BIOLOGICAL"],[11,19,"BIOLOGICAL"]]}],["stercoralis, children adult aged 5-18 subSaharan African countries (Ethiopia, Kenya Mozambique) hypothesise FDC Ivermectin (IVM) ALB single 3- day regimens effective species Soil Transmitted Helminths (STH) (T.",{"entities":[[68,76,"COUNTRY"],[78,83,"COUNTRY"],[84,94,"COUNTRY"],[112,122,"DRUG"],[191,200,"BIOLOGICAL"]]}],["trichiura, hookworm S.",{"entities":[[0,9,"BIOLOGICAL"],[11,19,"BIOLOGICAL"]]}],["stercoralis) compared current single dose regimen 400mg ALB.",{"entities":[[56,59,"DRUG"]]}],null,["* Treatment Arm 1: Single dose tablet ALB 400 (active control arm).",{"entities":[[38,41,"DRUG"]]}],["* Treatment Arm 2: Single dose tablet FDC 400mg-18mg 400mg-9mg.",{"entities":[[38,41,"DRUG"]]}],["* participants \\\\<45 body weight baseline: FDC 400mg ALB- 9mg IVM.",{"entities":[[43,46,"DRUG"]]}],["* participants ≥45 body weight baseline: FDC 400mg ALB-18mg IVM.",{"entities":[[41,44,"DRUG"],[51,59,"DRUG"]]}],["* Treatment Arm 3: Daily dose tablet FDC 400mg-18mg 400mg9mg 3 days.",{"entities":[[37,40,"DRUG"]]}],["* participants \\\\<45 body weight baseline: FDC 400mg ALB-9mg IVM.",{"entities":[[43,46,"DRUG"],[53,60,"DRUG"]]}],["* participants ≥45 body weight baseline: FDC 400mg ALB- 18mg IVM.",{"entities":[[41,44,"DRUG"],[51,55,"DRUG"]]}],null,null,null,null,["Participants recruited Mozambique offered tested HIV serostatus HIV prevalence country, result determine participant's eligibility.",{"entities":[[23,33,"COUNTRY"]]}],["Kenya Ethiopia, HIV prevalence justify HIV testing",{"entities":[[0,5,"COUNTRY"],[6,14,"COUNTRY"]]}],null,null,null,null,null,null,null,["injections, cabotegravir rilpivirine, clinic 8 weeks.",{"entities":[[12,24,"DRUG"],[25,36,"DRUG"]]}],null,null,null,null,null,null,null,["option switch tablet cabotegravir tablet rilpivirine 4-5 weeks starting injections.",{"entities":[[21,33,"DRUG"],[41,52,"DRUG"]]}],null,null,null,null,["However, trial, participants change oral medications combination dolutegravir tenofovir lamivudine emtricitabine single tablet day, called TLD.",{"entities":[[65,77,"DRUG"],[78,87,"DRUG"],[88,98,"DRUG"]]}],["LATA trial enrol 460 people living HIV-1 Kenya, South Africa, Uganda Zimbabwe.",{"entities":[[41,46,"COUNTRY"],[48,60,"COUNTRY"],[62,68,"COUNTRY"],[69,77,"COUNTRY"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["additional blood sample year, urine samples week 96; stored samples health people's kidneys, bone, heart organ systems; optional.",{"entities":[[84,91,"BODY_PART"],[93,97,"BODY_PART"],[99,104,"BODY_PART"]]}],null,null,null,null,null,null,null,null,null,null,null,null,["evaluated 12 weeks HIV sexually transmitted infections (STIs).",{"entities":[[19,22,"CONDITION"],[23,60,"CONDITION"]]}],null,null,null,["Title Phase II: Multicentre Clinical Study Assess Performance Bioneer IRONqPCR ™ RFIA Kit INH-, RIF-, FQ- AG-Resistance Detection Background rationale Evidence clinical diagnostic accuracy operational characteristics Bioneer IRONqPCR ™ RFIA Kit comprehensively evaluate Bioneer RFIA validity inform global national policy decision-making.",{"entities":[[90,94,"DRUG"]]}],null,["Investigational (IUO) product intended detection MTB mutations RIF, INH, FQ AMG drug resistance.",{"entities":[[63,66,"DRUG"],[68,71,"DRUG"],[76,79,"DRUG"]]}],null,["cartridge intended IRON qPCR system.",{"entities":[[19,23,"BIOLOGICAL"]]}],["IRON qPCR study testing IUO product study samples.",{"entities":[[0,4,"BIOLOGICAL"],[5,9,"BIOLOGICAL"]]}],["IRON qPCR instrument developed Bioneer intended healthcare systems.",{"entities":[[0,4,"BIOLOGICAL"],[5,9,"BIOLOGICAL"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,["* Phenotypic DST INH, RIF, fluoroquinolone (moxifloxacin levofloxacin), AMK, KAN resistance culture positive MTB complex patient.",{"entities":[[17,20,"DRUG"],[22,25,"DRUG"],[27,42,"DRUG"],[44,56,"DRUG"],[57,69,"DRUG"]]}],["* Molecular testing MTB-complex confirmed cultures GenoType MTBDRplus MTBDRsl * genome sequencing samples Bioneer result (from sputum culture testing) discordant phenotypic DST * Bioneer Accupower Q-RFIA MTBC confirmed cultures diagnostic (smear, Bioneer IRONqPCR ™ RFIA Kit direct sample, Xpert MTB/RIF Ultra direct sample, Xpert MTB/XDR direct sample, MGIT, LJ, Bioneer Accupower RFIA culture isolate, MTBDRplus, MTBDRsl, phenotypic DST results) recorded laboratory technicians laboratory CRF.",{"entities":[[290,303,"INTERVENTION"],[325,338,"INTERVENTION"]]}],null,["event routine testing retrospective specimens, smear Xpert MTB/RIF Ultra repeated.",{"entities":[[53,66,"INTERVENTION"]]}],null,["Xpert MTB/XDR performed selected specimen.",{"entities":[[0,13,"INTERVENTION"]]}],null,null,null,null,null,["culture reference standard imperfect paucibacillary (smear-negative) TB.",{"entities":[[37,51,"BIOLOGICAL"]]}],["lead bias accuracy estimates test: (i) sensitivity overestimated reference standard yield negative patient TB; (ii) specificity underestimated positive result patient TB tests negative reference standard.",{"entities":[[107,109,"CONDITION"],[167,169,"CONDITION"]]}],null,["However, near-perfect specificity required TB assays, bias specificity problematic.",{"entities":[[43,45,"CONDITION"]]}],null,null,null,null,null,null,null,null,null,null,null,["MGIT DST determine culture drug-susceptibility INH, RIF, moxifloxacin, levofloxacin, AMK, KAN revised critical concentrations15.",{"entities":[[47,50,"DRUG"],[52,55,"DRUG"],[57,69,"DRUG"],[71,83,"DRUG"],[85,88,"DRUG"],[90,93,"DRUG"]]}],null,null,null,null,null,null,null,null,null,["International Livestock Institute (ILRI), partners, pioneered approach improving safety food sold informal markets professionalizing informal traders operate markets low- middle-income countries.",{"entities":[[0,33,"ORG"]]}],null,null,null,["study conducted peri-urban Eldoret, Kenya.",{"entities":[[27,34,"LOCATION"],[36,41,"COUNTRY"]]}],null,null,["Importantly, estimated 70% (Kenya Market Trust, 2016) milk consumed study sold informal dairy vendors-vendors sell unpackaged not-formally processed milk-who focus study.",{"entities":[[28,46,"ORG"]]}],null,null,["safety) unpacked milk sold informal markets? * \"\"training, certification marketing\"\" intervention dairy vendors operating informal dairy markets peri-urban Eldoret increase natural log dietary adequacy protein, Ca, vitamin B12 children 12-48 months (at baseline) consumer households? study population include dairy vendors operating informal sector (businesses selling unpackaged not-formally processed milk individual consumers; includes raw, boiled unpacked pasteurized milk) study consumer households purchase weekly milk vendors.",{"entities":[[156,163,"LOCATION"],[211,213,"BIOLOGICAL"],[215,226,"BIOLOGICAL"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["one-third median daily milk consumption children 24-48 months age MilkMarkets data collected Dagoretti (peri-urban Nairobi) 2017.",{"entities":[[93,102,"LOCATION"],[115,122,"LOCATION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Samples tested total bacterial counts (TBC), enumeration enterobacteriaceae.",{"entities":[[15,43,"BIOLOGICAL"],[57,75,"BIOLOGICAL"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["HIV Vaccine Trials Network (HVTN) HIV Prevention Trials Network (HPTN) conducting study combination antibodies HIV.",{"entities":[[0,26,"ORG"],[28,32,"ORG"],[34,63,"ORG"],[65,69,"ORG"]]}],null,null,["Researchers antibodies laboratories people infusions vein skin.",{"entities":[[12,22,"BIOLOGICAL"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["India Tanzania, pragmatic cluster randomised controlled trials (RCTs) conducted (NCT04910750).",{"entities":[[0,5,"COUNTRY"],[6,14,"COUNTRY"],[26,62,"STUDY_DESIGN"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["estimated 17 facilities, recruiting average 690 children facility 3-month period Kenya, 18 facilities recruiting 510 children facility period Senegal.",{"entities":[[81,86,"COUNTRY"],[142,149,"COUNTRY"]]}],null,["minimum 7429 6760 children estimated period Kenya Senegal respectively, recruitment continuing meeting minimum sample size description time overlapping seasonal periods, intention original design.",{"entities":[[44,49,"COUNTRY"],[50,57,"COUNTRY"]]}],null,null,null,null,["HIV-uninfected non-pregnant cisgender women risk HIV randomly assigned 1 3 dosing frequencies observed therapy (DOT) Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) PrEP differentiate poor modest perfect dosing.",{"entities":[[117,126,"DRUG"],[127,137,"DRUG"],[138,160,"DRUG"],[162,169,"DRUG"],[171,175,"DRUG"]]}],null,null,null,["define cisgender women-specific expected blood concentrations dose-proportionality Tenofovir-diphosphate (TFV-DP) dried blood spots (DBS) Peripheral Blood Mononuclear Cells(PBMCs) observed TDF/FTC therapy 2, 4, 7 doses week.",{"entities":[[83,104,"DRUG"],[106,112,"DRUG"],[114,131,"BIOLOGICAL"],[133,136,"BIOLOGICAL"],[138,172,"BIOLOGICAL"],[173,178,"BIOLOGICAL"],[189,196,"DRUG"]]}],["2.",{"entities":[]}],["establish model predict adherence rate TDF/FTC level TFV-DP DBS cisgender women.",{"entities":[]}],["HIV-uninfected non-pregnant cisgender women randomly assigned 1 3 dosing frequencies observed therapy (DOT) TDF/FTC PrEP: 2, 4, 7 doses/week differentiate poor modest perfect adherence.",{"entities":[[108,115,"DRUG"],[116,120,"DRUG"]]}],["study define TDF-PrEP adherence-blood concentration thresholds African cisgender women, priority population HIV prevention.",{"entities":[[13,21,"DRUG"]]}],null,null,null,["TITLE label, Phase 2 study evaluate safety immunogenicity Ad26.ZEBOV booster dose Human Immunodeficiency Virus positive (HIV+) adults vaccinated Ad26.ZEBOV, MVA-BN-Filo vaccine regimen.",{"entities":[[82,110,"CONDITION"]]}],["RATIONALE previous Phase 2 3 trials, HIV+ adult participants vaccinated 2-dose Ebola vaccine regimen adenovirus serotype 26 expressing Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) Modified Vaccinia Ankara Bavarian Nordic vector expressing multiple filovirus proteins (MVA-BN-Filo).",{"entities":[[79,84,"CONDITION"],[135,146,"CONDITION"]]}],["Ebola vaccine regimen elicited humoral immune responses HIV+ adults comparable HIV-negative adults 21-days dose 2.",{"entities":[[0,5,"CONDITION"],[6,13,"INTERVENTION"]]}],null,null,["* assess humoral responses induced booster dose EBOV glycoprotein (GP), measured Filovirus Animal Non-Clinical (FANG) Enzyme-Linked Immunosorbent Assay (ELISA) 7 21 days.",{"entities":[[48,52,"INTERVENTION"],[53,65,"BIOLOGICAL"],[81,110,"BIOLOGICAL"],[112,116,"BIOLOGICAL"],[118,151,"BIOLOGICAL"],[153,158,"BIOLOGICAL"]]}],null,null,null,null,null,null,["Participants virologically suppressed immunologically controlled highly active antiretroviral therapy (HAART) regimen (HIV viral load \\\\< 50 copies/millilitres (mL) CD4+ cell count \\\\>/= 350 cells/microlitres (uL) 28 days study vaccination).",{"entities":[[65,101,"DRUG"],[103,108,"DRUG"],[165,169,"BIOLOGICAL"]]}],["study conducted VAC52150EBL2002 sites Kenya Uganda.",{"entities":[[38,43,"COUNTRY"],[44,50,"COUNTRY"]]}],null,["Travel active Ebola outbreak study period 2.",{"entities":[[14,19,"DRUG"]]}],null,["disallowed concomitant therapies INVESTIGATIONAL PRODUCT, DOSAGE ADMINISTRATION Ad26.ZEBOV replication-incompetent monovalent vaccine Ebola.",{"entities":[[134,139,"CONDITION"]]}],["consists adenovirus serotype 26 vector expressing full-length Ebola virus (EBOV, Zaire ebolavirus) Mayinga GP.",{"entities":[[62,67,"CONDITION"],[81,86,"LOCATION"],[87,97,"CONDITION"]]}],null,null,null,null,null,null,null,["Future scientific conducted investigate Ebola vaccine- disease-related questions study infections public health Kenya Uganda, neighboring countries.",{"entities":[[40,45,"CONDITION"],[112,117,"COUNTRY"],[118,124,"COUNTRY"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["ii) evaluate feasibility acceptability PoC VL monitoring children adolescents living HIV East Africa.",{"entities":[[89,100,"LOCATION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Study Sites: (20) health facilities spread 4 countries follows: Uganda (6), Kenya (4), Tanzania (6), Rwanda (4).",{"entities":[[64,70,"COUNTRY"],[76,81,"COUNTRY"],[87,95,"COUNTRY"],[101,107,"COUNTRY"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Long-acting (LA) antiretroviral therapy (ART), injectable cabotegravir rilpivirine, receiving global clinical approvals potential address barriers ART improve patient adherence persistence treatment.",{"entities":[[58,70,"DRUG"],[71,82,"DRUG"]]}],null,["major threat AGYW's health unintended pregnancies AGYWLHIV unique challenges uptake continuation contraceptives.",{"entities":[[13,17,"POPULATION"],[50,58,"POPULATION"]]}],["ART foster synergy usage contraceptives AGYWLHIV.",{"entities":[[40,48,"POPULATION"]]}],["proposed study main components: 1) prospective, non-randomized, parallel-group pharmacokinetic (PK) study sentinel cohort distinct AGYW, leverage existing control (Aim 1a); 2) qualitative study conduct individual interviews subgroups AGYWLHIV sentinel cohort study, focus discussions providers, policy makers, stakeholders health systems readiness wider scale-up (Aim 1b); 3) open-label, mixed methods, 48-week type hybrid trial randomizing AGYW viral suppression current ART regimen switch 1:1 cabotegravir/ rilpivirine (intervention arm) vs.",{"entities":[[131,135,"POPULATION"],[234,242,"POPULATION"]]}],null,["proposed study conducted HIV treatment facilities western Kenya regional Moi Teaching Referral Hospital (MTRH).",{"entities":[[73,103,"ORG"]]}],null,["Providing array method options HIV treatment pregnancy prevention potential revolutionize personal decision-making improve long-term outcomes AGYWLHIV.",{"entities":[[142,150,"POPULATION"]]}],null,null,null,null,null,["Demonstrating successful implementation outcomes inform wider-scale implementation ART, service client outcomes realized.",{"entities":[[83,86,"POPULATION"]]}],null,null,null,null,null,null,null,null,null,null,null,["Strengthening evidence policy RTS,S/AS01 malaria vaccine: assessment safety effectiveness case-control studies embedded Malaria Vaccine Pilot Evaluation (MVPE).",{"entities":[[41,48,"CONDITION"],[49,56,"INTERVENTION"],[120,152,"INTERVENTION"]]}],["project support embedding case-control studies ongoing evaluation component RTS,S malaria vaccine pilot implementation programme (MVIP) Ghana, Kenya, Malawi.",{"entities":[[82,89,"CONDITION"],[90,97,"INTERVENTION"],[136,141,"COUNTRY"],[143,148,"COUNTRY"],[150,156,"COUNTRY"]]}],null,["case-control studies period 36 months countries (Ghana, Kenya, Malawi).",{"entities":[[49,54,"COUNTRY"],[56,61,"COUNTRY"],[63,69,"COUNTRY"]]}],null,null,null,null,null,["Children living study ongoing MVPE recruited catchment sentinel hospital MVPE recruited.",{"entities":[[30,34,"INTERVENTION"],[73,77,"INTERVENTION"]]}],null,["eligible identified MVPE sentinel hospital surveillance systems recruited.",{"entities":[[20,24,"INTERVENTION"]]}],["Data collected MVPE sentinel surveillance updated consent.",{"entities":[[15,19,"INTERVENTION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Poor person-centered maternal health care (PCMHC) contributes maternal neonatal mortality sub-Saharan Africa (SSA), disparities PCMHC driving disparities maternal health services., However, exists improve PCMHC reduce disparities.",{"entities":[[90,108,"LOCATION"],[110,113,"LOCATION"]]}],null,null,null,null,["examined levels provider stress unconscious bias types stressors biases Migori County, Kenya.",{"entities":[[72,85,"LOCATION"],[87,92,"COUNTRY"]]}],null,null,null,null,["Purpose study hypothesis treatment inclisiran sodium 300 s.c.",{"entities":[[35,52,"DRUG"]]}],["administered Day 1, Month 3 (Day 90), 6 months addition well-tolerated high-intensity statin therapy participants established ASCVD reduce risk 3-Point-Major Adverse Cardiovascular Events (3P-MACE) defined composite death, non-fatal myocardial infarction (MI) non-fatal ischemic stroke.",{"entities":[[233,254,"CONDITION"],[270,285,"CONDITION"]]}],["compared placebo adjunct well-tolerated high-intensity statin therapy.",{"entities":[[55,61,"DRUG"]]}],null,["Women randomized standard-of-care arm undergo Visual Inspection Lugol's Iodine (VILI).",{"entities":[[64,78,"DRUG"]]}],null,null,null,null,null,null,null,null,null,["Malaria vectors exhibit behavioural characteristics mitigate effectiveness vector control strategies.",{"entities":[[0,7,"CONDITION"]]}],null,null,null,["Arabiensis drier environments zoophagic outdoor biting resting behaviours.",{"entities":[[0,10,"BIOLOGICAL"]]}],null,null,null,null,["arabiensis.",{"entities":[[0,10,"BIOLOGICAL"]]}],null,["Gambiae s.s.",{"entities":[[0,7,"BIOLOGICAL"]]}],null,null,null,null,null,null,["Entomological field trials Mali ATSBs reduce mosquito densities longevity potential reduce malaria transmission.",{"entities":[[27,31,"COUNTRY"]]}],null,null,["Mitapivat molecule, oral activator pyruvate kinase (PKR).",{"entities":[[0,9,"DRUG"],[35,50,"BIOLOGICAL"]]}],["PKR involved maintaining health, energy, longevity red blood cells (RBCs).",{"entities":[[51,66,"BIOLOGICAL"],[68,72,"BIOLOGICAL"]]}],["study aims evaluate efficacy safety treatment mitapivat participants sickle cell disease.",{"entities":[[69,88,"CONDITION"]]}],["study Phase 2/3 study recommended dose mitapivat selected evaluated.",{"entities":[]}],["Phase 2 portion includes 12-week randomized, placebo-controlled period participants randomized 1:1:1 ratio receive 2 dose levels mitapivat placebo.",{"entities":[[129,138,"DRUG"],[139,146,"INTERVENTION"]]}],["Phase 3 portion includes 52-week randomized, placebo-controlled period participants randomized 2:1 ratio receive recommended mitapivat dose level placebo.",{"entities":[[125,134,"DRUG"],[146,153,"INTERVENTION"]]}],["Participants complete Phase 2 Phase 3 portion option 216-week label extension period receive mitapivat.",{"entities":[[93,102,"DRUG"]]}],null,["Pre-exposure prophylaxis (PrEP) HIV prevention highly effective, uptake remains women sub-Saharan Africa, populations HIV risk.",{"entities":[[0,24,"DRUG"],[26,30,"DRUG"],[86,104,"LOCATION"]]}],["Kenya, target HIV incidence reduction women (16-24 years), account 33% total HIV infections, comprise 10% population.",{"entities":[[0,5,"COUNTRY"]]}],null,null,null,null,["HIV self-testing (HIVST) technology potential enhance peer PrEP referral.",{"entities":[[0,16,"INTERVENTION"],[18,23,"INTERVENTION"]]}],["emphasis HIVST identifying individuals living HIV facilitating linkage treatment, majority individuals self-test negative facilitated linkage prevention services, PrEP.",{"entities":[[9,14,"INTERVENTION"],[46,49,"CONDITION"],[163,167,"DRUG"]]}],["hypothesize formalized peer PrEP referral + HIVST delivery model amplify PrEP initiation Kenyan women HIV risk.",{"entities":[[28,32,"DRUG"],[44,49,"INTERVENTION"],[73,77,"DRUG"]]}],["conducted formative qualitative stakeholder engagement develop model formalized peer PrEP referral + HIVST delivery increase PrEP initiation Kenyan women.",{"entities":[[101,106,"INTERVENTION"]]}],null,null,["peer providers) Thika, Kenya deliver formalized peer PrEP referral + HIVST model \\\\~4 peers (i.e., peer clients, =64 peer clients total).",{"entities":[[16,21,"LOCATION"],[23,28,"COUNTRY"]]}],null,null,["trial, randomize 80 peer providers to: 1) \"\"formal peer PrEP referral + HIVST delivery\"\", encouraged refer 4 peer clients PrEP educational brochure, HIVSTs (2/peer, =8 total), MOH-style referral slip, vs.",{"entities":[[56,60,"DRUG"],[72,77,"INTERVENTION"],[122,126,"DRUG"],[149,155,"INTERVENTION"]]}],null,null,null,null,null,null,["\"\"standard care\"\" single standardized treatment regimen recommended drug resistant-tuberculosis (DR- TB).",{"entities":[[68,95,"CONDITION"],[97,103,"CONDITION"]]}],["Current DR-TB treatments tolerated effects.",{"entities":[[8,13,"CONDITION"]]}],["identify drugs anti-TB activity (treatment TB) safety profiles improve outcomes treatment DR-TB.",{"entities":[[43,45,"CONDITION"],[90,95,"CONDITION"]]}],["main purpose study evaluate efficacy tolerability shorter anti-TB treatment regimen compares dosing strategies linezolid (LZD), combined bedaquiline (BDQ), delamanid (DLM), clofazimine (CFZ).",{"entities":[[111,120,"DRUG"],[122,125,"DRUG"],[137,148,"DRUG"],[150,153,"DRUG"],[156,165,"DRUG"],[167,170,"DRUG"],[173,184,"DRUG"],[186,189,"DRUG"]]}],null,["study drugs day entire treatment period: BDQ, DLM, CFZ.",{"entities":[[41,44,"DRUG"],[46,49,"DRUG"],[51,54,"DRUG"]]}],["difference treatment study participants fourth drug: LZD.",{"entities":[[53,56,"DRUG"]]}],["Participants dose LZD day entire treatment period.",{"entities":[[18,21,"DRUG"]]}],["Participants dose LZD day 4 weeks continue dose LZD times week rest treatment period.",{"entities":[[18,21,"DRUG"],[48,51,"DRUG"]]}],["",{"entities":[]}],null,null,["Purposive sampling select hospitals, rural setting urban setting Nakuru County, Kenya.",{"entities":[[65,78,"LOCATION"],[80,85,"COUNTRY"]]}],null,null,null,null,null,null,null,null,null,null,null,["HbA1c levels compared 12 weeks arms ANCOVA control baseline HbA1c levels.",{"entities":[[0,5,"BIOLOGICAL"],[60,65,"BIOLOGICAL"]]}],null,null,null,null,null,["UNAIDS '95-95-95' targets achieved additional support adolescents living HIV (ALHIV) increase retention care support viral suppression.",{"entities":[[54,76,"POPULATION"],[78,83,"POPULATION"]]}],["Risk prediction tools stepped care approach care support differentiation ALHIV risk groups, tailor care based risk.",{"entities":[[73,78,"POPULATION"]]}],["investigators conducted informative ALHIV, caregivers, healthcare workers (HCW) policy makers, developed clinical prediction tool identify ALHIV risk retained care poor viral suppression adapted identify adolescents support care.",{"entities":[[36,41,"POPULATION"],[43,53,"POPULATION"],[55,73,"POPULATION"],[75,78,"POPULATION"],[139,144,"POPULATION"],[204,215,"POPULATION"]]}],["Understanding risk prediction tool tailor services based risk ultimately result efficient HIV care services, adequate support ALHIV risk poor outcomes.",{"entities":[[126,131,"POPULATION"]]}],["Building informative work, protocol, investigators conduct Phase III cluster randomized controlled trial (cRCT) implementing data-informed stepped care (DiSC) intervention ALHIV HIV treatment management high-volume HIV clinics Kenya.",{"entities":[[172,177,"POPULATION"]]}],["cRCT conducted 24 HIV care treatment facilities located Kisumu, Homabay, Migori county Western Kenya, 6000 HIV positive adolescents adults ages 10-24 enrolled HIV care, 900 caregivers ALHIV, 200 HCW recruited study.",{"entities":[[56,62,"LOCATION"],[64,71,"LOCATION"],[73,86,"LOCATION"],[87,100,"LOCATION"]]}],["Clinics randomized DiSC intervention arm data-driven assign ALHIV levels care depending current anticipated health care needs.",{"entities":[[60,65,"POPULATION"]]}],null,null,null,null,null,null,["Youth Living HIV (YLH) spared.",{"entities":[[0,16,"POPULATION"]]}],["study conducted Kenya, 33% 46% youth attending HIV clinic reported harmful patterns alcohol illicit substance respectively.",{"entities":[[84,91,"SUBSTANCE"]]}],["Substance YLH negative outcomes including antiretroviral therapy (ART) non-adherence, neurocognitive deficits, poor virologic control depression.",{"entities":[[86,109,"CONDITION"]]}],["Unfortunately, YLH SSA lack access substance interventions.",{"entities":[[15,18,"POPULATION"]]}],null,null,null,null,null,null,null,null,null,null,["project with: (i) Kenyan Ministry Health guidelines delivery adolescent youth friendly services lists substance counseling essential service, (ii) United Nations Programme HIV/AIDS (UNAIDS) Fast-track target 95-95-95, requires 2030, 95% people ART virally suppressed (12) target 3.5 Sustainable Development Goals (SDGs) requires governments strengthen treatment prevention substance abuse.",{"entities":[[25,40,"ORG"],[147,161,"ORG"],[182,188,"ORG"]]}],null,null,["children globally suffer consequences stunted growth development, millions experience deficiencies zinc, iron, iodine, vitamins B12, nutrients bioavailable fish foods.",{"entities":[[99,103,"BIOLOGICAL"],[105,109,"BIOLOGICAL"],[111,117,"BIOLOGICAL"],[119,131,"BIOLOGICAL"]]}],null,null,null,null,["matched intervention/control study conducted examine multifaceted Samaki Salama (\"\"fish security\"\" Kiswahili) intervention Kilifi, Kenya.",{"entities":[[123,129,"LOCATION"],[131,136,"COUNTRY"]]}],null,null,["Participants 400 small-scale fisher households recruited enrolled Kenyan partners Egerton University Pwani University eligibility criteria.",{"entities":[[82,100,"ORG"],[101,117,"ORG"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["BOHEMIA cluster randomized trials carried Mozambique (Southern Africa) Kenya (Eastern Africa).",{"entities":[[42,52,"COUNTRY"],[71,76,"COUNTRY"]]}],["sites encompass transmission dynamics increase generalizability results, namely: (a) gradient malaria transmission: moderate Kenya Mozambique, (b) species composition vector population, (c) rain patterns environmental conditions, (d) livestock species human/livestock ratios (in Mozambique).",{"entities":[[125,130,"COUNTRY"],[131,141,"COUNTRY"]]}],null,["Efficacy determined pediatric active cohort (children 5 age Mozambique 5-15 Kenya), safety determined receives drug.",{"entities":[[60,70,"COUNTRY"],[76,81,"COUNTRY"]]}],null,["Treatment Groups: clusters (three Mozambique) randomized receive (a) ivermectin humans, (b) ivermectin humans + livestock (only Mozambique), (c) albendazole control.",{"entities":[[69,79,"DRUG"],[92,102,"DRUG"],[145,156,"DRUG"]]}],["Mozambique, study district subject enhanced passive surveillance malaria.",{"entities":[[0,10,"COUNTRY"],[65,72,"CONDITION"]]}],null,null,null,["Estimated Duration Study: study participants enrolled, receiving treatment (\\\\>15 kg) active pediatric cohort main outcome malaria incidence (the ages incidence country, 5 age Mozambique 5-15 Kenya).",{"entities":[[176,186,"COUNTRY"],[192,197,"COUNTRY"]]}],null,null,null,null,null,null,null,null,null,null,["Women receive intramuscular vaccines (influenza yellow fever).",{"entities":[[38,47,"CONDITION"],[48,60,"CONDITION"]]}],null,null,null,null,["Women receive 1st dose COVID-19 vaccine.",{"entities":[[23,31,"CONDITION"],[32,39,"INTERVENTION"]]}],null,["28 days, participants receive 2nd dose COVID-19 vaccine.",{"entities":[[39,47,"CONDITION"],[48,55,"INTERVENTION"]]}],null,null,["BACKGROUND Viral suppression proxy successful anti-retroviral therapy (ART) \"\"3rd 90\"\" (Joint United Nations Programme HIV/AIDS (UNAIDS) 90-90-90 strategy.",{"entities":[[94,108,"ORG"],[129,135,"ORG"]]}],null,null,null,null,null,null,null,null,["Observational data EGPAF-supported sites Homa Bay Turkana counties children adolescents viral load \\\\> 1000 copies/ml, 40 percent received recommended minimum EAC sessions.",{"entities":[[41,49,"LOCATION"],[50,57,"LOCATION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,["Guidelines Antiretroviral Drugs Treating Preventing HIV Infection Kenya.",{"entities":[[11,31,"DRUG"],[52,55,"CONDITION"],[66,71,"COUNTRY"]]}],["2016 Kenya Ministry Health guidelines ART treating preventing HIV recommend ART started patients possible, preferably 2 weeks confirmation HIV infection.",{"entities":[[62,65,"CONDITION"],[139,142,"CONDITION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Sites Selection 171 facilities supported EGPAF Timiza90 project Homa Bay County.",{"entities":[[64,79,"LOCATION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Phase III study global multicenter, randomized, double-blind, placebo-controlled clinical trial evaluate efficacy, safety, immunogenicity recombinant COVID-19 vaccine (Sf9 cells) 40,000 participants aged 18 history SARS-CoV-2 infection locations circumstances appreciable risk acquiring COVID-19 SARS-CoV-2 infection.",{"entities":[[150,158,"CONDITION"],[215,225,"CONDITION"],[287,295,"CONDITION"],[296,306,"CONDITION"]]}],null,null,null,null,null,null,null,null,null,null,["study include 280 adult adolescent participants (≥ 12 age) SCD.",{"entities":[[59,62,"CONDITION"]]}],["Eligible participants administered inclacumab placebo intravenous (IV) single dose.",{"entities":[[35,45,"DRUG"],[46,53,"INTERVENTION"]]}],null,null,["Eligible participants administered inclacumab placebo intravenous (IV) 12 weeks.",{"entities":[[35,45,"DRUG"],[46,53,"INTERVENTION"]]}],null,null,null,["outbreak severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) declared Public Health Emergency International Concern January 2020 upgraded pandemic March 2020.",{"entities":[[43,54,"CONDITION"],[58,68,"CONDITION"]]}],["vaccines prevent COVID-19 authorized emergency December 2020, unknowns remains.",{"entities":[[17,25,"CONDITION"]]}],null,null,null,null,null,null,null,["RV460 exploratory study assess safety, tolerability, immunogenicity vaccine regimen consisting priming Env-C Plasmid DNA vaccine (with adjuvants) adjuvanted HIV Env gp145 C.6980 protein vaccine boosting adjuvanted gp145 C.6980 protein gp120 DNA vaccine.",{"entities":[[109,116,"BIOLOGICAL"],[117,120,"BIOLOGICAL"],[165,185,"BIOLOGICAL"],[214,234,"BIOLOGICAL"],[235,244,"BIOLOGICAL"]]}],["study carried Kericho, Kenya.",{"entities":[[14,21,"LOCATION"],[23,28,"COUNTRY"]]}],null,null,null,null,["Background: Remote ischaemic conditioning (RIC) transient limb ischaemia reperfusion reduce myocardial infarct size animal studies proof-of-concept clinical studies ST-segment elevation myocardial infarction (STEMI) patients.",{"entities":[[48,72,"CONDITION"],[92,110,"CONDITION"],[165,214,"CONDITION"]]}],null,null,["RIC-AFRICA trial investigate RIC improve clinical outcomes higher-risk STEMI patients treated thrombolysis sub-Saharan Africa.",{"entities":[[71,76,"CONDITION"]]}],["Study design: RIC-AFRICA trial multi-centre, sham-controlled, double-blinded, randomised controlled trial (RCT) involving 1200 ST-segment elevation myocardial infarction (STEMI) patients ≤ 24 hours myocardial infarction (MI) onset, 20 sites sub-Saharan African countries (South Africa, Kenya, Sudan Uganda).",{"entities":[[78,105,"STUDY_DESIGN"],[127,169,"CONDITION"],[171,176,"CONDITION"],[198,219,"CONDITION"],[221,223,"CONDITION"],[272,284,"COUNTRY"],[286,291,"COUNTRY"],[293,298,"COUNTRY"],[299,305,"COUNTRY"]]}],null,null,null,["primary composite endpoint all-cause death new-onset heart failure 30-days post STEMI.",{"entities":[[80,85,"CONDITION"]]}],["Patients STEMI deemed ineligible RIC AFRICA RCT \\\\>24 hours MI onset 72 hours, recruited observational arm study endpoints trial.",{"entities":[[9,14,"CONDITION"]]}],["Implications: RIC-AFRICA trial determine RIC reduce rates death prevent heart failure higher-risk STEMI patients treated thrombolytic therapy sub-Saharan Africa, providing low-cost, non-invasive therapy improving health outcomes.",{"entities":[[121,133,"CONDITION"]]}],null,null,["study conduct randomization trials evaluate dynamic treatment interventions tailored heavy alcohol users mobile populations.",{"entities":[[91,98,"SUBSTANCE"]]}],null,null,["community based intervention hypertension.",{"entities":[[29,41,"CONDITION"]]}],null,["clinical study complete 12 healthy, non-pregnant, HIV-uninfected women aged 18-50 contraceptive arm, risk sexually transmitted infections (STIs) clinical sites, total 96 completed participants.",{"entities":[[106,137,"CONDITION"],[139,143,"CONDITION"]]}],null,["Participants randomized (1:1:1:1) four, marketed, approved contraceptive dosing forms: Levonorgestrel (LNG) 52 mg.",{"entities":[[87,101,"DRUG"]]}],["Intrauterine (IUS), Copper Intrauterine Device (IUD), etonogestrel (ETG, Nexplanon, Implanon) contraceptive implant, DMPA contraceptive injection.",{"entities":[[20,46,"INTERVENTION"],[48,51,"INTERVENTION"],[54,66,"DRUG"],[73,82,"INTERVENTION"],[84,92,"INTERVENTION"],[94,115,"INTERVENTION"],[117,145,"INTERVENTION"]]}],null,null,["study recruit HIV-negative adolescents girls (AG) aged 15-19 Siaya County, western Kenya.",{"entities":[[61,73,"LOCATION"]]}],null,null,null,null,null,null,["Typhoid enteric disease caused bacterium Salmonella Typhi; estimated 11 20 people contract typhoid 128 000 161 000 die disease; children 5 risk contracting disease.",{"entities":[[41,57,"BIOLOGICAL"]]}],["Typhoid endemic located South Asia Sub-Saharan Africa transmitted contaminated water food.",{"entities":[[0,7,"CONDITION"]]}],null,["symptoms typhoid undifferentiated febrile illnesses typhoid mistaken vector borne febrile illnesses scrub typhus.",{"entities":[[9,16,"CONDITION"],[52,59,"CONDITION"],[100,112,"CONDITION"]]}],["Blood bone marrow cultures considered gold standard diagnosis typhoid.",{"entities":[[6,17,"BODY_PART"],[62,69,"CONDITION"]]}],null,null,["consequence, alternatives blood culture LMIC.",{"entities":[[26,39,"BIOLOGICAL"]]}],null,null,null,null,["collaboration international typhoid experts developed target product profile outlining ideal characteristics care tests.",{"entities":[[28,35,"CONDITION"]]}],null,["Africa Asia).",{"entities":[[0,6,"LOCATION"],[7,11,"LOCATION"]]}],null,["lack characterized samples reduces ability targeted innovation typhoid space.",{"entities":[[63,70,"CONDITION"]]}],null,null,null,null,null,null,null,["250 children living HIV received treatment IMPAACT network studies studies sponsored National Institutes Health (NIH) enrolled semi-annually years.",{"entities":[[85,111,"ORG"]]}],null,null,["Cervical cancer caused oncogenic HPV, main cancer-related death Kenyan women.",{"entities":[[0,15,"CONDITION"],[33,36,"CONDITION"]]}],["malignancy preventable combination screening adult women vaccination children adolescents HPV infection.",{"entities":[[90,103,"CONDITION"]]}],["However, 5% Kenyan women regularly screened, 14% screened, Kenya method Visual Inspection Acetic Acid (VIA).",{"entities":[[90,101,"DRUG"],[103,106,"DRUG"]]}],["Obstacles screening include travel clinics, costs, poor specificity VIA, lack trained personnel, others.",{"entities":[[68,71,"DRUG"]]}],null,null,["addition, studies HPV vaccination African children, two-dose regimens provide adequate protective antibody levels children chronically exposed aflatoxin, potent immunosuppressive agent contaminated corn.",{"entities":[[143,152,"BIOLOGICAL"]]}],["Investigators propose study strategy designed 1) increase cervical cancer screening community-based approach, 2) determine efficacy HPV vaccination region Kenya children chronically exposed aflatoxin.",{"entities":[[58,73,"CONDITION"]]}],["Objective 1 (Cervical cancer screening): Evaluate High-Risk (HR)-HPV DNA testing self-collected vaginal swabs triage step rural Kenyan women.",{"entities":[[13,28,"CONDITION"]]}],["Hypothesis: women negative HR-HPV DNA tests normal examinations falsely-abnormal examinations based cervical biopsy results.",{"entities":[[100,108,"BODY_PART"],[109,115,"BIOLOGICAL"]]}],null,["Objective 2 (HPV vaccination): Determine effects chronic aflatoxin exposure Kenyan children/adolescents likelihood seroconversion HPV types represented HPV vaccine.",{"entities":[[57,66,"BIOLOGICAL"]]}],["Hypothesis: Compared children/adolescents detectable plasma aflatoxin, children/adolescents evidence chronic aflatoxin exposure reduced likelihood seroconversion HPV types represented HPV vaccine.",{"entities":[[21,41,"POPULATION"],[60,69,"BIOLOGICAL"],[109,118,"BIOLOGICAL"]]}],["rationale hypothesis correctly proven, adjustments vaccination doses/schedules children chronic exposure aflatoxin assure adequate protection HPV infection.",{"entities":[[79,87,"POPULATION"]]}],null,null,null,null,null,["critical develop surveillance systems assess safety drugs pregnancy.",{"entities":[[58,67,"CONDITION"]]}],["Malaria pregnancy requires prompt effective treatment prevent adverse health consequences mother unborn baby.",{"entities":[[0,7,"CONDITION"],[8,17,"CONDITION"]]}],["Malaria infection trimester miscarriage, preterm birth birth weight.",{"entities":[[0,7,"CONDITION"],[28,39,"CONDITION"]]}],["Pregnant women trimester inadvertently treated antimalarials adult population concern drugs contraindicated pregnancy, artemisinin combination therapies (ACTs).",{"entities":[[119,130,"DRUG"]]}],["occurs aware report pregnant, quinine, standard care malaria treatment trimester available.",{"entities":[[20,28,"CONDITION"],[30,37,"DRUG"],[53,60,"CONDITION"]]}],["limited data safety ACTs pregnancy.",{"entities":[[25,34,"CONDITION"]]}],["Investigators develop pregnancy registry monitoring safety antimalarial drugs pregnancy focus trimester.",{"entities":[[78,87,"CONDITION"]]}],["Aim: aim pregnancy registry generate robust data safety range antimalarials pregnancy trimester inform regulators policymakers.",{"entities":[[62,75,"DRUG"],[76,85,"CONDITION"]]}],["Methods Brief: Investigators set-up pregnancy exposure registry antimalarial drugs capture safety data women inadvertently exposed (i.e.",{"entities":[[36,45,"CONDITION"],[64,76,"DRUG"]]}],null,["capture safety data, sentinel sites set-up multiple malaria-endemic countries follow women moment pregnancy identified capture pregnancy outcomes (i.e.",{"entities":[[127,136,"CONDITION"]]}],["miscarriage, stillbirth, live birth).",{"entities":[[0,11,"CONDITION"],[13,23,"CONDITION"]]}],["sites (including Kenya) provide pregnancy tests enable pregnancy detection referral ANC capture miscarriages.",{"entities":[[32,41,"CONDITION"],[55,64,"CONDITION"],[96,108,"CONDITION"]]}],null,null,null,null,["Exposure data collected acute illnesses occurring pregnancy, malaria COVID-19, chronic conditions, HIV, TB, epilepsy diabetes, details treatment (including antimalarials).",{"entities":[[50,59,"CONDITION"],[61,68,"CONDITION"],[69,77,"CONDITION"],[99,102,"CONDITION"],[104,106,"CONDITION"],[108,116,"CONDITION"],[117,125,"CONDITION"]]}],null,null,["pregnancy outcomes prevalence congenital anomalies compared pregnancies exposed exposed specific antimalarials trimester.",{"entities":[[97,110,"DRUG"]]}],["Expected Outcomes: expected outcome study reassurance safety profile specific antimalarials, focus trimester, inform malaria treatment guidelines.",{"entities":[[78,91,"DRUG"],[117,124,"CONDITION"]]}],null,["Data generated pooled data pregnancy registries malaria-endemic countries shared WHO/TDR Central registry epidemiological surveillance drug safety pregnancy relevant pregnancy exposure registries.",{"entities":[[166,175,"CONDITION"]]}],null,null,null,null,null,null,null,["recommendation, Jhpiego Impact Malaria project Kenya, funding technical oversight Center Disease Prevention Control (CDC) supporting Kenya MOH NMP conduct TES assess efficacy current treatment policy Kenya.",{"entities":[[16,23,"ORG"],[82,115,"ORG"],[117,120,"ORG"],[139,142,"ORG"]]}],["study conducted Kenya MOH NMP, technical oversight funding CDC Jhpiego Impact Malaria project Kenya.",{"entities":[[16,21,"COUNTRY"],[22,25,"ORG"],[26,29,"ORG"],[59,62,"ORG"],[63,70,"ORG"]]}],["Objective: assess efficacy Artemether Lumefantrine (AL) Dihydroartemisinin-Piperaquine (DHP) treatment uncomplicated P.",{"entities":[[27,50,"DRUG"],[52,54,"DRUG"],[56,86,"DRUG"],[88,91,"DRUG"]]}],["falciparum malaria infections.",{"entities":[[0,18,"CONDITION"]]}],null,null,null,null,null,null,null,["Primary endpoints: proportion patients treatment failure, late clinical failure, late parasitological failure adequate clinical parasitological response indicators efficacy.",{"entities":[[86,101,"BIOLOGICAL"]]}],["Recrudescence distinguished re-infection polymerase chain reaction (PCR) analysis.",{"entities":[[41,66,"BIOLOGICAL"],[68,71,"BIOLOGICAL"]]}],null,null,null,null,["address knowledge gap, western Kenya selected estimate impact transfluthrin-based spatial repellent malaria-related outcomes Busia County, baseline malaria transmission ranges 2.5 4.1 infections person year.",{"entities":[[23,36,"LOCATION"]]}],null,null,null,null,["Children selected inclusion baseline cohort eligible selection cohort 1 2 both.",{"entities":[[0,8,"POPULATION"]]}],null,null,null,["incidence malaria cohort intervention estimated compared determine benefit high, year-round transmission malaria.",{"entities":[[10,17,"CONDITION"],[105,112,"CONDITION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Background: Based 2013 Kenya AIDS Indicator Survey, 58% people living HIV/AIDS (PLWHA) aged 15-64 Kenya eligible Antiretroviral Therapy (ART), 63% initiated.",{"entities":[[80,85,"POPULATION"],[113,135,"DRUG"],[137,140,"DRUG"]]}],null,null,["study Kenyan national ART program suggests 27% patients second-line failure switch third-line therapy, 25% demonstrating complete exhaustion alternative second-line regimens.",{"entities":[[22,25,"DRUG"]]}],null,null,["Fortunately, virological (VL) failure second-line ART warrant switch third-line regimen, Protease Inhibitors (PIs) genetic barrier resistance mutations, PI naïve patients.",{"entities":[[89,108,"BIOLOGICAL"],[110,113,"BIOLOGICAL"],[153,155,"BIOLOGICAL"]]}],["failure second-line ART suboptimal adherence drug resistance, management VL failure second-line typically involves intensified adherence counselling drug substitutions recommended documented resistance mutations, severe adverse drug reactions (ADR) drug interactions.",{"entities":[[220,242,"CONDITION"],[244,247,"CONDITION"]]}],null,null,null,["ART changed dynamic HIV epidemic suppression HIV-1 RNA undetectable plasma levels.",{"entities":[[45,54,"BIOLOGICAL"]]}],null,["antiretroviral therapy suppress HIV-1 infection undetectable levels plasma viremia, HIV DNA integrate persist resting CD4+ cells.",{"entities":[[68,74,"BIOLOGICAL"],[88,91,"BIOLOGICAL"],[118,122,"BIOLOGICAL"]]}],["Latent HIV infection CD4+ cells, established stages infection, necessitates lifelong ART, treatment failure lead selection drug resistance mutations viral genome, archived cellular reservoir.",{"entities":[[21,31,"BIOLOGICAL"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Mombasa County be; 107 HIV infected individuals 2.",{"entities":[[0,14,"LOCATION"]]}],["Meru County be; 43 HIV infected individuals 3.",{"entities":[[0,4,"LOCATION"]]}],["Kilifi County be; 52 HIV infected individuals Therefore, minimum sample size 202 HIV infected individuals required study.",{"entities":[[0,13,"LOCATION"]]}],null,["Ethical consideration: commencement study, approval sought Centre Microbiology -KEMRI, Centre Scientific Committee (CSC) KEMRI Scientific Ethical Review Unit (SERU).",{"entities":[[79,85,"ORG"],[87,114,"ORG"],[121,126,"ORG"]]}],["approval KEMRI, investigator pursue approval study respective county Director medical services study carried out.",{"entities":[[9,14,"ORG"],[16,28,"OCCUPATION"]]}],null,null,null,null,null,null,null,null,["Data collection laboratory methods: Participant sociodemographic data, ART regimen, CD4+ cell count, opportunistic infections, Health Organization (WHO) staging, physician-reported adherence retrospectively collected patient folders.",{"entities":[[84,88,"BIOLOGICAL"]]}],["participants undergo plasma HIV-1 RNA CD4 quantification enrollment 6 months follow up.",{"entities":[[28,37,"BIOLOGICAL"],[38,41,"BIOLOGICAL"]]}],["Baseline viral load CD4+ cell counts closest ART regimen start.",{"entities":[[20,29,"BIOLOGICAL"]]}],["HIV-1 RNA levels study, respective physician.",{"entities":[[0,9,"BIOLOGICAL"]]}],["investigator evaluate paired HIV-1 viral load (VL) CD4 count performed analyze durability viral suppression risk rebound patients virologic suppression.",{"entities":[[51,54,"BIOLOGICAL"]]}],null,null,null,null,null,null,null,null,null,null,null,["review reported risk iron-deficiency anaemia infants supplemented.",{"entities":[[21,44,"CONDITION"],[45,52,"POPULATION"]]}],["However, iron supplements iron-containing micronutrient powders (MNPs) efficacy; example, intervention trial Pakistan, 12 months iron supplementation haemoglobin status.",{"entities":[[9,25,"DRUG"],[109,117,"COUNTRY"],[150,161,"BIOLOGICAL"]]}],["potential factors contributing limited success health nutrition policies reducing prevalence iron deficiency, increased iron losses iron supplementation considered.",{"entities":[[93,108,"CONDITION"]]}],["study Gambian toddlers, 3.4-fold increase iron losses detected, 0.22 (0.19;0.29) mg/d 0.75 (0.55;0.87) mg/d, 12-week iron intervention daily consumption 12 iron ferrous fumarate MNPs routinely distributed United Nations Children's Fund Food Program.",{"entities":[[156,177,"BIOLOGICAL"]]}],null,["iron supplementation pilot study Kenyan toddlers, investigators measured increase faecal haemoglobin concentration iron supplementation.",{"entities":[[0,4,"BIOLOGICAL"],[40,48,"POPULATION"],[82,100,"BIOLOGICAL"],[115,119,"BIOLOGICAL"]]}],null,null,null,["Intervention product 6 iron / body weight ferric ammonium citrate ferrous fumarate syrup (Ranbaxy Ranferon-12 Syrup, Ranbaxy Laboratories, Gurgaon, India) administered daily.",{"entities":[[42,88,"DRUG"]]}],null,["study population consist 24 anaemic 2-years children Kwale County southern coastal Kenya.",{"entities":[[53,65,"LOCATION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Background: Schistosomiasis classified world's neglected tropical diseases (NTD).",{"entities":[[12,27,"CONDITION"],[47,74,"CONDITION"]]}],["Morbidity Schistosoma mansoni (S.mansoni) school-age children typically burden infection.",{"entities":[[10,29,"CONDITION"],[31,40,"CONDITION"]]}],null,null,null,null,null,null,null,["Based above, designed nutritional food supplement, Ujiplus®, potential homegrown mass drug administration tool intestinal parasites including S.mansoni.",{"entities":[[142,151,"CONDITION"]]}],null,null,null,null,["previous clinical trial, Ujiplus® reduced Ascaris lumbricoides egg count 63.9% month period compared albendazole arm, 78.8%.",{"entities":[[25,33,"INTERVENTION"],[42,62,"BIOLOGICAL"],[101,112,"DRUG"]]}],["study, primary school children (ages 6-8) schools Homabay County Kenya randomized arms: Children schools receive 300 Ujiplus® porridge daily (test school), schools receive serving plain porridge (cornflour micronutrients only) Praziquantel.",{"entities":[[50,64,"LOCATION"],[117,125,"INTERVENTION"],[227,239,"DRUG"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Population: Professionals craft prosthesis amputees (CPOs) Below-knee amputees desire prosthesis reside Kenya.",{"entities":[[12,51,"POPULATION"],[59,78,"POPULATION"],[86,96,"INTERVENTION"]]}],["Outcome Measures: CPO comfort level, perceived competence, acceptance Confidence Socket Technology.",{"entities":[[18,21,"INTERVENTION"]]}],null,["Starting introduction technology final interview CPO completed.",{"entities":[[49,52,"INTERVENTION"]]}],null,["Background: Africa, COVID-19 potential cripple continent's fragile healthcare systems devastating economically.",{"entities":[[20,28,"CONDITION"]]}],["unknown malaria infection worsens COVID-19, acquisition protective antibodies SARS-CoV-2 virus, contributes onwards spread viral loads and/or duration viral shedding.",{"entities":[[34,42,"CONDITION"],[78,88,"CONDITION"]]}],null,["study determine antimalarial pyronaridine, fixed-dose combination pyronaridine-artesunate, positive, negative negligible COVID-19 disease progression duration viral carriage seroconversion rate SARS-CoV-2.",{"entities":[[16,28,"DRUG"],[29,41,"DRUG"],[66,89,"DRUG"],[194,204,"CONDITION"]]}],["Methods: malaria treatment trial conducted nested larger observational COVID-19 cohort study highly malaria-endemic western Kenya Burkina-Faso.",{"entities":[[124,129,"COUNTRY"],[130,142,"COUNTRY"]]}],["COVID-19 cohort study consists 708 newly diagnosed COVID-19 patient ages.",{"entities":[[51,59,"CONDITION"]]}],["enrolled source population 4,720 individuals ages screened SARS-CoV-2.",{"entities":[[59,69,"CONDITION"]]}],null,["co-infected participants enrolled nested malaria treatment trial uncomplicated malaria oral medication.",{"entities":[[41,48,"CONDITION"]]}],["randomized receive standard 3-day treatment artemether-lumefantrine (the current first-line treatment) pyronaridine-artesunate, highly effective antimalarial combination rolled second-line treatment western Kenya Burkina Faso.",{"entities":[[103,126,"DRUG"],[207,212,"COUNTRY"],[213,225,"COUNTRY"]]}],null,null,["primary endpoint rate SARS-CoV-2 clearance day-7.",{"entities":[[22,32,"CONDITION"]]}],["limit transmission SARS-CoV-2, strict adherence infection prevention control (IPC) guidelines, including personal protection equipment (PPE), measures patient transport national guidelines country.",{"entities":[[19,29,"CONDITION"],[105,134,"INTERVENTION"],[136,139,"INTERVENTION"]]}],null,["Partners: 18-months study funded Melinda Gates Foundation collaboration Kenyan Medical Institute (KEMRI) Kenya; Centers Disease Control Prevention (CDC); Liverpool School Tropical Medicine (LSTM); Ministry Health, Kenya; Groupe Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso; Ministry Health Burkina Faso, London School Hygiene Tropical Medicine (LSHTM).",{"entities":[[33,57,"ORG"],[72,96,"ORG"],[98,103,"ORG"],[112,135,"ORG"],[148,151,"ORG"],[154,188,"ORG"],[197,212,"ORG"],[221,253,"ORG"],[262,273,"LOCATION"],[275,287,"COUNTRY"],[319,358,"ORG"],[360,365,"ORG"]]}],["LSTM LSHTM sponsors studies Kenya Burkina Faso, respectively.",{"entities":[[0,4,"ORG"],[5,10,"ORG"],[28,33,"COUNTRY"],[34,46,"COUNTRY"]]}],null,null,null,null,null,null,null,null,null,["Typhoid fever enteric bacterial infection caused Salmonella enterica serovar Typhi (Salmonella Typhi; S.",{"entities":[[0,7,"CONDITION"],[49,82,"BIOLOGICAL"],[84,100,"BIOLOGICAL"]]}],null,null,null,["Typhoid fever common inadequate sanitation hygiene.",{"entities":[[0,13,"CONDITION"]]}],["routine practice, diagnosis typhoid fever rarely confirmed diagnostic tests unavailable limited diagnostic accuracy.",{"entities":[[28,41,"CONDITION"]]}],null,null,null,["Clinician rapid diagnostic tests diagnose typhoid.",{"entities":[[42,49,"CONDITION"]]}],["typhoid fever RDTs commercially performance data consistent study another.",{"entities":[[0,13,"CONDITION"]]}],["prospective, multicentre, cross-sectional study carried 3 hospitals Nairobi, Kenya.",{"entities":[[68,75,"LOCATION"],[77,82,"COUNTRY"]]}],null,null,["collaborative study Kenya Medical Institute (KEMRI) Foundation Innovative Diagnostics (FIND) systematically compare care typhoid tests market set reference standard.",{"entities":[[20,43,"ORG"],[45,50,"ORG"],[52,85,"ORG"],[87,91,"ORG"]]}],null,["result trial inform Ministry Health Kenya Health Organization (WHO) Essential Diagnostic list (EDL) stakeholder decision broadly.",{"entities":[[20,41,"ORG"],[42,61,"ORG"],[63,66,"ORG"]]}],null,null,null,["1B study designed offer participants age Emergency Authorization (EUA) eligible unblinded participants received placebo 1A request 2 doses open-label mRNA-1273 vaccine.",{"entities":[[41,64,"ORG"]]}],null,["1C-2 designed provide heterologous mRNA-1273 eligible participants completed primary COVID-19 vaccination series non-Moderna vaccine EUA 3 months dose.",{"entities":[[35,44,"BIOLOGICAL"]]}],null,["Participants receive 2 doses receive booster dose mRNA-1273 SARS-CoV-2 vaccine.",{"entities":[[50,59,"BIOLOGICAL"],[60,70,"CONDITION"],[71,78,"INTERVENTION"]]}],null,["Participants receive 2 doses mRNA-1273.222 vaccine.",{"entities":[[29,50,"INTERVENTION"]]}],null,null,null,null,null,null,["PATH GlaxoSmithKline (GSK) committed developing malaria vaccine reduce burden malaria disease children contribute malaria elimination.",{"entities":[[5,20,"ORG"],[22,25,"ORG"]]}],["GSK developed candidate vaccine malaria caused P.",{"entities":[[0,3,"ORG"]]}],null,null,null,["falciparum infection neutralization circumsporozoite (CS) antigen parasites invading mosquito bite individuals immunized RTS,S/AS01E vaccine.",{"entities":[[0,10,"BIOLOGICAL"],[36,52,"BIOLOGICAL"]]}],null,["However, previous trials, vaccine effective adults malaria before.",{"entities":[[44,50,"POPULATION"],[51,58,"CONDITION"]]}],null,null,null,null,["falciparum measured highly sensitive polymerase chain reaction (PCR) assay treated antimalarial medications prior immunization RTS,S/AS01E comparator rabies vaccine, respectively, primary objective evaluating vaccine efficacy RTS,S/AS01E relative rabies vaccine context.",{"entities":[[150,156,"CONDITION"]]}],null,["falciparum measured highly sensitive PCR assay treated antimalarial medications prior immunization RTS,S/AS01E comparator rabies vaccine, respectively, secondary objective evaluating vaccine efficacy RTS,S/AS01 relative rabies vaccine context.",{"entities":[[220,226,"CONDITION"]]}],null,["falciparum measured highly sensitive PCR assay treated antimalarial medications prior immunization RTS,S/AS01E vaccine; immunological profile 1 2 evaluated secondary exploratory objectives.",{"entities":[[0,10,"BIOLOGICAL"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Two-way mobile health (mHealth) communication strategies enable mothers remotely interact healthcare worker (HCW) receive real-time education, counseling, encouragement, motivation decisional guidance support care-seeking decisions ultimately neonatal health survival.",{"entities":[[90,107,"OCCUPATION"],[109,112,"OCCUPATION"]]}],null,null,null,null,null,null,null,null,null,["purpose study examine safety immunogenicity doses parenteral synthetic carbohydrate-based conjugate vaccine Shigella flexneri 2a (Shigella flexneri 2a-Tetanus Toxoid15 (SF2a-TT15)) adjuvanted Alhydrogel infants endemic country (Kenya), target population vaccine, age-descending approach.",{"entities":[[108,125,"CONDITION"],[130,147,"CONDITION"],[148,167,"DRUG"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Driven differences PMTCT retention, viral suppression, modeled estimates pediatric HIV infections averted, investigators hypothesize HITSystem 2.1 cost-effective, based Health Organization criteria.",{"entities":[[19,24,"POPULATION"]]}],["proposal aimed improving quality PMTCT services health facility setting.",{"entities":[[33,38,"POPULATION"]]}],null,null,null,null,null,null,null,null,null,["Phase 1 clinical trial HIV-CORE (COnserved REgions) 006 trial combined vaccine regimen determine safety immunogenicity healthy adults Kenya, Uganda Zambia.",{"entities":[[134,139,"COUNTRY"],[141,147,"COUNTRY"],[148,154,"COUNTRY"]]}],null,null,null,["aim induce effective cytotoxic lymphocytes (CTL) HIV-1.",{"entities":[[21,42,"BIOLOGICAL"],[44,47,"BIOLOGICAL"]]}],null,null,null,["central principle strategy focus T-cell immune responses conserved regions HIV-1 proteome.",{"entities":[[33,39,"BIOLOGICAL"]]}],null,null,null,null,null,["Adenoviruses, grow, respiratory gastrointestinal ailments, unmodified chimpanzee adenovirus disease humans; engineered vaccine vector called ChAdOx1 crippled grow.",{"entities":[[0,12,"BIOLOGICAL"],[32,57,"CONDITION"],[81,91,"BIOLOGICAL"]]}],null,null,null,["Humans microbiota, consist bacteria, fungi, viruses eukaryotic species, co-evolved millions coexistence beneficial parties.",{"entities":[[52,62,"BIOLOGICAL"]]}],null,null,["reports influence gut microbiota diversity composition responses vaccination emerging time.",{"entities":[[22,32,"BIOLOGICAL"]]}],null,null,null,["parallel HIV-CORE 006, vaccines tested safety United Kingdom, phase trial HIV-CORE 0052.",{"entities":[[46,60,"COUNTRY"]]}],null,null,null,null,null,null,["Gay, bisexual, sex (GBMSM) risk HIV-1 acquisition, rights-constrained settings Kenya, men's access HIV prevention impeded homophobia, stigma, discrimination.",{"entities":[[20,25,"POPULATION"],[79,84,"COUNTRY"]]}],null,null,null,null,null,["Severe malnutrition intestinal inflammation fecal microbiome ('dysbiosis').",{"entities":[[62,72,"CONDITION"]]}],["intestine, dysbiosis (upper) intestine, increased bacterial density altered microbial composition contribute intestinal inflammation intestinal dysfunction ultimately contribute development sepsis death.",{"entities":[[11,20,"CONDITION"],[29,38,"BODY_PART"]]}],["bacterial density composition intestine altered antibiotics.",{"entities":[]}],null,null,null,["investigators hypothesize supplementing enzymes exogenously severely malnourished children improve clinical outcome reducing dysbiosis, intestinal inflammation sepsis.",{"entities":[[69,81,"CONDITION"],[125,134,"CONDITION"],[136,146,"BODY_PART"],[147,159,"CONDITION"],[160,166,"CONDITION"]]}],null,["investigators conduct double blind, randomized clinical trial 2x2 factorial design hospitalized severely malnourished children.",{"entities":[[105,117,"CONDITION"],[118,126,"POPULATION"]]}],["Participants treated pediatric formulations pancreatic enzymes, bile acids, placebo 21 days.",{"entities":[[21,30,"POPULATION"],[64,74,"BIOLOGICAL"]]}],null,null,null,null,null,null,["Kenya Bangladesh, daily blood gases, lactate biochemistry 5 days assess clinical progress.",{"entities":[[0,5,"COUNTRY"],[6,16,"COUNTRY"]]}],["Malawi Uganda, hydrogen breath testing evaluate impact upper intestinal bacterial overgrowth.",{"entities":[[0,6,"COUNTRY"],[7,13,"COUNTRY"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["hypertension diabetes) suggested link COVID19 urgent initiate robust studies clarify issues reports engendered.",{"entities":[[0,12,"CONDITION"],[13,21,"CONDITION"],[38,45,"CONDITION"]]}],["investigators conduct global study understanding cardiovascular conditions increase risk developing severe COVID-19, characterization cardiovascular complications hospitalized patients COVID-19.",{"entities":[[107,115,"CONDITION"],[185,193,"CONDITION"]]}],["continued increase COVID-19 worldwide, study team launched WHF COVID-19 CVD Extension Study continue recruitment COVID-19 patients hospitalized selected high-income, middle-income, low-income countries (sample size = 3300 patients).",{"entities":[[19,27,"CONDITION"],[63,71,"CONDITION"]]}],["extension study provide valuable insights temporal trends clinical characteristics COVID-19, specific deaths sudden cardiac death relationship COVID-19 infection, impact COVID-19 vaccination clinical outcomes discharge mortality, anti-microbial resistance association outcomes COVID-19 patients.",{"entities":[[83,91,"CONDITION"],[143,151,"CONDITION"],[170,178,"CONDITION"],[277,285,"CONDITION"]]}],["Further, study team conducting WHF COVID-19 Long-term follow-up Study sample 2000 patients WHF COVID-19 extension study aims determine short- (3 month), medium- (6 month) long-term (9-12 month) sequelae COVID-19 including ongoing symptomatology, re-hospitalizations, mortality, impact physical function psycho-social consequences.",{"entities":[[35,43,"CONDITION"],[95,103,"CONDITION"],[203,211,"CONDITION"]]}],null,["study provide invaluable intermediate long-term effects COVID-19 disease burden economic impact COVID-19 patients term sequelae.",{"entities":[[56,64,"CONDITION"],[96,104,"CONDITION"]]}],null,["WHF COVID-19 CVD Study (primary cohort): 5200 participants 2.",{"entities":[[4,12,"CONDITION"]]}],null,null,null,null,["phase 2b, randomized, double-blind, placebo-controlled, multicenter study subjects sickle cell disease (SCD; homozygous sickle hemoglobin \\\\[HbSS\\\\], sickle-β0 \\\\[HbSβ0\\\\] thalassemia, sickle-β+ \\\\[HbSβ+\\\\] thalassemia) evaluate safety efficacy phosphodiesterase type 9 (PDE9) inhibitor, IMR-687, administered daily (qd) 52 weeks.",{"entities":[[83,102,"CONDITION"],[104,107,"CONDITION"],[172,183,"CONDITION"],[185,194,"CONDITION"],[198,205,"CONDITION"],[207,218,"CONDITION"],[245,262,"BIOLOGICAL"]]}],null,null,null,null,["Intervention arm phones app Tumaini programmed them, control arm phones commercially game determined prior start randomized clinical trial.",{"entities":[[28,35,"INTERVENTION"]]}],null,null,null,null,null,null,null,null,null,null,["purpose implementation study generate evidence informs successful uptake adoption Ellavi UBT Kenyan MOH PPH management programs public private sector programs.",{"entities":[[82,88,"INTERVENTION"]]}],["investigators aim generate evidence Kenyan stakeholders decision-making Ellavi UBT Kenyan PPH management programs.",{"entities":[[72,78,"INTERVENTION"]]}],null,["determine adoption, penetration, sustainability fidelity implementing Ellavi UBT device PPH care health care facilities (2 public facilities, 1 private facility).",{"entities":[[70,80,"INTERVENTION"]]}],["investigators explore health workers facilities receive PPH Ellavi UBT training, percent health workers facilities adopt Ellavi UBT device 6-month period.",{"entities":[[56,59,"CONDITION"],[60,70,"INTERVENTION"],[121,131,"INTERVENTION"]]}],["investigators assess factors influence adoption, penetration, sustainability, fidelity operations survey, Ellavi UBT questionnaire.",{"entities":[[106,116,"INTERVENTION"]]}],null,["determine appropriateness, acceptability feasibility Ellavi UBT participating health facilities levels care Nairobi County, investigators explore user comprehension Ellavi UBT usage steps, accuracy use, perceptions device, attitudes device, user confidence, usability, facilitators use, barriers use, use-patterns, insights training effectiveness.",{"entities":[[108,122,"LOCATION"],[165,175,"INTERVENTION"]]}],null,null,null,["Conduct half-day trainings PPH Ellavi UBT participating health facilities separated by: 1) obstetricians, medical clinical officers, 2) midwives.",{"entities":[[31,41,"INTERVENTION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["disseminate national (KOGS), regional (ECSACOG, AFOG), international forums support sharing, increased awareness role UBT refractory PPH, adoption use.",{"entities":[[22,26,"ORG"],[39,46,"ORG"],[48,52,"ORG"]]}],null,null,null,null,["Host national level meeting Kenyan MOH stakeholders participating facilities g.",{"entities":[[35,38,"ORG"]]}],null,null,["Ellavi UBT poster presentations demonstration sessions international obstetrics meetings: FIGO, UBT group, Women Deliver funding permits.",{"entities":[[90,94,"ORG"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,["STUDY POPULATION: study conducted Kenya, country malaria burden.",{"entities":[[34,39,"COUNTRY"],[49,56,"CONDITION"]]}],null,null,null,["specific study western Kenya (Bungoma County Trans Nzoia county).",{"entities":[[15,28,"LOCATION"],[30,37,"LOCATION"],[45,63,"LOCATION"]]}],null,null,null,["receive initial start-up stock RDTs contact RDT wholesalers provide replenishment stocks demand.",{"entities":[[31,35,"INTERVENTION"],[44,47,"INTERVENTION"]]}],["addition, attendants trained mobile reporting app captures basic suspected malaria cases.",{"entities":[]}],["app assess outcomes, monitoring tool serve conduit payments arm assignment.",{"entities":[]}],["training, shops randomized arms: * Arm 1 (control): RDTs study-recommended price, providers trained mobile app * Arm 2 (client-directed intervention): subsidy client conditional positive RDT, RDTs study-recommended price * Arm 3 (client-directed provider-directed intervention): providers reimbursed RDT consumers positive eligible subsidy quality-assured ACT.",{"entities":[[52,56,"INTERVENTION"],[187,190,"INTERVENTION"],[192,196,"INTERVENTION"],[300,303,"INTERVENTION"]]}],["RDTs study recommended price.",{"entities":[[0,4,"INTERVENTION"]]}],["Customers participating outlet arm fever suspected malaria eligible RDT study-recommended price and, arms 2 3, conditional subsidy RDT positive.",{"entities":[[68,71,"INTERVENTION"],[131,134,"INTERVENTION"]]}],null,["Customers purchasing medicine someone's behalf malaria eligible RDT testing conditional subsidies.",{"entities":[[64,67,"INTERVENTION"]]}],null,null,null,null,null,["Exit interviews capture customer demographics, symptoms current illness, malaria diagnostic outlet elsewhere, paid test, test, drug(s) purchased.",{"entities":[[73,80,"CONDITION"]]}],null,null,null,["particular, pictures RDTs reviewed reported outlet attendants ensure correct interpretation RDTs.",{"entities":[[21,25,"INTERVENTION"],[92,96,"INTERVENTION"]]}],null,["monitoring step identify major discrepancies actions reported shop reported customers testing rates, RDT positivity rates, dispensing qualified ACTs prices charged RDTs ACTs.",{"entities":[[101,104,"INTERVENTION"],[164,168,"INTERVENTION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["prospective study acute immune responses SARSCoV-2 infection.",{"entities":[[41,60,"CONDITION"]]}],null,null,null,["Additional follow visit(s) time response evolving SARS-CoV-2 infection COVID-19.",{"entities":[[50,70,"CONDITION"],[71,79,"CONDITION"]]}],null,null,null,["Cancer Quality Life Questionnaire-CIPN twenty-item scale) * FACT-GOG NTX v.4© (Functional Assessment Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity) * TNSn© (total neuropathy score, nurse version) * PGIC (patient global impression change) * OXA-NQ (oxaliplatin neurotoxicity questionnaire) Extended study (at sites - combination assessment methods allowed, minimum baseline treatment) * EORTC CIPN15 * CIPN-R-ODS (CIPN Rash disability scale) * TNSc© time questionnaire * OXA-NQ (also mid-treatment) * nerve conduction study radial (motor sensory), ulnar (motor sensory), sural, dorsal sural common peroneal nerves (\\\\*) * QST (\\\\*) \\\\[quantitative sensory testing\\\\] * Serum biomarkers search (\\\\*) * DN4 Rationale: multi-center international collaboration experienced neurologists, oncologists, nurses symptom scientists, principal aim study evaluate responsiveness set outcome measures CIPN evaluation define gold standard assessment.",{"entities":[[557,562,"BODY_PART"],[580,585,"BODY_PART"],[600,622,"BODY_PART"],[778,790,"OCCUPATION"],[792,803,"OCCUPATION"],[805,811,"OCCUPATION"],[820,830,"OCCUPATION"]]}],null,null,["Extended study add combination listed assessment methods/biological sample collection, ascertain approach provide careful clinically-relevant estimate peripheral nervous damage.",{"entities":[[151,169,"BODY_PART"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Pre-Exposure Prophylaxis (PrEP) HIV prevention method recommended.",{"entities":[[0,24,"DRUG"],[26,30,"DRUG"],[32,35,"CONDITION"]]}],null,null,null,["Kenya, resource-limited countries, retail pharmacies (i.e., chemists) gap health care providing access treatment, monitoring preventive care urgent prolonged conditions.",{"entities":[[0,5,"COUNTRY"]]}],null,null,["core components PrEP - including HIV testing, adherence risk reduction counselling, assessment effects provision refills - scope practice pharmaceutical technologists pharmacists Kenya.",{"entities":[[16,20,"DRUG"]]}],null,null,["Study 1a (13 months), pilot care pathway 2 retail pharmacies split 2 geographies Kenya: Kisumu Thika.",{"entities":[[88,94,"LOCATION"],[95,100,"LOCATION"]]}],null,null,null,null,["global response HIV reached close 20 persons life-saving antiretroviral therapy (ART) saved 60 life-years, progress uneven adolescents adults (AYA) aged 14-24 represent key left behind.",{"entities":[[57,79,"DRUG"],[81,84,"DRUG"],[123,141,"POPULATION"],[143,146,"POPULATION"]]}],["Compared adults, AYA HIV numerous, diverse intense barriers adherence retention.",{"entities":[[17,20,"POPULATION"]]}],["investigators utilize SMART study design stages 880 AYA HIV Kenya improve retention viral suppression current MOH guidelines.",{"entities":[[52,55,"POPULATION"]]}],null,null,null,["primary outcomes include (1) prevention: lapse engagement viral non-suppression current MOH guidelines; (2) re-engagement: viral suppression months re-randomization; (3) strategies: sustained viral suppression sustained engagement care years.",{"entities":[[88,91,"ORG"]]}],["investigators anticipate enrolling 880 AYA result 99% power detect 15% difference primary outcome intervention groups.",{"entities":[[39,42,"POPULATION"]]}],["investigators study yield evidence specific AYA HIV, quantify relative magnitude sequenced interventions, capture costs, direct relevance public health programming AIDS epidemic engaging adolescents adults HIV.",{"entities":[[44,47,"POPULATION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,["include establishing Data Coordinating Center based Indiana University (IU) serve hub collecting, disseminating archiving data study Kenya data collected similar, ongoing study health facilities South Africa affiliated IeDEA.",{"entities":[[52,70,"ORG"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,["ImmStat@Cure undertaken 4 treatment centres leishmaniasis East Africa; Institute Endemic Diseases, University Khartoum, Khartoum, Sudan, University Gondar, Gondar, Ethiopia, Amudat Hospital, Amudat, Uganda Kimalel Chemolingot Health Centres, Baringo County, Kenya.",{"entities":[[99,118,"ORG"],[120,128,"LOCATION"],[130,135,"COUNTRY"],[137,154,"ORG"],[156,162,"LOCATION"],[164,172,"COUNTRY"],[174,189,"ORG"],[191,197,"LOCATION"],[199,205,"COUNTRY"],[206,240,"ORG"],[242,256,"LOCATION"],[258,263,"COUNTRY"]]}],["primary objective study assess systemic skin immune responses parasite load patients before, treatment visceral leishmaniasis.",{"entities":[[103,125,"CONDITION"]]}],null,null,null,null,null,null,null,null,null,["patients clinically parasitologically confirmed visceral leishmaniasis (VL) receive sodium stibgluconate/paramomycin (SSG/PM) treatment normal clinical practice regional guidelines.",{"entities":[[48,70,"CONDITION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Diarrhoea accounts 7% under-five deaths Kenya.",{"entities":[[0,9,"CONDITION"]]}],null,["study assesses prompting supply zinc low-osmolarity oral rehydration salts (LO-ORS) co-packs private sector coupled increasing demand co-packs caregivers on: 1) treatment uncomplicated childhood diarrhoea, 2) care-seeking private sector, 3) availability co-packs private sector.",{"entities":[[52,74,"INTERVENTION"]]}],["target population children age caregivers Vihiga County.",{"entities":[[42,55,"LOCATION"]]}],null,["existing sub-counties Vihiga selected convenience assigned study arms.",{"entities":[[22,28,"LOCATION"]]}],null,null,null,null,null,null,null,null,null,["Scabies skin infestation caused mite called Sarcoptes scabiei.",{"entities":[[0,7,"CONDITION"],[8,12,"BODY_PART"],[44,61,"BIOLOGICAL"]]}],["Scabies characterised rash severe itching, allergic reaction eggs feces females deposit tunnel skin.",{"entities":[[0,7,"CONDITION"]]}],["Oral ivermectin safe beneficial drug highly effective treatment scabies dozen neglected tropical diseases (NTDs), public health problems.",{"entities":[[5,15,"DRUG"],[78,105,"CONDITION"],[107,111,"CONDITION"]]}],["Current label indications ivermectin prevent children weighing 15 kg, limited safety data group.",{"entities":[]}],["NTD treatment options children rely compounds safe and/or efficacious compared oral ivermectin.",{"entities":[[0,3,"CONDITION"]]}],["proposal establish safety pharmacokinetics escalating doses ivermectin (200, 400, 800 µg/kg) treat scabies infected children weighing 5 15 kg.",{"entities":[[60,70,"DRUG"]]}],null,null,["Assessment efficacy ivermectin, compared permethrin cream, treatment scabies children provide alternative treatment widespread disease.",{"entities":[[20,30,"DRUG"]]}],["trial funded Wellcome Trust (grant reference number: 218524/Z/19/Z).",{"entities":[[13,27,"ORG"]]}],null,["study evaluate pharmacokinetic (PK) properties antiretroviral (ARV) anti-tuberculosis (TB) drugs administered pregnancy postpartum.",{"entities":[[87,89,"CONDITION"],[110,119,"CONDITION"],[120,130,"CONDITION"]]}],null,null,null,["ARVs TB treatment drugs supplied study.",{"entities":[[0,4,"DRUG"],[5,7,"CONDITION"]]}],null,null,null,null,null,["1.5): Pregnant women living HIV (WLHIV) receiving oral ARVs TB drugs, infants.",{"entities":[[6,14,"CONDITION"],[15,31,"POPULATION"],[33,38,"POPULATION"],[60,62,"CONDITION"],[70,77,"POPULATION"]]}],["* Component 2 (Arm 2.1): Pregnant WLHIV HIV-uninfected women received long-acting/extended release ARVs pregnancy, infants.",{"entities":[[25,33,"CONDITION"],[34,39,"POPULATION"],[99,103,"DRUG"],[104,113,"CONDITION"],[115,122,"POPULATION"]]}],["* Component 3 (Arms 3.1, 3.2, 3.3): Pregnant WLHIV receiving ARVs first-line TB treatment, infants.",{"entities":[[36,44,"CONDITION"],[45,50,"POPULATION"],[77,79,"CONDITION"],[91,98,"POPULATION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Phase (3-6 months) prospective observational cohort Mbagathi County Hospital Nairobi, Kenya, Jinja Regional Referral Hospital Jinja, Uganda.",{"entities":[[52,76,"ORG"],[77,84,"LOCATION"],[86,91,"COUNTRY"],[93,125,"ORG"],[126,131,"LOCATION"]]}],null,null,null,null,null,["Control (Phase I, 12 months): Kiambu County Referral Hospital Nairobi, Kenya serve control intervention implemented.",{"entities":[[30,61,"ORG"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Meningococcal disease gonorrhoea caused bacteria closely diseases spread ways.",{"entities":[[0,21,"CONDITION"],[22,32,"CONDITION"]]}],["evidence suggests Meningococcal vaccine (Bexsero®) licensed Kenya meningococcal disease effective gonorrhoea genetic similarities organisms causing diseases.",{"entities":[[18,31,"CONDITION"],[66,79,"CONDITION"],[98,108,"CONDITION"]]}],["Investigators conduct clinical trial Meningococcal vaccine (Bexsero®) 50 male female participants aged 18-25 follow KEMRI cohorts (including HIV-uninfected infected individuals) KEMRI clinic Mtwapa.",{"entities":[[116,121,"ORG"],[178,183,"ORG"],[191,197,"LOCATION"]]}],null,["Instead, investigators assess immunisation individuals risk gonococcal infection 4CMenB (Bexsero®) elicits humoral cell cross-reactive responses Neisseria gonorrhoeae (Ng).",{"entities":[[60,80,"CONDITION"],[145,166,"CONDITION"]]}],null,["InvestigatorsF offer vaccination Meningococcal vaccine (Bexsero®) vaccine enrolment visit 2 months later.",{"entities":[[33,46,"CONDITION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Thus, main outcomes study be: (1) optimisation sporozoite dose infections success individuals moderate-high malaria exposure; (2) sub-curative anti-malaria treatment induction gametocytes; (3) infection mosquitoes mosquito feeding assays induced gametocytes.",{"entities":[[176,187,"BIOLOGICAL"],[246,257,"BIOLOGICAL"]]}],["achieve this, 250 semi-immune adults recruited malaria endemicity Kenya varying exposure malaria undergo screening procedures informed consent enrol 105 individuals conduct CHMI studies serial quantitative polymerase chain reaction (PCR) measure asexual parasite growth induction transmission stages vivo.",{"entities":[[206,231,"BIOLOGICAL"],[233,236,"BIOLOGICAL"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["falciparum malaria.",{"entities":[[0,18,"CONDITION"]]}],null,null,null,null,null,null,null,null,null,null,["E-MOTIVE intervention consists elements: 1) strategy detection PPH, triggering 'first response' treatment bundle; 2) 'first response' bundle called \"\"MOTIVE\"\", based guideline recommendations consisting uterine Massage, Oxytocic drugs, Tranexamic acid, IV fluids Examination \\\\& Escalation; 3) implementation strategy, focusing simulation-based training peer-assisted learning, local E-MOTIVE champions, feedback actionable data providers, calibrated drape trigger line, MOTIVE emergency trolley and/or carry case.",{"entities":[[203,210,"BODY_PART"],[220,234,"DRUG"],[236,251,"DRUG"]]}],null,null,null,["key secondary implementation outcomes special 1) PPH detection (with numerator denominator: women objectively PPH (source-verified blood loss ≥ 500 weighing drape) diagnosed PPH birth attendants divided total women objectively PPH (source verified blood loss ≥ 500 weighing drape), 2) compliance MOTIVE bundle (with numerator denominator: women objectively PPH treated PPH bundle diagnosis PPH birth attendants divided total women objectively PPH (blood loss ≥ 500 weighing drape).",{"entities":[[49,52,"CONDITION"],[110,113,"CONDITION"],[174,177,"CONDITION"],[227,230,"CONDITION"],[357,360,"CONDITION"],[369,372,"CONDITION"],[390,393,"CONDITION"],[443,446,"CONDITION"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,["Background Purpose Research: Current Kenya National Antiretroviral(ARV) Guidelines recommend failing NNRTI-based first-line regimen, patients ritonavir-boosted protease inhibitor (PI/r) + 2 nucleoside reverse transcript inhibitors second-line regimen.",{"entities":[[52,66,"DRUG"],[67,70,"DRUG"],[142,159,"DRUG"],[160,178,"DRUG"],[190,230,"DRUG"]]}],["randomised trials support sequencing, drug resistance testing guide choice second-line NRTIs.",{"entities":[[87,92,"DRUG"]]}],["Kenya guidelines recommended PI/r-based second-line regimens decade essentially second-line patients Kenya PI/r-based regimens 75% patients virally suppressed.",{"entities":[[107,117,"DRUG"]]}],null,["contexts Tuberculosis (TB) prevalence, impact potential drug-drug interactions considerable, requiring super boosting PI ritonavir toxic tolerated result adequate drug levels LPV/r ATV/r DRV/r or, rifabutin co-formulated anti-mycobacterial agents leads pill burden adherence.",{"entities":[[175,180,"DRUG"],[181,186,"DRUG"],[187,192,"DRUG"],[197,206,"DRUG"]]}],["supply rifabutin unreliable Kenya.",{"entities":[[7,16,"DRUG"]]}],["study evaluated switch strategy PI/r DTG virally suppressed treatment experienced patients failed prior regimen consisting NNRTI + NRTIs.",{"entities":[[32,36,"DRUG"],[37,40,"DRUG"],[123,128,"DRUG"],[131,136,"DRUG"]]}],null,["Summary Previous Studies study second-line regimen dolutegravir (DTG) + 2 NRTIs superior LPV/r + 2 NRTIs failing regimen NNRTI + 2 NRTIs presence active NRTI (Aboud 2019).",{"entities":[[51,63,"DRUG"],[65,68,"DRUG"],[74,79,"DRUG"],[89,94,"DRUG"],[99,104,"DRUG"],[121,126,"DRUG"],[131,136,"DRUG"],[153,157,"DRUG"]]}],["study excluded patients active NRTI line, applied scenarios reliably predict activity NRTIs first-line failure DRT available.",{"entities":[[31,35,"DRUG"],[86,91,"DRUG"],[111,114,"DRUG"]]}],["Kenya National ARV Guidelines recommend patients alternative regimen, NNRTI based PI/r based, virologic suppression switched DTG/TDF/3TC.",{"entities":[[70,75,"DRUG"],[125,136,"DRUG"]]}],["evidence strategy studies switch virally suppressed patients DTG-based regimens inferior viral suppression, improved patient satisfaction improved lipid profiles NEAT022 study, investigators enrolled individuals cardiovascular disease risk goal analysing efficacy impact change boosted PI dolutegravir.",{"entities":[[212,234,"CONDITION"],[286,288,"DRUG"],[289,301,"DRUG"]]}],["Participants suppressed HIV RNA boosted PI NRTIs, documented NRTI resistance mutations previous virologic failure.",{"entities":[[40,42,"DRUG"],[43,48,"DRUG"],[61,65,"DRUG"]]}],["participants age 50 Framingham estimated 10-year risk cardiovascular events 10%.",{"entities":[[54,68,"CONDITION"]]}],["415 individuals randomised continue NRTI's boosted PI switch dolutegravir maintaining NRTIs.",{"entities":[[36,40,"DRUG"],[51,53,"DRUG"],[61,73,"DRUG"],[86,91,"DRUG"]]}],null,null,null,["Primary Objective evaluate non-inferiority switching DTG regimen relative maintaining PI/r second-line regimen virologically suppressed, INSTI-naive HIV-1 positive adults (≥ 18 old) determined HIV-1 RNA ≥ 50 copies/ml week 48.",{"entities":[[53,56,"DRUG"],[86,90,"DRUG"]]}],["Secondary Objectives assess impact switching DTG development virological failure week 24 assess impact switching DTG maintenance virological suppression weeks 24 48 assess impact switching DTG change CD4 count weeks 24 48 assess impact switching DTG change cardiovascular risk determined change lipid values (total cholesterol, LDL, HDL, triglycerides TC:HDL ratio) weeks 24 48 change fasting blood glucose weeks 24 48 investigate impact switching DTG change anthropometric measurements (weight, body-mass index, waist-hip ratio, waist circumference) investigate impact switching DTG safety tolerability investigate impact switching DTG patient satisfaction, determined HIV Treatment Satisfaction Questionnaire investigate outcomes based PI/r investigate outcomes based NRTI (TDF, ABC, AZT) investigate outcomes patients switch NRTIs clinical reasons study relative patients switch NRTIs study investigate outcomes based NRTIs changed first-line second-line genotypic resistance patterns participants meeting protocol-defined virological failure Study Design open-label, randomized, non-inferiority, multicenter trial 48 weeks, describing efficacy safety switching second-line ARV regimen ritonavir-boosted protease inhibitor 2 NRTIs DTG 2 NRTIs patients achieved virological suppression 12 weeks prior INSTI exposure.",{"entities":[[45,48,"DRUG"],[246,249,"DRUG"],[315,326,"BIOLOGICAL"],[328,331,"BIOLOGICAL"],[333,336,"BIOLOGICAL"],[338,351,"BIOLOGICAL"],[352,354,"BIOLOGICAL"],[355,358,"BIOLOGICAL"],[448,451,"DRUG"],[580,583,"DRUG"],[633,636,"DRUG"],[670,673,"CONDITION"],[770,774,"DRUG"],[776,779,"DRUG"],[781,784,"DRUG"],[786,789,"DRUG"],[828,833,"DRUG"],[882,887,"DRUG"],[1177,1180,"DRUG"],[1207,1227,"DRUG"],[1228,1233,"DRUG"],[1234,1237,"DRUG"],[1240,1245,"DRUG"],[1303,1308,"DRUG"]]}],null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,["sample size calculation assumes true difference efficacy treatment arms virological failure rate 3% week 48.",{"entities":[]}],["total 766 participants (383 participants study arm) required provide 90% power demonstrate non-inferiority DTG arm, compared control arm, one-sided significance level 2.5% non-inferiority margin 4%.",{"entities":[]}],["Study Location: study sites Kenya include: Kenyatta National Hospital, Thika Level 5 Hospital, Kiambu Level 5 Hospital Jaramogi Oginga Odinga Teaching Referral Hospital.",{"entities":[[43,69,"ORG"],[71,93,"ORG"],[95,118,"ORG"],[119,168,"ORG"]]}]]}